BRCA1	O
is	O
secreted	O
and	O
exhibits	O
properties	O
of	O
a	O
granin	O
.	O

Germline	O
mutations	O
in	O
BRCA1	O
are	O
responsible	O
for	O
most	O
cases	O
of	O
inherited	B-DISO
breast	I-DISO
and	I-DISO
ovarian	I-DISO
cancer	E-DISO
.	O

However	O
,	O
the	O
function	O
of	O
the	O
BRCA1	O
protein	O
has	O
remained	O
elusive	O
.	O

We	O
now	O
show	O
that	O
BRCA1	O
encodes	O
a	O
190	O
-	O
kD	O
protein	O
with	O
sequence	O
homology	O
and	O
biochemical	O
analogy	O
to	O
the	O
granin	O
protein	O
family	O
.	O

Interestingly	O
,	O
BRCA2	O
also	O
includes	O
a	O
motif	O
similar	O
to	O
the	O
granin	O
consensus	O
at	O
the	O
C	O
terminus	O
of	O
the	O
protein	O
.	O

Both	O
BRCA1	O
and	O
the	O
granins	O
localize	O
to	O
secretory	O
vesicles	O
,	O
are	O
secreted	O
by	O
a	O
regulated	O
pathway	O
,	O
are	O
post	O
-	O
translationally	O
glycosylated	O
and	O
are	O
responsive	O
to	O
hormones	O
.	O

As	O
a	O
regulated	O
secretory	O
protein	O
,	O
BRCA1	O
appears	O
to	O
function	O
by	O
a	O
mechanism	O
not	O
previously	O
described	O
for	O
tumour	S-DISO
suppressor	O
gene	O
products	O
.	O
.	O

Ovarian	B-DISO
cancer	E-DISO
risk	O
in	O
BRCA1	O
carriers	O
is	O
modified	O
by	O
the	O
HRAS1	O
variable	O
number	O
of	O
tandem	O
repeat	O
(	O
VNTR	O
)	O
locus	O
.	O

Women	O
who	O
carry	O
a	O
mutation	O
in	O
the	O
BRCA1	O
gene	O
(	O
on	O
chromosome	O
17q21	O
)	O
,	O
have	O
an	O
80	O
%	O
risk	O
of	O
breast	B-DISO
cancer	E-DISO
and	O
a	O
40	O
%	O
risk	O
of	O
ovarian	B-DISO
cancer	E-DISO
by	O
the	O
age	O
of	O
70	O
(	O
ref	O
.	O
1	O
)	O
.	O

The	O
variable	O
penetrance	O
of	O
BRCA1	O
suggests	O
that	O
other	O
genetic	O
and	O
non	O
-	O
genetic	O
factors	O
play	O
a	O
role	O
in	O
tumourigenesis	O
in	O
these	O
individuals	O
.	O

The	O
HRAS1	O
variable	O
number	O
of	O
tandem	O
repeats	O
(	O
VNTR	O
)	O
polymorphism	O
,	O
located	O
1	O
kilobase	O
(	O
kb	O
)	O
downstream	O
of	O
the	O
HRAS1	O
proto	O
-	O
oncogene	O
(	O
chromosome	O
11p15	O
.	O
5	O
)	O
is	O
one	O
possible	O
genetic	O
modifier	O
of	O
cancer	S-DISO
penetrance	O
.	O

Individuals	O
who	O
have	O
rare	O
alleles	O
of	O
the	O
VNTR	O
have	O
an	O
increased	O
risk	O
of	O
certain	O
types	O
of	O
cancers	S-DISO
,	O
including	O
breast	B-DISO
cancer	E-DISO
(	O
2	O
-	O
4	O
)	O
.	O

To	O
investigate	O
whether	O
the	O
presence	O
of	O
rare	O
HRAS1	O
alleles	O
increases	O
susceptibility	O
to	O
hereditary	B-DISO
breast	I-DISO
and	I-DISO
ovarian	I-DISO
cancer	E-DISO
,	O
we	O
have	O
typed	O
a	O
panel	O
of	O
307	O
female	O
BRCA1	O
carriers	O
at	O
this	O
locus	O
using	O
a	O
PCR	O
-	O
based	O
technique	O
.	O

The	O
risk	O
for	O
ovarian	B-DISO
cancer	E-DISO
was	O
2	O
.	O

11	O
times	O
greater	O
for	O
BRCA1	O
carriers	O
harbouring	O
one	O
or	O
two	O
rare	O
HRAS1	O
alleles	O
,	O
compared	O
to	O
carriers	O
with	O
only	O
common	O
alleles	O
(	O
P	O
=	O
0	O
.	O
015	O
)	O
.	O

The	O
magnitude	O
of	O
the	O
relative	O
risk	O
associated	O
with	O
a	O
rare	O
HRAS1	O
allele	O
was	O
not	O
altered	O
by	O
adjusting	O
for	O
the	O
other	O
known	O
risk	O
factors	O
for	O
hereditary	B-DISO
ovarian	I-DISO
cancer	E-DISO
(	O
5	O
)	O
.	O

Susceptibility	O
to	O
breast	B-DISO
cancer	E-DISO
did	O
not	O
appear	O
to	O
be	O
affected	O
by	O
the	O
presence	O
of	O
rare	O
HRAS1	O
alleles	O
.	O

This	O
study	O
is	O
the	O
first	O
to	O
show	O
the	O
effect	O
of	O
a	O
modifying	O
gene	O
on	O
the	O
penetrance	O
of	O
an	O
inherited	B-DISO
cancer	I-DISO
syndrome	E-DISO

A	O
novel	O
homeodomain	O
-	O
encoding	O
gene	O
is	O
associated	O
with	O
a	O
large	O
CpG	O
island	O
interrupted	O
by	O
the	O
myotonic	B-DISO
dystrophy	E-DISO
unstable	O
(	O
CTG	O
)	O
n	O
repeat	O
.	O

Myotonic	B-DISO
dystrophy	E-DISO
(	O
DM	S-DISO
)	O
is	O
associated	O
with	O
a	O
(	O
CTG	O
)	O
n	O
trinucleotide	O
repeat	O
expansion	O
in	O
the	O
3	O
-	O
untranslated	O
region	O
of	O
a	O
protein	O
kinase	O
-	O
encoding	O
gene	O
,	O
DMPK	O
,	O
which	O
maps	O
to	O
chromosome	O
19q13	O
.	O

3	O
.	O

Characterisation	O
of	O
the	O
expression	O
of	O
this	O
gene	O
in	O
patient	O
tissues	O
has	O
thus	O
far	O
generated	O
conflicting	O
data	O
on	O
alterations	O
in	O
the	O
steady	O
state	O
levels	O
of	O
DMPK	O
mRNA	O
,	O
and	O
on	O
the	O
final	O
DMPK	O
protein	O
levels	O
in	O
the	O
presence	O
of	O
the	O
expansion	O
.	O

The	O
DM	S-DISO
region	O
of	O
chromosome	O
19	O
is	O
gene	O
rich	O
,	O
and	O
it	O
is	O
possible	O
that	O
the	O
repeat	O
expansion	O
may	O
lead	O
to	O
dysfunction	O
of	O
a	O
number	O
of	O
transcription	O
units	O
in	O
the	O
vicinity	O
,	O
perhaps	O
as	O
a	O
consequence	O
of	O
chromatin	O
disruption	O
.	O

We	O
have	O
searched	O
for	O
genes	O
associated	O
with	O
a	O
CpG	O
island	O
at	O
the	O
3	O
end	O
of	O
DMPK	O
.	O

Sequencing	O
of	O
this	O
region	O
shows	O
that	O
the	O
island	O
extends	O
over	O
3	O
.	O

5	O
kb	O
and	O
is	O
interrupted	O
by	O
the	O
(	O
CTG	O
)	O
n	O
repeat	O
.	O

Comparison	O
of	O
genomic	O
sequences	O
downstream	O
(	O
centromeric	O
)	O
of	O
the	O
repeat	O
in	O
human	O
and	O
mouse	O
identified	O
regions	O
of	O
significant	O
homology	O
.	O

These	O
correspond	O
to	O
exons	O
of	O
a	O
gene	O
predicted	O
to	O
encode	O
a	O
homeodomain	O
protein	O
.	O

RT	O
-	O
PCR	O
analysis	O
shows	O
that	O
this	O
gene	O
,	O
which	O
we	O
have	O
called	O
DM	S-DISO
locus	O
-	O
associated	O
homeodomain	O
protein	O
(	O
DMAHP	O
)	O
,	O
is	O
expressed	O
in	O
a	O
number	O
of	O
human	O
tissues	O
,	O
including	O
skeletal	O
muscle	O
,	O
heart	O
and	O
brain	O
.	O

Germline	O
mutations	O
in	O
the	O
RB1	O
gene	O
in	O
patients	O
with	O
hereditary	B-DISO
retinoblastoma	E-DISO
.	O

We	O
have	O
analyzed	O
the	O
27	O
exons	O
and	O
the	O
promoter	O
region	O
of	O
the	O
RB1	O
gene	O
in	O
familial	B-DISO
or	I-DISO
sporadic	I-DISO
bilateral	I-DISO
retinoblastoma	E-DISO
by	O
using	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
analysis	O
.	O

For	O
improvement	O
over	O
previous	O
studies	O
,	O
a	O
new	O
set	O
of	O
primers	O
has	O
been	O
designed	O
,	O
which	O
allow	O
for	O
amplification	O
of	O
the	O
coding	O
and	O
splicing	O
sequences	O
only	O
.	O

The	O
positioning	O
of	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
primers	O
was	O
such	O
that	O
the	O
resulting	O
PCR	O
products	O
were	O
of	O
different	O
sizes	O
,	O
which	O
enabled	O
us	O
to	O
analyze	O
two	O
different	O
exons	O
simultaneously	O
and	O
still	O
distinguish	O
between	O
the	O
banding	O
profiles	O
for	O
both	O
(	O
biplex	O
analysis	O
)	O
.	O

By	O
using	O
this	O
approach	O
,	O
we	O
were	O
able	O
to	O
identify	O
mutation	O
in	O
22	O
new	O
patients	O
,	O
but	O
the	O
overall	O
efficiency	O
of	O
the	O
procedure	O
when	O
we	O
used	O
a	O
single	O
-	O
pass	O
regimen	O
was	O
only	O
48	O
%	O
.	O

The	O
mutations	O
were	O
small	O
insertions	O
and	O
deletions	O
and	O
point	O
mutations	O
in	O
roughly	O
equal	O
proportions	O
.	O
.	O

Type	B-DISO
II	I-DISO
human	I-DISO
complement	I-DISO
C2	I-DISO
deficiency	E-DISO
.	O

Allele	O
-	O
specific	O
amino	O
acid	O
substitutions	O
(	O
Ser189	O
-	O
-	O
>	O
Phe	O
;	O
Gly444	O
-	O
-	O
>	O
Arg	O
)	O
cause	O
impaired	O
C2	O
secretion	O
.	O

Type	B-DISO
II	I-DISO
complement	I-DISO
protein	I-DISO
C2	I-DISO
deficiency	E-DISO
is	O
characterized	O
by	O
a	O
selective	O
block	O
in	O
C2	O
secretion	O
.	O

The	O
Type	O
II	O
C2	O
null	O
allele	O
(	O
C2Q0	O
)	O
is	O
linked	O
to	O
two	O
major	O
histocompatibility	O
haplotypes	O
(	O
MHC	O
)	O
that	O
differ	O
from	O
the	O
MHC	O
of	O
the	O
more	O
common	O
Type	B-DISO
I	I-DISO
C2	I-DISO
deficiency	E-DISO
.	O

To	O
determine	O
the	O
molecular	O
basis	O
of	O
Type	B-DISO
II	I-DISO
deficiency	E-DISO
the	O
two	O
Type	O
II	O
C2Q0	O
genes	O
were	O
isolated	O
and	O
transfected	O
separately	O
into	O
L	O
-	O
cells	O
.	O

Subsequent	O
molecular	O
biology	O
,	O
biosynthetic	O
,	O
and	O
immunofluorescence	O
studies	O
demonstrated	O
that	O
C2	O
secretion	O
is	O
impaired	O
in	O
Type	B-DISO
II	I-DISO
C2	I-DISO
deficiency	E-DISO
because	O
of	O
different	O
missense	O
mutations	O
at	O
highly	O
conserved	O
residues	O
in	O
each	O
of	O
the	O
C2Q0	O
alleles	O
.	O

One	O
is	O
in	O
exon	O
5	O
(	O
nucleotide	O
C566	O
-	O
-	O
>	O
T	O
;	O
Ser189	O
-	O
-	O
>	O
Phe	O
)	O
of	O
the	O
C2Q0	O
gene	O
linked	O
to	O
the	O
MHC	O
haplotype	O
A11	O
,	O
B35	O
,	O
DRw1	O
,	O
BFS	O
,	O
C4A0B1	O
.	O

The	O
other	O
is	O
in	O
exon	O
11	O
(	O
G1930	O
-	O
-	O
>	O
A	O
;	O
Gly444	O
-	O
-	O
>	O
Arg	O
)	O
of	O
the	O
C2Q0	O
gene	O
linked	O
to	O
the	O
MHC	O
haplotype	O
A2	O
,	O
B5	O
,	O
DRw4	O
,	O
BFS	O
,	O
C4A3B1	O
.	O

Each	O
mutant	O
C2	O
gene	O
product	O
is	O
retained	O
early	O
in	O
the	O
secretory	O
pathway	O
.	O

These	O
mutants	O
provide	O
models	O
for	O
elucidating	O
the	O
C2	O
secretory	O
pathway	O
.	O
.	O

Defective	O
dimerization	O
of	O
von	B-DISO
Willebrand	E-DISO
factor	O
subunits	O
due	O
to	O
a	O
Cys	O
-	O
>	O
Arg	O
mutation	O
in	O
type	B-DISO
IID	I-DISO
von	I-DISO
Willebrand	I-DISO
disease	E-DISO
.	O

The	O
same	O
heterozygous	O
T	O
-	O
>	O
C	O
transition	O
at	O
nt	O
8567	O
of	O
the	O
von	B-DISO
Willebrand	E-DISO
factor	O
(	O
vWF	O
)	O
transcript	O
was	O
found	O
in	O
two	O
unrelated	O
patients	O
with	O
type	B-DISO
IID	I-DISO
von	I-DISO
Willebrand	I-DISO
disease	E-DISO
,	O
with	O
no	O
other	O
apparent	O
abnormality	O
.	O

In	O
one	O
family	O
,	O
both	O
alleles	O
were	O
normal	O
in	O
the	O
parents	O
and	O
one	O
sister	O
;	O
thus	O
,	O
the	O
mutation	O
originated	O
de	O
novo	O
in	O
the	O
proposita	O
.	O

The	O
second	O
patient	O
also	O
had	O
asymptomatic	O
parents	O
who	O
,	O
however	O
,	O
were	O
not	O
available	O
for	O
study	O
.	O

The	O
structural	O
consequences	O
of	O
the	O
identified	O
mutation	O
,	O
resulting	O
in	O
the	O
CyS2010	O
-	O
>	O
Arg	O
substitution	O
,	O
were	O
evaluated	O
by	O
expression	O
of	O
the	O
vWF	O
carboxyl	O
-	O
terminal	O
domain	O
containing	O
residues	O
1366	O
-	O
2050	O
.	O

Insect	O
cells	O
infected	O
with	O
recombinant	O
baculovirus	O
expressing	O
normal	O
vWF	O
sequence	O
secreted	O
a	O
disulfide	O
linked	O
dimeric	O
molecule	O
with	O
an	O
apparent	O
molecular	O
mass	O
of	O
150	O
kDa	O
before	O
reduction	O
,	O
yielding	O
a	O
single	O
band	O
of	O
80	O
kDa	O
after	O
disulfide	O
bond	O
reduction	O
.	O

In	O
contrast	O
,	O
cells	O
expressing	O
the	O
mutant	O
fragment	O
secreted	O
a	O
monomeric	O
molecule	O
of	O
apparent	O
molecular	O
mass	O
of	O
80	O
kDa	O
,	O
which	O
remained	O
unchanged	O
after	O
reduction	O
.	O

We	O
conclude	O
that	O
CyS2010	O
is	O
essential	O
for	O
normal	O
dimerization	O
of	O
vWF	O
subunits	O
through	O
disulfide	O
bonding	O
of	O
carboxyl	O
-	O
terminal	O
domains	O
and	O
that	O
a	O
heterozygous	O
mutation	O
in	O
the	O
corresponding	O
codon	O
is	O
responsible	O
for	O
defective	O
multimer	O
formation	O
in	O
type	B-DISO
IID	I-DISO
von	I-DISO
Willebrand	I-DISO
disease	E-DISO
.	O
.	O

Wiskott	B-DISO
-	I-DISO
Aldrich	I-DISO
syndrome	E-DISO
protein	O
,	O
a	O
novel	O
effector	O
for	O
the	O
GTPase	O
CDC42Hs	O
,	O
is	O
implicated	O
in	O
actin	O
polymerization	O
.	O

The	O
Rho	O
family	O
of	O
GTPases	O
control	O
diverse	O
biological	O
processes	O
,	O
including	O
cell	O
morphology	O
and	O
mitogenesis	O
.	O

We	O
have	O
identified	O
WASP	O
,	O
the	O
protein	O
that	O
is	O
defective	O
in	O
Wiskott	B-DISO
-	I-DISO
Aldrich	I-DISO
syndrome	E-DISO
(	O
WAS	S-DISO
)	O
,	O
as	O
a	O
novel	O
effector	O
for	O
CDC42Hs	O
,	O
but	O
not	O
for	O
the	O
other	O
Rho	O
family	O
members	O
,	O
Rac	O
and	O
Rho	O
.	O

This	O
interaction	O
is	O
dependent	O
on	O
the	O
presence	O
of	O
the	O
G	O
protein	O
-	O
binding	O
domain	O
.	O

Cellular	O
expression	O
of	O
epitope	O
-	O
tagged	O
WASP	O
produces	O
clusters	O
of	O
WASP	O
that	O
are	O
highly	O
enriched	O
in	O
polymerized	O
actin	O
.	O

This	O
clustering	O
is	O
not	O
observed	O
with	O
a	O
C	O
-	O
terminally	O
deleted	O
WASP	O
and	O
is	O
inhibited	O
by	O
coexpression	O
with	O
dominant	O
negative	O
CDC42Hs	O
-	O
N17	O
,	O
but	O
not	O
with	O
dominant	O
negative	O
forms	O
of	O
Rac	O
or	O
Rho	O
.	O

Thus	O
,	O
WASP	O
provides	O
a	O
novel	O
link	O
between	O
CDC42Hs	O
and	O
the	O
actin	O
cytoskeleton	O
,	O
which	O
suggests	O
a	O
molecular	O
mechanism	O
for	O
many	O
of	O
the	O
cellular	O
abnormalities	O
in	O
WAS	S-DISO
.	O

The	O
WASP	O
sequence	O
contains	O
two	O
novel	O
domains	O
that	O
are	O
homologous	O
to	O
other	O
proteins	O
involved	O
in	O
action	O
organization	O
.	O
.	O

X	B-DISO
-	I-DISO
linked	I-DISO
adrenoleukodystrophy	E-DISO
is	O
a	O
frequent	O
cause	O
of	O
idiopathic	O
Addison	B-DISO
'	I-DISO
s	I-DISO
disease	E-DISO
in	O
young	O
adult	O
male	O
patients	O
.	O

X	B-DISO
-	I-DISO
Linked	I-DISO
adrenoleukodystrophy	E-DISO
(	O
ALD	S-DISO
)	O
is	O
a	O
genetic	B-DISO
disease	E-DISO
associated	O
with	O
demyelination	B-DISO
of	I-DISO
the	I-DISO
central	I-DISO
nervous	I-DISO
system	E-DISO
,	O
adrenal	B-DISO
insufficiency	E-DISO
,	O
and	O
accumulation	O
of	O
very	O
long	O
chain	O
fatty	O
acids	O
in	O
tissue	O
and	O
body	O
fluids	O
.	O

ALD	S-DISO
is	O
due	O
to	O
mutation	O
of	O
a	O
gene	O
located	O
in	O
Xq28	O
that	O
encodes	O
a	O
peroxisomal	O
transporter	O
protein	O
of	O
unknown	O
function	O
.	O

The	O
most	O
common	O
phenotype	O
of	O
ALD	S-DISO
is	O
the	O
cerebral	O
form	O
(	O
45	O
%	O
)	O
that	O
develops	O
in	O
boys	O
between	O
5	O
-	O
12	O
yr	O
.	O

Adrenomyeloneuropathy	S-DISO
(	O
AMN	S-DISO
)	O
involves	O
the	O
spinal	O
cord	O
and	O
peripheral	O
nerves	O
in	O
young	O
adults	O
(	O
35	O
%	O
)	O
.	O

Adrenal	B-DISO
insufficiency	E-DISO
(	O
Addisons	B-DISO
disease	E-DISO
)	O
is	O
frequently	O
associated	O
with	O
AMN	S-DISO
or	O
cerebral	B-DISO
ALD	E-DISO
and	O
may	O
remain	O
the	O
only	O
clinical	O
expression	O
of	O
ALD	S-DISO
(	O
8	O
%	O
of	O
cases	O
)	O
.	O

The	O
prevalence	O
of	O
ALD	S-DISO
among	O
adults	O
with	O
Addisons	B-DISO
disease	E-DISO
remains	O
unknown	O
.	O

To	O
evaluate	O
this	O
prevalence	O
,	O
we	O
performed	O
biochemical	O
analysis	O
of	O
very	O
long	O
chain	O
fatty	O
acids	O
in	O
14	O
male	O
patients	O
(	O
age	O
ranging	O
from	O
12	O
-	O
45	O
yr	O
at	O
diagnosis	O
)	O
previously	O
diagnosed	O
as	O
having	O
primary	O
idiopathic	O
adrenocortical	B-DISO
insufficiency	E-DISO
.	O

In	O
5	O
of	O
14	O
patients	O
(	O
35	O
%	O
)	O
,	O
elevated	O
plasma	O
concentrations	O
of	O
very	O
long	O
chain	O
fatty	O
acids	O
were	O
detected	O
.	O

None	O
of	O
these	O
patients	O
had	O
adrenocortical	O
antibodies	O
.	O

By	O
electrophysiological	O
tests	O
and	O
magnetic	O
resonance	O
imaging	O
it	O
was	O
determined	O
that	O
two	O
patients	O
had	O
cerebral	B-DISO
ALD	E-DISO
,	O
one	O
had	O
adrenomyeloneuropathy	S-DISO
with	O
cerebral	O
involvement	O
,	O
and	O
two	O
had	O
preclinical	O
AMN	S-DISO
.	O

Our	O
data	O
support	O
the	O
hypothesis	O
that	O
ALD	S-DISO
is	O
a	O
frequent	O
cause	O
of	O
idiopathic	O
Addisons	B-DISO
disease	E-DISO
in	O
children	O
and	O
adults	O
.	O
.	O

Tumor	S-DISO
suppression	O
and	O
apoptosis	O
of	O
human	O
prostate	B-DISO
carcinoma	E-DISO
mediated	O
by	O
a	O
genetic	O
locus	O
within	O
human	O
chromosome	O
10pter	O
-	O
q11	O
.	O

Prostate	B-DISO
cancer	E-DISO
is	O
the	O
second	O
leading	O
cause	O
of	O
male	O
cancer	S-DISO
deaths	O
in	O
the	O
United	O
States	O
.	O

Yet	O
,	O
despite	O
a	O
large	O
international	O
effort	O
,	O
little	O
is	O
known	O
about	O
the	O
molecular	O
mechanisms	O
that	O
underlie	O
this	O
devastating	O
disease	O
.	O

Prostate	O
secretory	O
epithelial	O
cells	O
and	O
androgen	O
-	O
dependent	O
prostate	B-DISO
carcinomas	E-DISO
undergo	O
apoptosis	O
in	O
response	O
to	O
androgen	O
deprivation	O
and	O
,	O
furthermore	O
,	O
most	O
prostate	B-DISO
carcinomas	E-DISO
become	O
androgen	O
independent	O
and	O
refractory	O
to	O
further	O
therapeutic	O
manipulations	O
during	O
disease	O
progression	O
.	O

Definition	O
of	O
the	O
genetic	O
events	O
that	O
trigger	O
apoptosis	O
in	O
the	O
prostate	O
could	O
provide	O
important	O
insights	O
into	O
critical	O
pathways	O
in	O
normal	O
development	O
as	O
well	O
as	O
elucidate	O
the	O
perturbations	O
of	O
those	O
key	O
pathways	O
in	O
neoplastic	O
transformation	O
.	O

We	O
report	O
the	O
functional	O
definition	O
of	O
a	O
novel	O
genetic	O
locus	O
within	O
human	O
chromosome	O
10pter	O
-	O
q11	O
that	O
mediates	O
both	O
in	O
vivo	O
tumor	O
suppression	O
and	O
in	O
vitro	O
apoptosis	O
of	O
prostatic	B-DISO
adenocarcinoma	E-DISO
cells	O
.	O

A	O
defined	O
fragment	O
of	O
human	O
chromosome	O
10	O
was	O
transferred	O
via	O
microcell	O
fusion	O
into	O
a	O
prostate	B-DISO
adenocarcinoma	E-DISO
cell	O
line	O
.	O

Microcell	O
hybrids	O
containing	O
only	O
the	O
region	O
10pter	O
-	O
q11	O
were	O
suppressed	O
for	O
tumorigenicity	O
following	O
injection	O
of	O
microcell	O
hybrids	O
into	O
nude	O
mice	O
.	O

Furthermore	O
,	O
the	O
complemented	O
hybrids	O
undergo	O
programmed	O
cell	O
death	O
in	O
vitro	O
via	O
a	O
mechanism	O
that	O
does	O
not	O
require	O
nuclear	O
localization	O
of	O
p53	O
.	O

These	O
data	O
functionally	O
define	O
a	O
novel	O
genetic	O
locus	O
,	O
designated	O
PAC1	O
,	O
for	O
prostate	O
adenocarcinoma	O
1	O
,	O
involved	O
in	O
tumor	O
suppression	O
of	O
human	O
prostate	B-DISO
carcinoma	E-DISO
and	O
furthermore	O
strongly	O
suggest	O
that	O
the	O
cell	O
death	O
pathway	O
can	O
be	O
functionally	O
restored	O
in	O
prostatic	B-DISO
adenocarcinoma	E-DISO
.	O
.	O

Low	O
incidence	O
of	O
BRCA2	O
mutations	O
in	O
breast	B-DISO
carcinoma	E-DISO
and	O
other	O
cancers	S-DISO
.	O

Inherited	O
mutant	O
alleles	O
of	O
familial	O
tumour	S-DISO
suppressor	O
genes	O
predispose	O
individuals	O
to	O
particular	O
types	O
of	O
cancer	S-DISO
.	O

In	O
addition	O
to	O
an	O
involvement	O
in	O
inherited	O
susceptibility	O
to	O
cancer	S-DISO
,	O
these	O
tumour	S-DISO
suppressor	O
genes	O
are	O
targets	O
for	O
somatic	O
mutations	O
in	O
sporadic	B-DISO
cancers	E-DISO
of	O
the	O
same	O
type	O
found	O
in	O
the	O
familial	O
forms	O
.	O

An	O
exception	O
is	O
BRCA1	O
,	O
which	O
contributes	O
to	O
a	O
significant	O
fraction	O
of	O
familial	B-DISO
breast	I-DISO
and	I-DISO
ovarian	I-DISO
cancer	E-DISO
,	O
but	O
undergoes	O
mutation	O
at	O
very	O
low	O
rates	O
in	O
sporadic	B-DISO
breast	I-DISO
and	I-DISO
ovarian	I-DISO
cancers	E-DISO
.	O

This	O
finding	O
suggests	O
that	O
other	O
genes	O
may	O
be	O
the	O
principal	O
targets	O
for	O
somatic	O
mutation	O
in	O
breast	B-DISO
carcinoma	E-DISO
.	O

A	O
second	O
,	O
recently	O
identified	O
familial	B-DISO
breast	I-DISO
cancer	E-DISO
gene	O
,	O
BRCA2	O
(	O
refs	O
5	O
-	O
8	O
)	O
,	O
accounts	O
for	O
a	O
proportion	O
of	O
breast	B-DISO
cancer	E-DISO
roughly	O
equal	O
to	O
BRCA1	O
.	O

Like	O
BRCA1	O
,	O
BRCA2	O
behaves	O
as	O
a	O
dominantly	O
inherited	O
tumour	S-DISO
suppressor	O
gene	O
.	O

Individuals	O
who	O
inherit	O
one	O
mutant	O
allele	O
are	O
at	O
increased	O
risk	O
for	O
breast	B-DISO
cancer	E-DISO
,	O
and	O
the	O
tumours	S-DISO
they	O
develop	O
lose	O
the	O
wild	O
-	O
type	O
allele	O
by	O
heterozygous	O
deletion	O
.	O

The	O
BRCA2	O
coding	O
sequence	O
is	O
huge	O
,	O
composed	O
of	O
26	O
exons	O
that	O
span	O
10	O
,	O
443	O
bp	O
.	O

Here	O
we	O
investigate	O
the	O
rate	O
of	O
BRCA2	O
mutation	O
in	O
sporadic	B-DISO
breast	I-DISO
cancers	E-DISO
and	O
in	O
a	O
set	O
of	O
cell	O
lines	O
that	O
represent	O
twelve	O
other	O
tumour	S-DISO
types	O
.	O

Surprisingly	O
,	O
mutations	O
in	O
BRCA2	O
are	O
infrequent	O
in	O
cancers	S-DISO
including	O
breast	B-DISO
carcinoma	E-DISO
.	O

However	O
,	O
a	O
probable	O
germline	O
mutation	O
in	O
a	O
pancreatic	B-DISO
tumour	E-DISO
cell	O
line	O
suggests	O
a	O
role	O
for	O
BRCA2	O
in	O
susceptibility	O
to	O
pancreatic	B-DISO
cancer	E-DISO
.	O
.	O

Founding	O
BRCA1	O
mutations	O
in	O
hereditary	B-DISO
breast	I-DISO
and	I-DISO
ovarian	I-DISO
cancer	E-DISO
in	O
southern	O
Sweden	O
.	O

Nine	O
different	O
germ	O
-	O
line	O
mutations	O
in	O
the	O
BRCA1	O
breast	B-DISO
and	I-DISO
ovarian	I-DISO
cancer	E-DISO
susceptibility	O
gene	O
were	O
identified	O
in	O
15	O
of	O
47	O
kindreds	O
from	O
southern	O
Sweden	O
,	O
by	O
use	O
of	O
SSCP	O
and	O
heteroduplex	O
analysis	O
of	O
all	O
exons	O
and	O
flanking	O
intron	O
region	O
and	O
by	O
a	O
protein	O
-	O
truncation	O
test	O
for	O
exon	O
11	O
,	O
followed	O
by	O
direct	O
sequencing	O
.	O

All	O
but	O
one	O
of	O
the	O
mutations	O
are	O
predicted	O
to	O
give	O
rise	O
to	O
premature	O
translation	O
termination	O
and	O
include	O
seven	O
frameshift	O
insertions	O
or	O
deletions	O
,	O
a	O
nonsense	O
mutation	O
,	O
and	O
a	O
splice	O
acceptor	O
site	O
mutation	O
.	O

The	O
remaining	O
mutation	O
is	O
a	O
missense	O
mutation	O
(	O
Cys61Gly	O
)	O
in	O
the	O
zinc	O
-	O
binding	O
motif	O
.	O

Four	O
novel	O
Swedish	O
founding	O
mutations	O
were	O
identified	O
the	O
nucleotide	O
2595	O
deletion	O
A	O
was	O
found	O
in	O
five	O
families	O
,	O
the	O
C	O
1806	O
T	O
nonsense	O
mutation	O
in	O
three	O
families	O
,	O
the	O
3166	O
insertion	O
TGAGA	O
in	O
three	O
families	O
,	O
and	O
the	O
nucleotide	O
1201	O
deletion	O
11	O
in	O
two	O
families	O
.	O

Analysis	O
of	O
the	O
intragenic	O
polymorphism	O
D17S855	O
supports	O
common	O
origins	O
of	O
the	O
mutations	O
.	O

Eleven	O
of	O
the	O
15	O
kindreds	O
manifesting	O
BRCA1	O
mutations	O
were	O
breast	B-DISO
-	I-DISO
ovarian	I-DISO
cancer	E-DISO
families	O
,	O
several	O
of	O
them	O
with	O
a	O
predominant	O
ovarian	B-DISO
cancer	E-DISO
phenotype	O
.	O

The	O
set	O
of	O
32	O
families	O
in	O
which	O
no	O
BRCA1	O
alterations	O
were	O
detected	O
included	O
1	O
breast	B-DISO
-	I-DISO
ovarian	I-DISO
cancer	E-DISO
kindred	O
manifesting	O
clear	O
linkage	O
to	O
the	O
BRCA1	O
region	O
and	O
loss	O
of	O
the	O
wild	O
-	O
type	O
chromosome	O
in	O
associated	O
tumors	S-DISO
.	O

Other	O
tumor	S-DISO
types	O
found	O
in	O
BRCA1	O
mutation	O
/	O
haplotype	O
carriers	O
included	O
prostatic	B-DISO
,	I-DISO
pancreas	I-DISO
,	I-DISO
skin	I-DISO
,	I-DISO
and	I-DISO
lung	I-DISO
cancer	E-DISO
,	O
a	O
malignant	B-DISO
melanoma	E-DISO
,	O
an	O
oligodendroglioma	S-DISO
,	O
and	O
a	O
carcinosarcoma	S-DISO
.	O

In	O
all	O
,	O
12	O
of	O
16	O
kindreds	O
manifesting	O
BRCA1	O
mutation	O
or	O
linkage	O
contained	O
ovarian	B-DISO
cancer	E-DISO
,	O
as	O
compared	O
with	O
only	O
6	O
of	O
the	O
remaining	O
31	O
families	O
(	O
P	O
<	O
.	O
001	O
)	O
.	O

The	O
present	O
study	O
confirms	O
the	O
involvement	O
of	O
BRCA1	O
in	O
disease	O
predisposition	O
for	O
a	O
subset	O
of	O
hereditary	B-DISO
breast	I-DISO
cancer	E-DISO
families	O
often	O
characterized	O
by	O
ovarian	B-DISO
cancers	E-DISO
.	O

Rapid	O
detection	O
of	O
regionally	O
clustered	O
germ	O
-	O
line	O
BRCA1	O
mutations	O
by	O
multiplex	O
heteroduplex	O
analysis	O
.	O

UKCCCR	O
Familial	O
Ovarian	B-DISO
Cancer	E-DISO
Study	O
Group	O
.	O

Germ	O
-	O
line	O
mutations	O
of	O
the	O
BRCA1	O
gene	O
are	O
responsible	O
for	O
a	O
substantial	O
proportion	O
of	O
families	O
with	O
multiple	O
cases	O
of	O
early	O
-	O
onset	O
breast	B-DISO
and	I-DISO
/	I-DISO
or	I-DISO
ovarian	I-DISO
cancer	E-DISO
.	O

Since	O
the	O
isolation	O
of	O
BRCA1	O
last	O
year	O
,	O
>	O
65	O
distinct	O
mutations	O
scattered	O
throughout	O
the	O
coding	O
region	O
have	O
been	O
detected	O
,	O
making	O
analysis	O
of	O
the	O
gene	O
time	O
consuming	O
and	O
technically	O
challenging	O
.	O

We	O
have	O
developed	O
a	O
multiplex	O
heteroduplex	O
analysis	O
that	O
is	O
designed	O
to	O
analyze	O
one	O
-	O
quarter	O
of	O
the	O
coding	O
sequence	O
in	O
a	O
single	O
-	O
step	O
screening	O
procedure	O
and	O
that	O
will	O
detect	O
approximately	O
50	O
%	O
of	O
all	O
BRCA1	O
mutations	O
so	O
far	O
reported	O
in	O
breast	B-DISO
/	I-DISO
ovarian	I-DISO
cancer	E-DISO
families	O
.	O

We	O
have	O
used	O
this	O
technique	O
to	O
analyze	O
BRCA1	O
in	O
162	O
families	O
with	O
a	O
history	O
of	O
breast	B-DISO
and	I-DISO
/	I-DISO
or	I-DISO
ovarian	I-DISO
cancer	E-DISO
and	O
identified	O
12	O
distinct	O
mutations	O
in	O
35	O
families	O
.	O
.	O

A	O
previously	O
undescribed	O
mutation	O
within	O
the	O
tetramerisation	O
domain	O
of	O
TP53	O
in	O
a	O
family	O
with	O
Li	B-DISO
-	I-DISO
Fraumeni	I-DISO
syndrome	E-DISO
.	O

We	O
report	O
details	O
of	O
a	O
family	O
with	O
classic	O
Li	B-DISO
-	I-DISO
Fraumeni	I-DISO
syndrome	E-DISO
in	O
which	O
there	O
is	O
a	O
mutation	O
in	O
codon	O
344	O
of	O
the	O
tumour	S-DISO
suppressor	O
gene	O
TP53	O
.	O

Codon	O
344	O
is	O
a	O
key	O
residue	O
within	O
the	O
tetramerisation	O
domain	O
,	O
and	O
the	O
amino	O
acid	O
substitution	O
of	O
a	O
proline	O
for	O
a	O
leucine	O
is	O
predicted	O
to	O
have	O
profound	O
implications	O
for	O
tetramerisation	O
and	O
potentially	O
DNA	O
binding	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
a	O
mutation	O
at	O
this	O
residue	O
in	O
either	O
sporadic	B-DISO
tumours	E-DISO
or	O
in	O
the	O
germline	O
and	O
the	O
first	O
report	O
of	O
a	O
germline	O
mutation	O
within	O
the	O
tetramerisation	O
domain	O
.	O

The	O
family	O
does	O
not	O
appear	O
to	O
be	O
remarkable	O
in	O
the	O
spectrum	O
of	O
tumours	S-DISO
,	O
and	O
there	O
is	O
loss	O
of	O
the	O
wild	O
-	O
type	O
allele	O
in	O
a	O
leiomyosarcoma	S-DISO
from	O
the	O
proband	O
.	O

A	O
cell	O
line	O
has	O
been	O
established	O
from	O
the	O
tumour	S-DISO
of	O
the	O
proband	O
and	O
cytogenetic	O
and	O
molecular	O
studies	O
carried	O
out	O
,	O
providing	O
an	O
extensive	O
analysis	O
in	O
this	O
family	O
.	O
.	O

The	O
spectrum	O
of	O
RB1	O
germ	O
-	O
line	O
mutations	O
in	O
hereditary	B-DISO
retinoblastoma	E-DISO
.	O

We	O
have	O
searched	O
for	O
germ	O
-	O
line	O
RB1	O
mutations	O
in	O
119	O
patients	O
with	O
hereditary	B-DISO
retinoblastoma	E-DISO
.	O

Previous	O
investigations	O
by	O
Southern	O
blot	O
hybridization	O
and	O
PCR	O
fragment	O
-	O
length	O
analysis	O
had	O
revealed	O
mutations	O
in	O
48	O
patients	O
.	O

Here	O
we	O
report	O
on	O
the	O
analysis	O
of	O
the	O
remaining	O
71	O
patients	O
.	O

By	O
applying	O
heteroduplex	O
analysis	O
,	O
nonisotopic	O
SSCP	O
,	O
and	O
direct	O
sequencing	O
,	O
we	O
detected	O
germ	O
-	O
line	O
mutations	O
resulting	O
in	O
premature	O
termination	O
codons	O
or	O
disruption	O
of	O
splice	O
signals	O
in	O
51	O
(	O
72	O
%	O
)	O
of	O
the	O
71	O
patients	O
.	O

Four	O
patients	O
also	O
showed	O
rare	O
sequence	O
variants	O
.	O

No	O
region	O
of	O
the	O
RB1	O
gene	O
was	O
preferentially	O
involved	O
in	O
single	O
base	O
substitutions	O
.	O

Recurrent	O
transitions	O
were	O
observed	O
at	O
most	O
of	O
the	O
14	O
codons	O
within	O
the	O
RB1	O
.	O

No	O
mutation	O
was	O
observed	O
in	O
exons	O
25	O
-	O
27	O
,	O
although	O
this	O
region	O
contains	O
two	O
CGA	O
codons	O
.	O

This	O
suggests	O
that	O
mutations	O
within	O
the	O
3	O
-	O
terminal	O
region	O
of	O
the	O
RB1	O
gene	O
may	O
not	O
be	O
oncogenic	O
.	O

When	O
these	O
data	O
were	O
combined	O
with	O
the	O
results	O
of	O
our	O
previous	O
investigations	O
,	O
mutations	O
were	O
identified	O
in	O
a	O
total	O
of	O
99	O
(	O
83	O
%	O
)	O
of	O
119	O
patients	O
.	O

The	O
spectrum	O
comprises	O
15	O
%	O
large	O
deletions	O
,	O
26	O
%	O
small	O
length	O
alterations	O
,	O
and	O
42	O
%	O
base	O
substitutions	O
.	O

No	O
correlation	O
between	O
the	O
location	O
of	O
frameshift	O
or	O
nonsense	O
mutations	O
and	O
phenotypic	O
features	O
,	O
including	O
age	O
at	O
diagnosis	O
,	O
the	O
number	O
of	O
tumor	S-DISO
foci	O
,	O
and	O
manifestation	O
of	O
nonocular	B-DISO
tumors	E-DISO
was	O
observed	O
.	O
.	O

Phenotypic	O
characterization	O
of	O
individuals	O
with	O
30	O
-	O
40	O
CAG	O
repeats	O
in	O
the	O
Huntington	B-DISO
disease	E-DISO
(	O
HD	S-DISO
)	O
gene	O
reveals	O
HD	S-DISO
cases	O
with	O
36	O
repeats	O
and	O
apparently	O
normal	O
elderly	O
individuals	O
with	O
36	O
-	O
39	O
repeats	O
.	O

Abnormal	O
CAG	O
expansions	O
in	O
the	O
IT	O
-	O
15	O
gene	O
are	O
associated	O
with	O
Huntington	B-DISO
disease	E-DISO
(	O
HD	S-DISO
)	O
.	O

In	O
the	O
diagnostic	O
setting	O
it	O
is	O
necessary	O
to	O
define	O
the	O
limits	O
of	O
the	O
CAG	O
size	O
ranges	O
on	O
normal	O
and	O
HD	S-DISO
-	O
associated	O
chromosomes	O
.	O

Most	O
large	O
analyses	O
that	O
defined	O
the	O
limits	O
of	O
the	O
normal	O
and	O
pathological	O
size	O
ranges	O
employed	O
PCR	O
assays	O
,	O
which	O
included	O
the	O
CAG	O
repeats	O
and	O
a	O
CCG	O
repeat	O
tract	O
that	O
was	O
thought	O
to	O
be	O
invariant	O
.	O

Many	O
of	O
these	O
experiments	O
found	O
an	O
overlap	O
between	O
the	O
normal	O
and	O
disease	O
size	O
ranges	O
.	O

Subsequent	O
findings	O
that	O
the	O
CCG	O
repeats	O
vary	O
by	O
8	O
trinucleotide	O
lengths	O
suggested	O
that	O
the	O
limits	O
of	O
the	O
normal	O
and	O
disease	O
size	O
ranges	O
should	O
be	O
reevaluated	O
with	O
assays	O
that	O
exclude	O
the	O
CCG	O
polymorphism	O
.	O

Since	O
patients	O
with	O
between	O
30	O
and	O
40	O
repeats	O
are	O
rare	O
,	O
a	O
consortium	O
was	O
assembled	O
to	O
collect	O
such	O
individuals	O
.	O

All	O
178	O
samples	O
were	O
reanalyzed	O
in	O
Cambridge	O
by	O
using	O
assays	O
specific	O
for	O
the	O
CAG	O
repeats	O
.	O

We	O
have	O
optimized	O
methods	O
for	O
reliable	O
sizing	O
of	O
CAG	O
repeats	O
and	O
show	O
cases	O
that	O
demonstrate	O
the	O
dangers	O
of	O
using	O
PCR	O
assays	O
that	O
include	O
both	O
the	O
CAG	O
and	O
CCG	O
polymorphisms	O
.	O

Seven	O
HD	S-DISO
patients	O
had	O
36	O
repeats	O
,	O
which	O
confirms	O
that	O
this	O
allele	O
is	O
associated	O
with	O
disease	O
.	O

Individuals	O
without	O
apparent	O
symptoms	O
or	O
signs	O
of	O
HD	S-DISO
were	O
found	O
at	O
36	O
repeats	O
(	O
aged	O
74	O
,	O
78	O
,	O
79	O
,	O
and	O
87	O
years	O
)	O
,	O
37	O
repeats	O
(	O
aged	O
69	O
years	O
)	O
,	O
38	O
repeats	O
(	O
aged	O
69	O
and	O
90	O
years	O
)	O
,	O
and	O
39	O
repeats	O
(	O
aged	O
67	O
,	O
90	O
,	O
and	O
95	O
years	O
)	O
.	O

The	O
detailed	O
case	O
histories	O
of	O
an	O
exceptional	O
case	O
from	O
this	O
series	O
will	O
be	O
presented	O
a	O
95	O
-	O
year	O
-	O
old	O
man	O
with	O
39	O
repeats	O
who	O
did	O
not	O
have	O
classical	O
features	O
of	O
HD	S-DISO
.	O

The	O
apparently	O
healthy	O
survival	O
into	O
old	O
age	O
of	O
some	O
individuals	O
with	O
36	O
-	O
39	O
repeats	O
suggests	O
that	O
the	O
HD	S-DISO
mutation	O
may	O
not	O
always	O
be	O
fully	O
penetrant	O
.	O
.	O

Identification	O
and	O
expression	O
of	O
eight	O
novel	O
mutations	O
among	O
non	O
-	O
Jewish	O
patients	O
with	O
Canavan	B-DISO
disease	E-DISO
.	O

Canavan	B-DISO
disease	E-DISO
is	O
inherited	O
as	O
an	O
autosomal	O
recessive	O
trait	O
that	O
is	O
caused	O
by	O
the	O
deficiency	B-DISO
of	I-DISO
aspartoacylase	E-DISO
(	O
ASPA	O
)	O
.	O

The	O
majority	O
of	O
patients	O
with	O
Canavan	B-DISO
disease	E-DISO
are	O
from	O
an	O
Ashkenazi	O
Jewish	O
background	O
.	O

Mutations	O
in	O
ASPA	O
that	O
lead	O
to	O
loss	O
of	O
enzymatic	O
activity	O
have	O
been	O
identified	O
,	O
and	O
E285A	O
and	O
Y231X	O
are	O
the	O
two	O
predominant	O
mutations	O
that	O
account	O
for	O
97	O
%	O
of	O
the	O
mutant	O
chromosomes	O
in	O
Ashkenazi	O
Jewish	O
patients	O
.	O

The	O
current	O
study	O
was	O
aimed	O
at	O
finding	O
the	O
molecular	O
basis	O
of	O
Canavan	B-DISO
disease	E-DISO
in	O
25	O
independent	O
patients	O
of	O
non	O
-	O
Jewish	O
background	O
.	O

Eight	O
novel	O
and	O
three	O
previously	O
characterized	O
mutations	O
accounted	O
for	O
80	O
%	O
(	O
40	O
/	O
50	O
)	O
of	O
mutant	O
chromosomes	O
.	O

The	O
A305E	O
missense	O
mutation	O
accounted	O
for	O
48	O
%	O
(	O
24	O
/	O
50	O
)	O
of	O
mutant	O
chromosomes	O
in	O
patients	O
of	O
western	O
European	O
descent	O
,	O
while	O
the	O
two	O
predominant	O
Jewish	O
mutations	O
each	O
accounted	O
for	O
a	O
single	O
mutant	O
chromosome	O
.	O

The	O
eight	O
novel	O
mutations	O
identified	O
included	O
1	O
-	O
and	O
4	O
-	O
bp	O
deletions	O
(	O
32	O
deltaT	O
and	O
876	O
deltaAGAA	O
,	O
respectively	O
)	O
and	O
I16T	O
,	O
G27R	O
,	O
D114E	O
,	O
G123E	O
,	O
C152Y	O
,	O
and	O
R168C	O
missense	O
mutations	O
.	O

The	O
homozygous	O
32	O
deltaT	O
deletion	O
was	O
identified	O
in	O
the	O
only	O
known	O
patient	O
of	O
African	O
-	O
American	O
origin	O
with	O
Canavan	B-DISO
disease	E-DISO
.	O

The	O
heterozygosity	O
for	O
876	O
deltaAGAA	O
mutation	O
was	O
identified	O
in	O
three	O
independent	O
patients	O
from	O
England	O
.	O

Six	O
single	O
-	O
base	O
changes	O
leading	O
to	O
missense	O
mutations	O
were	O
identified	O
in	O
patients	O
from	O
Turkey	O
(	O
D114E	O
,	O
R168C	O
)	O
,	O
The	O
Netherlands	O
(	O
I16T	O
)	O
,	O
Germany	O
(	O
G27R	O
)	O
,	O
Ireland	O
(	O
C152Y	O
)	O
,	O
and	O
Canada	O
(	O
G123E	O
)	O
.	O

A	O
PCR	O
-	O
based	O
protocol	O
is	O
described	O
that	O
was	O
used	O
to	O
introduce	O
mutations	O
in	O
wild	O
-	O
type	O
cDNA	O
.	O

In	O
vitro	O
expression	O
of	O
mutant	O
cDNA	O
clones	O
demonstrated	O
that	O
all	O
of	O
these	O
mutations	O
led	O
to	O
a	O
deficiency	B-DISO
of	I-DISO
ASPA	E-DISO
and	O
should	O
therefore	O
result	O
in	O
Canavan	B-DISO
disease	E-DISO
.	O
.	O

Identification	O
and	O
chromosomal	O
localization	O
of	O
Atm	O
,	O
the	O
mouse	O
homolog	O
of	O
the	O
ataxia	B-DISO
-	I-DISO
telangiectasia	E-DISO
gene	O
.	O

Atm	O
,	O
the	O
mouse	O
homolog	O
of	O
the	O
human	O
ATM	O
gene	O
defective	O
in	O
ataxia	B-DISO
-	I-DISO
telangiectasia	E-DISO
(	O
A	B-DISO
-	I-DISO
T	E-DISO
)	O
,	O
has	O
been	O
identified	O
.	O

The	O
entire	O
coding	O
sequence	O
of	O
the	O
Atm	O
transcript	O
was	O
cloned	O
and	O
found	O
to	O
contain	O
an	O
open	O
reading	O
frame	O
encoding	O
a	O
protein	O
of	O
3066	O
amino	O
acids	O
with	O
84	O
%	O
overall	O
identity	O
and	O
91	O
%	O
similarity	O
to	O
the	O
human	O
ATM	O
protein	O
.	O

Variable	O
levels	O
of	O
expression	O
of	O
Atm	O
were	O
observed	O
in	O
different	O
tissues	O
.	O

Fluorescence	O
in	O
situ	O
hybridization	O
and	O
linkage	O
analysis	O
located	O
the	O
Atm	O
gene	O
on	O
mouse	O
chromosome	O
9	O
,	O
band	O
9C	O
,	O
in	O
a	O
region	O
homologous	O
to	O
the	O
ATM	O
region	O
on	O
human	O
chromosome	O
11q22	O
-	O
q23	O
.	O
.	O

The	O
mouse	O
homolog	O
of	O
the	O
Wiskott	B-DISO
-	I-DISO
Aldrich	I-DISO
syndrome	E-DISO
protein	O
(	O
WASP	O
)	O
gene	O
is	O
highly	O
conserved	O
and	O
maps	O
near	O
the	O
scurfy	O
(	O
sf	O
)	O
mutation	O
on	O
the	O
X	O
chromosome	O
.	O

The	O
mouse	O
WASP	O
gene	O
,	O
the	O
homolog	O
of	O
the	O
gene	O
mutated	O
in	O
Wiskott	B-DISO
-	I-DISO
Aldrich	I-DISO
syndrome	E-DISO
,	O
has	O
been	O
isolated	O
and	O
sequenced	O
.	O
the	O
predicted	O
amino	O
acid	O
sequence	O
is	O
86	O
%	O
identical	O
to	O
the	O
human	O
WASP	O
sequence	O
.	O

A	O
distinct	O
feature	O
of	O
the	O
mouse	O
gene	O
is	O
an	O
expanded	O
polymorphic	O
GGA	O
trinucleotide	O
repeat	O
that	O
codes	O
for	O
polyglycine	O
and	O
varies	O
from	O
15	O
to	O
17	O
triplets	O
in	O
different	O
Mus	O
musculus	O
strains	O
.	O

The	O
genomic	O
structure	O
of	O
the	O
mouse	O
WASP	O
gene	O
is	O
expressed	O
as	O
an	O
approximately	O
2	O
.	O

4	O
-	O
kb	O
mRNA	O
in	O
thymus	O
and	O
spleen	O
.	O

Chromosomal	O
mapping	O
in	O
an	O
interspecific	O
M	O
.	O

Musculus	O
/	O
M	O
.	O
spretus	O
backcross	O
placed	O
the	O
Wasp	O
locus	O
near	O
the	O
centromere	O
of	O
the	O
mouse	O
X	O
chromosome	O
,	O
inseparable	O
from	O
Gata1	O
,	O
Tcfe3	O
,	O
and	O
scurfy	O
(	O
sf	O
)	O
.	O

This	O
localization	O
makes	O
Wasp	O
a	O
candidate	O
for	O
involvement	O
in	O
scurfy	O
,	O
a	O
T	O
cell	O
-	O
mediated	O
fatal	B-DISO
lymphoreticular	I-DISO
disease	E-DISO
of	O
mice	O
that	O
has	O
previously	O
been	O
proposed	O
as	O
a	O
mouse	O
homolog	O
of	O
Wiskott	B-DISO
-	I-DISO
Aldrich	I-DISO
syndrome	E-DISO
.	O

Northern	O
analysis	O
of	O
sf	O
tissue	O
samples	O
indicated	O
the	O
presence	O
of	O
WASP	O
mRNA	O
in	O
liver	O
and	O
skin	O
,	O
presumably	O
as	O
a	O
consequence	O
of	O
lymphocytic	O
infiltration	O
,	O
but	O
non	O
abnormalities	O
in	O
the	O
amount	O
or	O
size	O
of	O
mRNA	O
present	O
.	O

Colchicine	O
in	O
breast	O
milk	O
of	O
patients	O
with	O
familial	B-DISO
Mediterranean	I-DISO
fever	E-DISO
.	O

OBJECTIVE	O
.	O

To	O
clarify	O
whether	O
colchicine	O
is	O
excreted	O
in	O
breast	O
milk	O
,	O
and	O
to	O
compare	O
its	O
concentrations	O
in	O
the	O
serum	O
and	O
breast	O
milk	O
of	O
lactating	O
women	O
who	O
have	O
familial	B-DISO
Mediterranean	I-DISO
fever	E-DISO
(	O
FMF	S-DISO
)	O
.	O

METHODS	O
.	O

Using	O
a	O
specific	O
radioimmunoassay	O
,	O
we	O
determined	O
colchicine	O
concentrations	O
in	O
the	O
serum	O
and	O
breast	O
milk	O
of	O
4	O
patients	O
at	O
various	O
time	O
points	O
,	O
following	O
oral	O
administration	O
of	O
the	O
drug	O
.	O

The	O
study	O
evaluated	O
4	O
patients	O
with	O
FMF	S-DISO
who	O
had	O
been	O
taking	O
colchicine	O
on	O
a	O
long	O
-	O
term	O
basis	O
.	O

RESULTS	O
.	O

Colchicine	O
was	O
found	O
to	O
be	O
excreted	O
in	O
breast	O
milk	O
.	O

Its	O
levels	O
ranged	O
between	O
1	O
.	O

9	O
and	O
8	O
.	O

6	O
ng	O
/	O
ml	O
,	O
which	O
were	O
similar	O
to	O
those	O
found	O
in	O
the	O
serum	O
(	O
parallel	O
concentration	O
time	O
curves	O
)	O
.	O

However	O
,	O
there	O
appeared	O
to	O
be	O
a	O
considerable	O
variation	O
in	O
colchicine	O
milk	O
concentration	O
among	O
the	O
different	O
patients	O
,	O
which	O
might	O
be	O
related	O
to	O
individual	O
breast	O
milk	O
composition	O
and	O
,	O
possibly	O
,	O
to	O
other	O
nutritional	O
or	O
metabolic	O
factors	O
.	O

CONCLUSION	O
.	O

The	O
extensive	O
peripheral	O
tissue	O
binding	O
and	O
relatively	O
low	O
concentration	O
of	O
colchicine	O
in	O
breast	O
milk	O
suggests	O
that	O
the	O
amount	O
ingested	O
by	O
the	O
infant	O
is	O
small	O
.	O

Furthermore	O
,	O
based	O
on	O
our	O
clinical	O
experience	O
,	O
nursing	O
appears	O
to	O
be	O
safe	O
for	O
lactating	O
women	O
with	O
FMF	S-DISO
who	O
continue	O
to	O
take	O
colchicine	O
.	O

Abnormal	O
myotonic	B-DISO
dystrophy	E-DISO
protein	O
kinase	O
levels	O
produce	O
only	O
mild	O
myopathy	S-DISO
in	O
mice	O
.	O

Myotonic	B-DISO
dystrophy	E-DISO
(	O
DM	S-DISO
)	O
is	O
commonly	O
associated	O
with	O
CTG	O
repeat	O
expansions	O
within	O
the	O
gene	O
for	O
DM	O
-	O
protein	O
kinase	O
(	O
DMPK	O
)	O
.	O

The	O
effect	O
of	O
altered	O
expression	O
levels	O
of	O
DMPK	O
,	O
which	O
is	O
ubiquitously	O
expressed	O
in	O
all	O
muscle	O
cell	O
lineages	O
during	O
development	O
,	O
was	O
examined	O
by	O
disrupting	O
the	O
endogenous	O
Dmpk	O
gene	O
and	O
overexpressing	O
a	O
normal	O
human	O
DMPK	O
transgene	O
in	O
mice	O
.	O

Nullizygous	O
(	O
-	O
/	O
-	O
)	O
mice	O
showed	O
only	O
inconsistent	O
and	O
minor	O
size	O
changes	O
in	O
head	O
and	O
neck	O
muscle	O
fibres	O
at	O
older	O
age	O
,	O
animals	O
with	O
the	O
highest	O
DMPK	O
transgene	O
expression	O
showed	O
hypertrophic	B-DISO
cardiomyopathy	E-DISO
and	O
enhanced	O
neonatal	O
mortality	O
.	O

However	O
,	O
both	O
models	O
lack	O
other	O
frequent	O
DM	S-DISO
symptoms	O
including	O
the	O
fibre	O
-	O
type	O
dependent	O
atrophy	S-DISO
,	O
myotonia	S-DISO
,	O
cataract	S-DISO
and	O
male	B-DISO
-	I-DISO
infertility	E-DISO
.	O

These	O
results	O
strengthen	O
the	O
contention	O
that	O
simple	O
loss	O
-	O
or	O
gain	O
-	O
of	O
-	O
expression	O
of	O
DMPK	O
is	O
not	O
the	O
only	O
crucial	O
requirement	O
for	O
development	O
of	O
the	O
disease	O
.	O
.	O

Mice	O
lacking	O
the	O
myotonic	B-DISO
dystrophy	E-DISO
protein	O
kinase	O
develop	O
a	O
late	O
onset	O
progressive	O
myopathy	S-DISO
.	O

Myotonic	B-DISO
dystrophy	E-DISO
(	O
DM	S-DISO
)	O
is	O
an	O
autosomal	B-DISO
dominant	I-DISO
disorder	E-DISO
resulting	O
from	O
the	O
expansion	O
of	O
a	O
CTG	O
repeat	O
in	O
the	O
3	O
untranslated	O
region	O
of	O
a	O
putative	O
protein	O
kinase	O
(	O
DMPK	O
)	O
.	O

To	O
elucidate	O
the	O
role	O
of	O
DMPK	O
in	O
DM	S-DISO
pathogenesis	O
we	O
have	O
developed	O
Dmpk	B-DISO
deficient	E-DISO
(	O
Dmpk	O
-	O
/	O
-	O
)	O
mice	O
.	O

Dmpk	O
-	O
/	O
-	O
mice	O
develop	O
a	O
late	O
-	O
onset	O
,	O
progressive	B-DISO
skeletal	I-DISO
myopathy	E-DISO
that	O
shares	O
some	O
pathological	O
features	O
with	O
DM	S-DISO
.	O

Muscles	O
from	O
mature	O
mice	O
show	O
variation	O
in	O
fibre	O
size	O
,	O
increased	O
fibre	B-DISO
degeneration	E-DISO
and	O
fibrosis	S-DISO
.	O

Adult	O
Dmpk	O
-	O
/	O
-	O
mice	O
show	O
ultrastructural	O
changes	O
in	O
muscle	O
and	O
a	O
50	O
%	O
decrease	O
in	O
force	O
generation	O
compared	O
to	O
young	O
mice	O
.	O

Our	O
results	O
indicate	O
that	O
DMPK	O
may	O
be	O
necessary	O
for	O
the	O
maintenance	O
of	O
skeletal	O
muscle	O
structure	O
and	O
function	O
and	O
suggest	O
that	O
a	O
decrease	O
in	O
DMPK	O
levels	O
may	O
contribute	O
to	O
DM	S-DISO
pathology	O
.	O
.	O

The	O
tumor	S-DISO
suppressor	O
gene	O
Brca1	O
is	O
required	O
for	O
embryonic	O
cellular	O
proliferation	O
in	O
the	O
mouse	O
.	O

Mutations	O
of	O
the	O
BRCA1	O
gone	O
in	O
humans	O
are	O
associated	O
with	O
predisposition	O
to	O
breast	B-DISO
and	I-DISO
ovarian	I-DISO
cancers	E-DISO
.	O

We	O
show	O
here	O
that	O
Brca1	O
+	O
/	O
-	O
mice	O
are	O
normal	O
and	O
fertile	O
and	O
lack	O
tumors	S-DISO
by	O
age	O
eleven	O
months	O
.	O

Homozygous	O
Brca1	O
(	O
5	O
-	O
6	O
)	O
mutant	O
mice	O
die	O
before	O
day	O
7	O
.	O

5	O
of	O
embryogenesis	O
.	O

Mutant	O
embryos	O
are	O
poorly	O
developed	O
,	O
with	O
no	O
evidence	O
of	O
mesoderm	O
formation	O
.	O

The	O
extraembryonic	O
region	O
is	O
abnormal	O
,	O
but	O
aggregation	O
with	O
wild	O
-	O
type	O
tetraploid	O
embryos	O
does	O
not	O
rescue	O
the	O
lethality	O
.	O

In	O
vivo	O
,	O
mutant	O
embryos	O
do	O
not	O
exhibit	O
increased	O
apoptosis	O
but	O
show	O
reduced	O
cell	O
proliferation	O
accompanied	O
by	O
decreased	O
expression	O
of	O
cyclin	O
E	O
and	O
mdm	O
-	O
2	O
,	O
a	O
regulator	O
of	O
p53	O
activity	O
.	O

The	O
expression	O
of	O
cyclin	O
-	O
dependent	O
kinase	O
inhibitor	O
p21	O
is	O
dramatically	O
increased	O
in	O
the	O
mutant	O
embryos	O
.	O

Buttressing	O
these	O
in	O
vivo	O
observations	O
is	O
the	O
fact	O
that	O
mutant	O
blastocyst	O
growth	O
is	O
grossly	O
impaired	O
in	O
vitro	O
.	O

Thus	O
,	O
the	O
death	O
of	O
Brca1	O
(	O
5	O
-	O
6	O
)	O
mutant	O
embryos	O
prior	O
to	O
gastrulation	O
may	O
be	O
due	O
to	O
a	O
failure	O
of	O
the	O
proliferative	O
burst	O
required	O
for	O
the	O
development	O
of	O
the	O
different	O
germ	O
layers	O
.	O

Increased	O
coronary	B-DISO
heart	I-DISO
disease	E-DISO
in	O
Japanese	O
-	O
American	O
men	O
with	O
mutation	O
in	O
the	O
cholesteryl	O
ester	O
transfer	O
protein	O
gene	O
despite	O
increased	O
HDL	O
levels	O
.	O

Plasma	O
high	O
density	O
lipoprotein	O
(	O
HDL	O
)	O
levels	O
are	O
strongly	O
genetically	O
determined	O
and	O
show	O
a	O
general	O
inverse	O
relationship	O
with	O
coronary	B-DISO
heart	I-DISO
disease	E-DISO
(	O
CHD	S-DISO
)	O
.	O

The	O
cholesteryl	O
ester	O
transfer	O
protein	O
(	O
CETP	O
)	O
mediates	O
the	O
transfer	O
of	O
cholesteryl	O
esters	O
from	O
HDL	O
to	O
other	O
lipoproteins	O
and	O
is	O
a	O
key	O
participant	O
in	O
the	O
reverse	O
transport	O
of	O
cholesterol	O
from	O
the	O
periphery	O
to	O
the	O
liver	O
.	O

A	O
high	O
prevalence	O
of	O
two	O
different	O
CETP	O
gene	O
mutations	O
(	O
D442G	O
,	O
5	O
.	O
1	O
%	O
;	O
intron	O
14G	O
A	O
,	O
0	O
.	O
5	O
%	O
)	O
,	O
was	O
found	O
in	O
3	O
,	O
469	O
men	O
of	O
Japanese	O
ancestry	O
in	O
the	O
Honolulu	O
Heart	O
Program	O
and	O
mutations	O
were	O
associated	O
with	O
decreased	O
CETP	O
(	O
-	O
35	O
%	O
)	O
and	O
increased	O
HDL	O
chol	O
levels	O
(	O
+	O
10	O
%	O
for	O
D442G	O
)	O
.	O

However	O
,	O
the	O
overall	O
prevalence	O
of	O
definite	O
CHD	S-DISO
was	O
21	O
%	O
in	O
men	O
with	O
mutations	O
and	O
16	O
%	O
in	O
men	O
without	O
mutations	O
.	O

The	O
relative	O
risk	O
(	O
RR	O
)	O
of	O
CHD	S-DISO
was	O
1	O
.	O

43	O
in	O
men	O
with	O
mutations	O
(	O
P	O
<	O
.	O
05	O
)	O
;	O
after	O
adjustment	O
for	O
CHD	S-DISO
risk	O
factors	O
,	O
the	O
RR	O
was	O
1	O
.	O

55	O
(	O
P	O
=	O
.	O
02	O
)	O
;	O
after	O
additional	O
adjustment	O
for	O
HDL	O
levels	O
,	O
the	O
RR	O
was	O
1	O
.	O

68	O
(	O
P	O
=	O
.	O
008	O
)	O
.	O

Similar	O
RR	O
values	O
were	O
obtained	O
for	O
the	O
D442G	O
mutation	O
alone	O
.	O

Increased	O
CHD	S-DISO
in	O
men	O
with	O
mutations	O
was	O
primarily	O
observed	O
for	O
HDL	O
chol	O
41	O
-	O
60	O
mg	O
/	O
dl	O
;	O
for	O
HDL	O
chol	O
>	O
60	O
mg	O
/	O
dl	O
men	O
with	O
and	O
without	O
mutations	O
had	O
low	O
CHD	S-DISO
prevalence	O
.	O

Thus	O
,	O
genetic	O
CETP	B-DISO
deficiency	E-DISO
appears	O
to	O
be	O
an	O
independent	O
risk	O
factor	O
for	O
CHD	S-DISO
,	O
primarily	O
due	O
to	O
increased	O
CHD	S-DISO
prevalence	O
in	O
men	O
with	O
the	O
D442G	O
mutation	O
and	O
HDL	O
cholesterol	O
between	O
41	O
and	O
60	O
mg	O
/	O
dl	O
.	O

The	O
findings	O
suggest	O
that	O
both	O
HDL	O
concentration	O
and	O
the	O
dynamics	O
of	O
cholesterol	O
transport	O
through	O
HDL	O
(	O
i	O
.	O
e	O
.	O
,	O
reverse	O
cholesterol	O
transport	O
)	O
determine	O
the	O
anti	O
-	O
atherogenicity	O
of	O
the	O
HDL	O
fraction	O
.	O

Mapping	O
the	O
homolog	O
of	O
the	O
human	O
Rb1	O
gene	O
to	O
chromosome	O
14	O
of	O
higher	O
primates	O
.	O

The	O
Rb1	O
gene	O
has	O
been	O
implicated	O
with	O
retinoblastoma	S-DISO
and	O
is	O
located	O
on	O
human	O
Chromosome	O
(	O
Chr	O
)	O
13q14	O
.	O

2	O
2	O
.	O

A	O
unique	O
sequence	O
human	O
Rb1	O
cosmid	O
DNA	O
probe	O
has	O
been	O
used	O
to	O
localize	O
this	O
region	O
on	O
apes	O
Chr	O
14	O
by	O
the	O
FISH	O
technique	O
.	O

The	O
conservation	O
of	O
the	O
Rb1	O
gene	O
in	O
higher	O
primates	O
at	O
the	O
corresponding	O
equivalent	O
chromosome	O
locus	O
(	O
14q14	O
)	O
of	O
the	O
human	O
may	O
serve	O
as	O
a	O
phylogenetic	O
marker	O
to	O
further	O
trace	O
the	O
evolutionary	O
pathway	O
of	O
human	O
descent	O
.	O

Wiskott	B-DISO
-	I-DISO
Aldrich	I-DISO
syndrome	E-DISO
:	O
no	O
strict	O
genotype	O
-	O
phenotype	O
correlations	O
but	O
clustering	O
of	O
missense	O
mutations	O
in	O
the	O
amino	O
-	O
terminal	O
part	O
of	O
the	O
WASP	O
gene	O
product	O
.	O

The	O
Wiskott	B-DISO
-	I-DISO
Aldrich	I-DISO
syndrome	E-DISO
protein	O
(	O
WASP	O
)	O
gene	O
was	O
found	O
to	O
be	O
mutated	O
in	O
patients	O
presenting	O
with	O
WAS	S-DISO
and	O
in	O
patients	O
showing	O
X	B-DISO
-	I-DISO
linked	I-DISO
thrombocytopenia	E-DISO
.	O

Mutation	O
analysis	O
in	O
19	O
families	O
of	O
German	O
,	O
Swiss	O
and	O
Turkish	O
descent	O
by	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
and	O
sequencing	O
resulted	O
in	O
the	O
detection	O
of	O
seven	O
novel	O
and	O
10	O
known	O
mutations	O
.	O

A	O
striking	O
clustering	O
of	O
missense	O
mutations	O
in	O
the	O
first	O
four	O
exons	O
contrasted	O
with	O
a	O
random	O
distribution	O
of	O
nonsense	O
mutations	O
.	O

More	O
than	O
85	O
%	O
of	O
all	O
known	O
missense	O
mutations	O
were	O
localized	O
in	O
the	O
amino	O
-	O
terminal	O
stretch	O
of	O
the	O
WASP	O
gene	O
product	O
;	O
this	O
region	O
contained	O
a	O
mutational	O
hot	O
spot	O
at	O
codon	O
86	O
.	O

No	O
genotype	O
-	O
phenotype	O
correlation	O
emerged	O
after	O
a	O
comparison	O
of	O
the	O
identified	O
mutations	O
with	O
the	O
resulting	O
clinical	O
picture	O
for	O
a	O
classical	O
WAS	S-DISO
phenotype	O
.	O

A	O
substitution	O
at	O
codon	O
86	O
resulted	O
in	O
an	O
extremely	O
variable	O
expression	O
of	O
the	O
disease	O
in	O
a	O
large	O
Swiss	O
family	O
.	O

An	O
extended	O
homology	O
search	O
revealed	O
a	O
distant	O
relationship	O
of	O
this	O
stretch	O
to	O
the	O
vasodilator	O
-	O
stimulated	O
phosphoprotein	O
(	O
VASP	O
)	O
,	O
which	O
is	O
involved	O
in	O
the	O
maintenance	O
of	O
cyto	O
-	O
architecture	O
by	O
interacting	O
with	O
actin	O
-	O
like	O
filaments	O
.	O
.	O

Influence	O
of	O
PAX6	O
gene	O
dosage	O
on	O
development	O
:	O
overexpression	O
causes	O
severe	O
eye	B-DISO
abnormalities	E-DISO
.	O

Aniridia	S-DISO
in	O
man	O
and	O
Small	O
eye	O
in	O
mice	O
are	O
semidominant	B-DISO
developmental	I-DISO
disorders	E-DISO
caused	O
by	O
mutations	O
within	O
the	O
paired	O
box	O
gene	O
PAX6	O
.	O

Whereas	O
heterozygotes	O
suffer	O
from	O
iris	B-DISO
hypoplasia	E-DISO
,	O
homozygous	O
mice	O
lack	O
eyes	O
and	O
nasal	O
cavities	O
and	O
exhibit	O
brain	B-DISO
abnormalities	E-DISO
.	O

To	O
investigate	O
the	O
role	O
of	O
gene	O
dosage	O
in	O
more	O
detail	O
,	O
we	O
have	O
generated	O
yeast	O
artificial	O
chromosome	O
transgenic	O
mice	O
carrying	O
the	O
human	O
PAX6	O
locus	O
.	O

When	O
crossed	O
onto	O
the	O
Small	O
eye	O
background	O
,	O
the	O
transgene	O
rescues	O
the	O
mutant	O
phenotype	O
.	O

Strikingly	O
,	O
mice	O
carrying	O
multiple	O
copies	O
on	O
a	O
wild	O
-	O
type	O
background	O
show	O
specific	O
developmental	B-DISO
abnormalities	I-DISO
of	I-DISO
the	I-DISO
eye	E-DISO
,	O
but	O
not	O
of	O
other	O
tissues	O
expressing	O
the	O
gene	O
.	O

Thus	O
,	O
at	O
least	O
five	O
different	O
eye	O
phenotypes	O
are	O
associated	O
with	O
changes	O
in	O
PAX6	O
expression	O
.	O

We	O
provide	O
evidence	O
that	O
not	O
only	O
reduced	O
,	O
but	O
also	O
increased	O
levels	O
of	O
transcriptional	O
regulators	O
can	O
cause	O
developmental	B-DISO
defects	E-DISO
.	O
.	O

Heterodimer	O
formation	O
and	O
activity	O
in	O
the	O
human	O
enzyme	O
galactose	O
-	O
1	O
-	O
phosphate	O
uridylyltransferase	O
.	O

One	O
of	O
the	O
fundamental	O
questions	O
concerning	O
expression	O
and	O
function	O
of	O
dimeric	O
enzymes	O
involves	O
the	O
impact	O
of	O
naturally	O
occurring	O
mutations	O
on	O
subunit	O
assembly	O
and	O
heterodimer	O
activity	O
.	O

This	O
question	O
is	O
of	O
particular	O
interest	O
for	O
the	O
human	O
enzyme	O
galactose	O
-	O
l	O
-	O
phosphate	O
uridylyl	O
-	O
transferase	O
(	O
GALT	O
)	O
,	O
impairment	O
of	O
which	O
results	O
in	O
the	O
inherited	B-DISO
metabolic	I-DISO
disorder	E-DISO
galactosemia	S-DISO
,	O
because	O
many	O
if	O
not	O
most	O
patients	O
studied	O
to	O
date	O
are	O
compound	O
heterozygotes	O
rather	O
than	O
true	O
molecular	O
homozygotes	O
.	O

Furthermore	O
,	O
the	O
broad	O
range	O
of	O
phenotypic	O
severity	O
observed	O
in	O
these	O
patients	O
raises	O
the	O
possibility	O
that	O
allelic	O
combination	O
,	O
not	O
just	O
allelic	O
constitution	O
,	O
may	O
play	O
some	O
role	O
in	O
determining	O
outcome	O
.	O

In	O
the	O
work	O
described	O
herein	O
,	O
we	O
have	O
selected	O
two	O
distinct	O
naturally	O
occurring	O
null	O
mutations	O
of	O
GALT	O
,	O
Q188R	O
and	O
R333W	O
,	O
and	O
asked	O
the	O
questions	O
(	O
i	O
)	O
what	O
are	O
the	O
impacts	O
of	O
these	O
mutations	O
on	O
subunit	O
assembly	O
,	O
and	O
(	O
ii	O
)	O
if	O
heterodimers	O
do	O
form	O
,	O
are	O
they	O
active	O
?	O

To	O
answer	O
these	O
questions	O
,	O
we	O
have	O
established	O
a	O
yeast	O
system	O
for	O
the	O
coexpression	O
of	O
epitope	O
-	O
tagged	O
alleles	O
of	O
human	O
GALT	O
and	O
investigated	O
both	O
the	O
extent	O
of	O
specific	O
GALT	O
subunit	O
interactions	O
and	O
the	O
activity	O
of	O
defined	O
heterodimer	O
pools	O
.	O

We	O
have	O
found	O
that	O
both	O
homodimers	O
and	O
heterodimers	O
do	O
form	O
involving	O
each	O
of	O
the	O
mutant	O
subunits	O
tested	O
and	O
that	O
both	O
heterodimer	O
pools	O
retain	O
substantial	O
enzymatic	O
activity	O
.	O

These	O
results	O
are	O
significant	O
not	O
only	O
in	O
terms	O
of	O
their	O
implications	O
for	O
furthering	O
our	O
understanding	O
of	O
galactosemia	S-DISO
and	O
GALT	O
holoenzyme	O
structure	O
-	O
function	O
relationships	O
but	O
also	O
because	O
the	O
system	O
described	O
may	O
serve	O
as	O
a	O
model	O
for	O
similar	O
studies	O
of	O
other	O
complexes	O
composed	O
of	O
multiple	O
subunits	O
.	O
.	O

Cleavage	O
of	O
huntingtin	O
by	O
apopain	O
,	O
a	O
proapoptotic	O
cysteine	O
protease	O
,	O
is	O
modulated	O
by	O
the	O
polyglutamine	O
tract	O
.	O

Apoptosis	O
has	O
recently	O
been	O
recognized	O
as	O
a	O
mode	O
of	O
cell	O
death	O
in	O
Huntington	B-DISO
disease	E-DISO
(	O
HD	S-DISO
)	O
.	O

Apopain	O
,	O
a	O
human	O
counterpart	O
of	O
the	O
nematode	O
cysteine	O
protease	O
death	O
-	O
gene	O
product	O
,	O
CED	O
-	O
3	O
,	O
has	O
a	O
key	O
role	O
in	O
proteolytic	O
events	O
leading	O
to	O
apoptosis	O
.	O

Here	O
we	O
show	O
that	O
apoptotic	O
extracts	O
and	O
apopain	O
itself	O
specifically	O
cleave	O
the	O
HD	S-DISO
gene	O
product	O
,	O
huntingtin	O
.	O

The	O
rate	O
of	O
cleavage	O
increases	O
with	O
the	O
length	O
of	O
the	O
huntingtin	O
polyglutamine	O
tract	O
,	O
providing	O
an	O
explanation	O
for	O
the	O
gain	O
-	O
of	O
-	O
function	O
associated	O
with	O
CAG	O
expansion	O
.	O

Our	O
results	O
show	O
that	O
huntingtin	O
is	O
cleaved	O
by	O
cysteine	O
proteases	O
and	O
suggest	O
that	O
HD	S-DISO
might	O
be	O
a	O
disorder	B-DISO
of	I-DISO
inappropriate	I-DISO
apoptosis	E-DISO
.	O
.	O

The	O
5	O
'	O
end	O
of	O
the	O
BRCA1	O
gene	O
lies	O
within	O
a	O
duplicated	O
region	O
of	O
human	O
chromosome	O
17q21	O
.	O

To	O
begin	O
to	O
address	O
the	O
hypothesis	O
that	O
abnormal	O
regulation	O
of	O
the	O
breast	B-DISO
/	I-DISO
ovarian	I-DISO
cancer	E-DISO
susceptibility	O
gene	O
BRCA1	O
is	O
a	O
critical	O
step	O
in	O
sporadic	O
breast	O
/	O
ovarian	O
tumorigenesis	O
,	O
we	O
have	O
determined	O
the	O
detailed	O
structure	O
of	O
the	O
BRCA1	O
genomic	O
region	O
.	O

We	O
show	O
that	O
this	O
region	O
of	O
the	O
genome	O
contains	O
a	O
tandem	O
duplication	O
of	O
approximately	O
30	O
kilobases	O
,	O
which	O
results	O
in	O
two	O
copies	O
of	O
BRCA1	O
exons	O
1	O
and	O
2	O
,	O
of	O
exons	O
1	O
and	O
3	O
of	O
the	O
adjacent	O
1A1	O
-	O
3B	O
gene	O
and	O
of	O
the	O
previously	O
reported	O
295	O
base	O
pair	O
intergenic	O
region	O
.	O

Sequence	O
analysis	O
of	O
the	O
duplicated	O
exons	O
of	O
BRCA1	O
and	O
1A1	O
-	O
3B	O
and	O
flanking	O
genomic	O
DNA	O
reveals	O
maintenance	O
of	O
the	O
intron	O
-	O
exon	O
structure	O
and	O
a	O
high	O
degree	O
of	O
nucleotide	O
sequence	O
identity	O
,	O
suggesting	O
that	O
these	O
are	O
non	O
-	O
processed	O
pseudogenes	O
and	O
that	O
the	O
duplication	O
is	O
a	O
recent	O
event	O
in	O
evolutionary	O
terms	O
.	O

We	O
also	O
show	O
that	O
a	O
processed	O
pseudogene	O
of	O
the	O
acidic	O
ribosomal	O
phosphoprotein	O
P1	O
(	O
ARPP1	O
)	O
is	O
inserted	O
directly	O
upstream	O
of	O
pseudo	O
-	O
BRCA1	O
exon	O
1A	O
.	O

We	O
believe	O
that	O
these	O
findings	O
could	O
not	O
only	O
confound	O
BRCA1	O
mutation	O
analysis	O
,	O
but	O
could	O
have	O
implications	O
for	O
the	O
normal	O
and	O
abnormal	O
regulation	O
of	O
BRCA1	O
transcription	O
,	O
translation	O
and	O
function	O
.	O
.	O

Deletion	O
of	O
small	O
nuclear	O
ribonucleoprotein	O
polypeptide	O
N	O
(	O
SNRPN	O
)	O
in	O
Prader	B-DISO
-	I-DISO
Willi	I-DISO
syndrome	E-DISO
detected	O
by	O
fluorescence	O
in	O
situ	O
hybridization	O
:	O
two	O
sibs	O
with	O
the	O
typical	O
phenotype	O
without	O
a	O
cytogenetic	O
deletion	O
in	O
chromosome	O
15q	O
.	O

The	O
small	O
nuclear	O
ribonucleoprotein	O
polypeptide	O
N	O
(	O
SNRPN	O
)	O
gene	O
is	O
regarded	O
as	O
one	O
of	O
the	O
candidates	O
for	O
Prader	B-DISO
-	I-DISO
Willi	I-DISO
syndrome	E-DISO
(	O
PWS	S-DISO
)	O
.	O

We	O
describe	O
two	O
sibs	O
with	O
typical	O
PWS	S-DISO
presenting	O
deletion	O
of	O
SNRPN	O
detected	O
by	O
fluorescence	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
.	O

Neither	O
a	O
cytogenetically	O
detectable	O
15q12	O
deletion	O
nor	O
a	O
deletion	O
for	O
the	O
D15S11	O
,	O
D15S10	O
,	O
and	O
GABRB3	O
cosmid	O
probes	O
were	O
found	O
in	O
either	O
patient	O
.	O

This	O
implies	O
a	O
smaller	O
deletion	O
limited	O
to	O
the	O
PWS	S-DISO
critical	O
region	O
.	O

FISH	O
with	O
a	O
SNRPN	O
probe	O
will	O
permit	O
analysis	O
of	O
PWS	S-DISO
patients	O
with	O
limited	O
deletions	O
not	O
detectable	O
with	O
other	O
probes	O
.	O
.	O

Expression	O
of	O
the	O
von	B-DISO
Hippel	I-DISO
-	I-DISO
Lindau	I-DISO
disease	I-DISO
tumour	E-DISO
suppressor	O
gene	O
during	O
human	O
embryogenesis	O
.	O

The	O
von	B-DISO
Hippel	I-DISO
-	I-DISO
Lindau	I-DISO
(	I-DISO
VHL	I-DISO
)	I-DISO
disease	E-DISO
product	O
is	O
thought	O
to	O
down	O
-	O
regulate	O
transcription	O
by	O
antagonizing	O
elongin	O
-	O
enhanced	O
transcriptional	O
elongation	O
.	O

Germline	O
VHL	S-DISO
gene	O
mutations	O
predispose	O
to	O
the	O
development	O
of	O
retinal	B-DISO
,	I-DISO
cerebellar	I-DISO
and	I-DISO
spinal	I-DISO
haemangioblastomas	E-DISO
,	O
renal	B-DISO
cell	I-DISO
carcinoma	E-DISO
and	O
phaeochromocytoma	S-DISO
.	O

In	O
addition	O
,	O
somatic	O
Inactivation	O
of	O
the	O
VHL	S-DISO
gene	O
is	O
frequent	O
in	O
sporadic	B-DISO
renal	I-DISO
cell	I-DISO
carcinoma	E-DISO
and	O
haemangioblastoma	S-DISO
.	O

Regulation	O
of	O
transcript	O
elongation	O
is	O
an	O
important	O
control	O
mechanism	O
for	O
gene	O
expression	O
and	O
the	O
VHL	S-DISO
gene	O
might	O
modify	O
the	O
expression	O
of	O
proto	O
-	O
oncogenes	O
and	O
growth	O
suppressor	O
genes	O
during	O
embryogenesis	O
.	O

We	O
therefore	O
investigated	O
the	O
expression	O
of	O
VHL	S-DISO
mRNA	O
during	O
human	O
embryogenesis	O
by	O
in	O
situ	O
hybridization	O
studies	O
at	O
4	O
,	O
6	O
and	O
10	O
weeks	O
post	O
conception	O
.	O

Although	O
VHL	S-DISO
mRNA	O
was	O
expressed	O
in	O
all	O
three	O
germ	O
layers	O
,	O
strong	O
expression	O
was	O
noted	O
in	O
the	O
central	O
nervous	O
system	O
,	O
kidneys	O
,	O
testis	O
and	O
lung	O
.	O

Within	O
the	O
kidney	O
,	O
VHL	S-DISO
mRNA	O
was	O
differentially	O
expressed	O
within	O
renal	O
tubules	O
suggesting	O
that	O
the	O
VHL	S-DISO
gene	O
product	O
may	O
have	O
a	O
specific	O
role	O
in	O
kidney	O
development	O
.	O

Two	O
alternatively	O
spliced	O
VHL	S-DISO
mRNAs	O
characterized	O
by	O
inclusion	O
(	O
isoform	O
I	O
)	O
or	O
exclusion	O
(	O
isoform	O
II	O
)	O
of	O
exon	O
2	O
are	O
transcribed	O
in	O
adult	O
tissues	O
.	O

To	O
investigate	O
if	O
the	O
two	O
isoforms	O
are	O
differentially	O
expressed	O
during	O
embryogenesis	O
,	O
VHL	S-DISO
mRNA	O
was	O
reverse	O
transcribed	O
from	O
13	O
fetal	O
tissues	O
(	O
8	O
-	O
10	O
weeks	O
gestation	O
)	O
.	O

The	O
quantitative	O
distribution	O
of	O
VHL	S-DISO
mRNA	O
within	O
fetal	O
tissues	O
reflected	O
that	O
seen	O
by	O
in	O
situ	O
hybridization	O
and	O
the	O
ratio	O
of	O
the	O
two	O
VHL	S-DISO
isoforms	O
was	O
similar	O
between	O
tissues	O
.	O

Although	O
the	O
genes	O
regulated	O
by	O
the	O
VHL	S-DISO
gene	O
product	O
have	O
not	O
yet	O
been	O
identified	O
,	O
our	O
findings	O
are	O
compatible	O
with	O
the	O
hypothesis	O
that	O
VHL	S-DISO
-	O
mediated	O
control	O
of	O
transcriptional	O
elongation	O
may	O
have	O
a	O
role	O
in	O
normal	O
human	O
development	O
.	O
.	O

Genetic	O
heterogeneity	O
in	O
hereditary	B-DISO
breast	I-DISO
cancer	E-DISO
:	O
role	O
of	O
BRCA1	O
and	O
BRCA2	O
.	O

The	O
common	O
hereditary	O
forms	O
of	O
breast	B-DISO
cancer	E-DISO
have	O
been	O
largely	O
attributed	O
to	O
the	O
inheritance	O
of	O
mutations	O
in	O
the	O
BRCA1	O
or	O
BRCA2	O
genes	O
.	O

However	O
,	O
it	O
is	O
not	O
yet	O
clear	O
what	O
proportion	O
of	O
hereditary	B-DISO
breast	I-DISO
cancer	E-DISO
is	O
explained	O
by	O
BRCA1	O
and	O
BRCA2	O
or	O
by	O
some	O
other	O
unidentified	O
susceptibility	O
gene	O
(	O
s	O
)	O
.	O

We	O
describe	O
the	O
proportion	O
of	O
hereditary	B-DISO
breast	I-DISO
cancer	E-DISO
explained	O
by	O
BRCA1	O
or	O
BRCA2	O
in	O
a	O
sample	O
of	O
North	O
American	O
hereditary	B-DISO
breast	I-DISO
cancers	E-DISO
and	O
assess	O
the	O
evidence	O
for	O
additional	O
susceptibility	O
genes	O
that	O
may	O
confer	O
hereditary	B-DISO
breast	I-DISO
or	I-DISO
ovarian	I-DISO
cancer	E-DISO
risk	O
.	O

Twenty	O
-	O
three	O
families	O
were	O
identified	O
through	O
two	O
high	O
-	O
risk	O
breast	B-DISO
cancer	E-DISO
research	O
programs	O
.	O

Genetic	O
analysis	O
was	O
undertaken	O
to	O
establish	O
linkage	O
between	O
the	O
breast	B-DISO
or	I-DISO
ovarian	I-DISO
cancer	E-DISO
cases	O
and	O
markers	O
on	O
chromosomes	O
17q	O
(	O
BRCA1	O
)	O
and	O
13q	O
(	O
BRCA2	O
)	O
.	O

Mutation	O
analysis	O
in	O
the	O
BRCA1	O
and	O
BRCA2	O
genes	O
was	O
also	O
undertaken	O
in	O
all	O
families	O
.	O

The	O
pattern	O
of	O
hereditary	B-DISO
cancer	E-DISO
in	O
14	O
(	O
61	O
%	O
)	O
of	O
the	O
23	O
families	O
studied	O
was	O
attributed	O
to	O
BRCA1	O
by	O
a	O
combination	O
of	O
linkage	O
and	O
mutation	O
analyses	O
.	O

No	O
families	O
were	O
attributed	O
to	O
BRCA2	O
.	O

Five	O
families	O
(	O
22	O
%	O
)	O
provided	O
evidence	O
against	O
linkage	O
to	O
both	O
BRCA1	O
and	O
BRCA2	O
.	O

No	O
BRCA1	O
or	O
BRCA2	O
mutations	O
were	O
detected	O
in	O
these	O
five	O
families	O
.	O

The	O
BRCA1	O
or	O
BRCA2	O
status	O
of	O
four	O
families	O
(	O
17	O
%	O
)	O
could	O
not	O
be	O
determined	O
.	O

BRCA1	O
and	O
BRCA2	O
probably	O
explain	O
the	O
majority	O
of	O
hereditary	B-DISO
breast	I-DISO
cancer	E-DISO
that	O
exists	O
in	O
the	O
North	O
American	O
population	O
.	O

However	O
,	O
one	O
or	O
more	O
additional	O
genes	O
may	O
yet	O
be	O
found	O
that	O
explain	O
some	O
proportion	O
of	O
hereditary	B-DISO
breast	I-DISO
cancer	E-DISO
.	O
.	O

An	O
intronic	O
mutation	O
in	O
a	O
lariat	O
branchpoint	O
sequence	O
is	O
a	O
direct	O
cause	O
of	O
an	O
inherited	B-DISO
human	I-DISO
disorder	E-DISO
(	O
fish	B-DISO
-	I-DISO
eye	I-DISO
disease	E-DISO
)	O
.	O

The	O
first	O
step	O
in	O
the	O
splicing	O
of	O
an	O
intron	O
from	O
nuclear	O
precursors	O
of	O
mRNA	O
results	O
in	O
the	O
formation	O
of	O
a	O
lariat	O
structure	O
.	O

A	O
distinct	O
intronic	O
nucleotide	O
sequence	O
,	O
known	O
as	O
the	O
branchpoint	O
region	O
,	O
plays	O
a	O
central	O
role	O
in	O
this	O
process	O
.	O

We	O
here	O
describe	O
a	O
point	O
mutation	O
in	O
such	O
a	O
sequence	O
.	O

Three	O
sisters	O
were	O
shown	O
to	O
suffer	O
from	O
fish	B-DISO
-	I-DISO
eye	I-DISO
disease	E-DISO
(	O
FED	S-DISO
)	O
,	O
a	O
disorder	O
which	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
gene	O
coding	O
for	O
lecithin	O
cholesterol	O
acyltransferase	O
(	O
LCAT	O
)	O
.	O

Sequencing	O
of	O
the	O
LCAT	O
gene	O
of	O
all	O
three	O
probands	O
revealed	O
compound	O
heterozygosity	O
for	O
a	O
missense	O
mutation	O
in	O
exon	O
4	O
which	O
is	O
reported	O
to	O
underlie	O
the	O
FED	S-DISO
phenotype	O
,	O
and	O
a	O
point	O
mutation	O
located	O
in	O
intron	O
4	O
(	O
IVS4	O
T	O
-	O
22C	O
)	O
.	O

By	O
performing	O
in	O
vitro	O
expression	O
of	O
LCAT	O
minigenes	O
and	O
reverse	O
transcriptase	O
PCR	O
on	O
mRNA	O
isolated	O
from	O
leukocytes	O
of	O
the	O
patient	O
,	O
this	O
gene	O
defect	O
was	O
shown	O
to	O
cause	O
a	O
null	O
allele	O
as	O
the	O
result	O
of	O
complete	O
intron	O
retention	O
.	O

In	O
conclusion	O
,	O
we	O
demonstrated	O
that	O
a	O
point	O
mutation	O
in	O
a	O
lariat	O
branchpoint	O
consensus	O
sequence	O
causes	O
a	O
null	O
allele	O
in	O
a	O
patient	O
with	O
FED	S-DISO
.	O

In	O
addition	O
,	O
our	O
finding	O
illustrates	O
the	O
importance	O
of	O
this	O
sequence	O
for	O
normal	O
human	O
mRNA	O
processing	O
.	O

Finally	O
,	O
this	O
report	O
provides	O
a	O
widely	O
applicable	O
strategy	O
which	O
ensures	O
fast	O
and	O
effective	O
screening	O
for	O
intronic	O
defects	O
that	O
underlie	O
differential	O
gene	O
expression	O
.	O
.	O

Mutations	O
associated	O
with	O
variant	O
phenotypes	O
in	O
ataxia	B-DISO
-	I-DISO
telangiectasia	E-DISO
.	O

We	O
have	O
identified	O
14	O
families	O
with	O
ataxia	B-DISO
-	I-DISO
telangiectasia	E-DISO
(	O
A	B-DISO
-	I-DISO
T	E-DISO
)	O
in	O
which	O
mutation	O
of	O
the	O
ATM	O
gene	O
is	O
associated	O
with	O
a	O
less	O
severe	O
clinical	O
and	O
cellular	O
phenotype	O
(	O
approximately	O
10	O
%	O
-	O
15	O
%	O
of	O
A	B-DISO
-	I-DISO
T	E-DISO
families	O
identified	O
in	O
the	O
United	O
Kingdom	O
)	O
.	O

In	O
10	O
of	O
these	O
families	O
,	O
all	O
the	O
homozygotes	O
have	O
a	O
137	O
-	O
bp	O
insertion	O
in	O
their	O
cDNA	O
caused	O
by	O
a	O
point	O
mutation	O
in	O
a	O
sequence	O
resembling	O
a	O
splice	O
-	O
donor	O
site	O
.	O

The	O
second	O
A	B-DISO
-	I-DISO
T	E-DISO
allele	O
has	O
a	O
different	O
mutation	O
in	O
each	O
patient	O
.	O

We	O
show	O
that	O
the	O
less	O
severe	O
phenotype	O
in	O
these	O
patients	O
is	O
caused	O
by	O
some	O
degree	O
of	O
normal	O
splicing	O
,	O
which	O
occurs	O
as	O
an	O
alternative	O
product	O
from	O
the	O
insertion	O
-	O
containing	O
allele	O
.	O

The	O
level	O
of	O
the	O
137	O
-	O
bp	O
PCR	O
product	O
containing	O
the	O
insertion	O
was	O
lowest	O
in	O
two	O
patients	O
who	O
showed	O
a	O
later	O
onset	O
of	O
cerebellar	B-DISO
ataxia	E-DISO
.	O

A	O
further	O
four	O
families	O
who	O
do	O
not	O
have	O
this	O
insertion	O
have	O
been	O
identified	O
.	O

Mutations	O
detected	O
in	O
two	O
of	O
four	O
of	O
these	O
are	O
missense	O
mutations	O
,	O
normally	O
rare	O
in	O
A	B-DISO
-	I-DISO
T	E-DISO
patients	O
.	O

The	O
demonstration	O
of	O
mutations	O
giving	O
rise	O
to	O
a	O
slightly	O
milder	O
phenotype	O
in	O
A	B-DISO
-	I-DISO
T	E-DISO
raises	O
the	O
interesting	O
question	O
of	O
what	O
range	O
of	O
phenotypes	O
might	O
occur	O
in	O
individuals	O
in	O
whom	O
both	O
mutations	O
are	O
milder	O
.	O

One	O
possibility	O
might	O
be	O
that	O
individuals	O
who	O
are	O
compound	O
heterozygotes	O
for	O
ATM	O
mutations	O
are	O
more	O
common	O
than	O
we	O
realize	O
.	O
.	O

Mutation	O
of	O
the	O
VHL	O
gene	O
is	O
associated	O
exclusively	O
with	O
the	O
development	O
of	O
non	B-DISO
-	I-DISO
papillary	I-DISO
renal	I-DISO
cell	I-DISO
carcinomas	E-DISO
.	O

To	O
define	O
the	O
possible	O
role	O
of	O
the	O
VHL	S-DISO
gene	O
in	O
the	O
development	O
of	O
sporadic	B-DISO
renal	I-DISO
cell	I-DISO
carcinomas	E-DISO
,	O
91	O
different	O
parenchymal	B-DISO
tumours	I-DISO
of	I-DISO
the	I-DISO
kidney	E-DISO
have	O
been	O
investigated	O
for	O
mutation	O
of	O
the	O
VHL	S-DISO
gene	O
by	O
single	O
strand	O
conformation	O
polymorphism	O
(	O
SSCP	O
)	O
and	O
/	O
or	O
heteroduplex	O
(	O
HD	O
)	O
techniques	O
.	O

Chromosome	O
3p	O
deletion	O
was	O
detected	O
in	O
98	O
per	O
cent	O
of	O
non	B-DISO
-	I-DISO
papillary	I-DISO
renal	I-DISO
cell	I-DISO
carcinomas	E-DISO
and	O
in	O
25	O
per	O
cent	O
of	O
chromophobe	O
renal	B-DISO
cell	I-DISO
carcinomas	E-DISO
.	O

In	O
22	O
of	O
the	O
43	O
non	B-DISO
-	I-DISO
papillary	I-DISO
renal	I-DISO
cell	I-DISO
carcinomas	E-DISO
,	O
abnormally	O
migrating	O
DNA	O
bands	O
were	O
detected	O
by	O
SSCP	O
and	O
/	O
or	O
HD	O
analysis	O
.	O

No	O
mobility	O
shift	O
was	O
seen	O
in	O
any	O
of	O
the	O
23	O
chromophobe	O
renal	B-DISO
cell	I-DISO
carcinomas	E-DISO
.	O

In	O
addition	O
,	O
15	O
papillary	B-DISO
renal	I-DISO
cell	I-DISO
tumours	E-DISO
and	O
ten	O
renal	B-DISO
oncocytomas	E-DISO
,	O
which	O
are	O
characterized	O
by	O
genetic	O
changes	O
other	O
than	O
loss	O
of	O
chromosome	O
3p	O
sequences	O
,	O
were	O
analysed	O
for	O
mutation	O
of	O
the	O
VHL	S-DISO
gene	O
.	O

None	O
of	O
these	O
tumours	S-DISO
showed	O
abnormal	O
migration	O
patterns	O
.	O

The	O
results	O
indicate	O
that	O
mutation	O
of	O
the	O
VHL	S-DISO
gene	O
is	O
associated	O
exclusively	O
with	O
the	O
development	O
of	O
non	B-DISO
-	I-DISO
papillary	I-DISO
renal	I-DISO
cell	I-DISO
carcinoma	E-DISO
.	O
.	O

The	O
Emery	B-DISO
-	I-DISO
Dreifuss	I-DISO
muscular	I-DISO
dystrophy	E-DISO
protein	O
,	O
emerin	O
,	O
is	O
a	O
nuclear	O
membrane	O
protein	O
.	O

A	O
large	O
fragment	O
of	O
emerin	O
cDNA	O
was	O
prepared	O
by	O
PCR	O
and	O
expressed	O
as	O
a	O
recombinant	O
protein	O
in	O
Escherichia	O
coli	O
.	O

Using	O
this	O
as	O
immunogen	O
,	O
we	O
prepared	O
a	O
panel	O
of	O
12	O
monoclonal	O
antibodies	O
which	O
recognise	O
at	O
least	O
four	O
different	O
epitopes	O
on	O
emerin	O
in	O
order	O
to	O
ensure	O
that	O
emerin	O
can	O
be	O
distinguished	O
from	O
non	O
-	O
specific	O
cross	O
-	O
reacting	O
proteins	O
.	O

All	O
the	O
mAbs	O
recognised	O
a	O
34	O
kDa	O
protein	O
in	O
all	O
tissues	O
tested	O
,	O
though	O
minor	O
emerin	O
-	O
related	O
bands	O
were	O
also	O
detected	O
in	O
some	O
tissues	O
.	O

Immunofluorescence	O
microscopy	O
showed	O
that	O
emerin	O
is	O
located	O
at	O
the	O
nuclear	O
rim	O
in	O
all	O
tissues	O
examined	O
.	O

A	O
muscle	O
biopsy	O
from	O
an	O
Emery	B-DISO
-	I-DISO
Dreifuss	I-DISO
muscular	I-DISO
dystrophy	E-DISO
(	O
EMDM	S-DISO
)	O
patient	O
showed	O
complete	O
absence	O
of	O
emerin	O
by	O
both	O
Western	O
blotting	O
and	O
immunohistochemistry	O
,	O
suggesting	O
a	O
simple	O
diagnostic	O
antibody	O
test	O
for	O
EDMD	S-DISO
families	O
.	O

Biochemical	O
fractionation	O
of	O
brain	O
and	O
liver	O
tissues	O
showed	O
that	O
emerin	O
was	O
present	O
in	O
nuclei	O
purified	O
by	O
centrifugation	O
through	O
65	O
%	O
sucrose	O
and	O
was	O
absent	O
from	O
soluble	O
fractions	O
(	O
post	O
-	O
100	O
,	O
000	O
g	O
)	O
.	O

From	O
these	O
results	O
,	O
together	O
with	O
sequence	O
and	O
structural	O
homologies	O
between	O
emerin	O
,	O
thymopoietins	O
and	O
the	O
nuclear	O
lamina	O
-	O
associated	O
protein	O
,	O
LAP2	O
,	O
we	O
suggest	O
that	O
emerin	O
will	O
prove	O
to	O
be	O
one	O
member	O
of	O
a	O
family	O
of	O
inner	O
nuclear	O
membrane	O
proteins	O
.	O
.	O

Mutation	O
of	O
MSH3	O
in	O
endometrial	B-DISO
cancer	E-DISO
and	O
evidence	O
for	O
its	O
functional	O
role	O
in	O
heteroduplex	O
repair	O
.	O

Many	O
human	O
tumours	S-DISO
have	O
length	O
alterations	O
in	O
repetitive	O
sequence	O
elements	O
.	O

Although	O
this	O
microsatellite	B-DISO
instability	E-DISO
has	O
been	O
attributed	O
to	O
mutations	O
in	O
four	O
DNA	O
mismatch	O
repair	O
genes	O
in	O
hereditary	B-DISO
nonpolyposis	I-DISO
colorectal	I-DISO
cancer	E-DISO
(	O
HNPCC	S-DISO
)	O
kindreds	O
,	O
many	O
sporadic	B-DISO
tumours	E-DISO
exhibit	O
instability	O
but	O
no	O
detectable	O
mutations	O
in	O
these	O
genes	O
.	O

It	O
is	O
therefore	O
of	O
interest	O
to	O
identify	O
other	O
genes	O
that	O
contribute	O
to	O
this	O
instability	O
.	O

In	O
yeast	O
,	O
mutations	O
in	O
several	O
genes	O
,	O
including	O
RTH	O
and	O
MSH3	O
,	O
cause	O
microsatellite	O
instability	O
.	O

Thus	O
,	O
we	O
screened	O
16	O
endometrial	B-DISO
carcinomas	E-DISO
with	O
microsatellite	O
instability	O
for	O
alterations	O
in	O
FEN1	O
(	O
the	O
human	O
homolog	O
of	O
RTH	O
)	O
and	O
in	O
MSH3	O
(	O
refs	O
12	O
-	O
14	O
)	O
.	O

Although	O
we	O
found	O
no	O
FEN1	O
mutations	O
,	O
a	O
frameshift	O
mutation	O
in	O
MSH3	O
was	O
observed	O
in	O
an	O
endometrial	B-DISO
carcinoma	E-DISO
and	O
in	O
an	O
endometrial	B-DISO
carcinoma	E-DISO
cell	O
line	O
.	O

Extracts	O
of	O
the	O
cell	O
line	O
were	O
deficient	O
in	O
repair	O
of	O
DNA	O
substrates	O
containing	O
mismatches	O
or	O
extra	O
nucleotides	O
.	O

Introducing	O
chromosome	O
5	O
,	O
encoding	O
the	O
MSH3	O
gene	O
,	O
into	O
the	O
mutant	O
cell	O
line	O
increased	O
the	O
stability	O
of	O
some	O
but	O
not	O
all	O
microsatellites	O
.	O

Extracts	O
of	O
these	O
cells	O
repaired	O
certain	O
substrates	O
containing	O
extra	O
nucleotides	O
,	O
but	O
were	O
deficient	O
in	O
repair	O
of	O
those	O
containing	O
mismatches	O
or	O
other	O
extra	O
nucleotides	O
.	O

A	O
subsequent	O
search	O
revealed	O
a	O
second	O
gene	O
mutation	O
in	O
HHUA	O
cells	O
,	O
a	O
missense	O
mutation	O
in	O
the	O
MSH6	O
gene	O
.	O

Together	O
the	O
data	O
suggest	O
that	O
the	O
MSH3	O
gene	O
encodes	O
a	O
product	O
that	O
functions	O
in	O
repair	O
of	O
some	O
but	O
not	O
all	O
pre	O
-	O
mutational	O
intermediates	O
,	O
its	O
mutation	O
in	O
tumours	S-DISO
can	O
result	O
in	O
genomic	O
instability	O
and	O
,	O
as	O
in	O
yeast	O
,	O
MSH3	O
and	O
MSH6	O
are	O
partially	O
redundant	O
for	O
mismatch	O
repair	O
.	O
.	O

Comparative	O
genome	O
mapping	O
of	O
the	O
ataxia	B-DISO
-	I-DISO
telangiectasia	E-DISO
region	O
in	O
mouse	O
,	O
rat	O
,	O
and	O
Syrian	O
hamster	O
.	O

Chromosomal	O
locations	O
of	O
the	O
Atm	O
(	O
ataxia	B-DISO
-	I-DISO
telangiectasia	E-DISO
(	O
AT	S-DISO
)	O
-	O
mutated	O
)	O
and	O
Acat1	O
(	O
mitochondrial	O
acetoacetyl	O
-	O
CoA	O
thiolase	O
)	O
genes	O
in	O
mouse	O
,	O
rat	O
,	O
and	O
Syrian	O
hamster	O
were	O
determined	O
by	O
direct	O
R	O
-	O
banding	O
FISH	O
.	O

Both	O
genes	O
were	O
colocalized	O
to	O
the	O
C	O
-	O
D	O
band	O
of	O
mouse	O
chromosome	O
9	O
,	O
the	O
proximal	O
end	O
of	O
q24	O
.	O

1	O
of	O
rat	O
chromosome	O
8	O
,	O
and	O
qa4	O
-	O
qa5	O
of	O
Syrian	O
hamster	O
chromosome	O
12	O
.	O

The	O
regions	O
in	O
the	O
mouse	O
and	O
rat	O
were	O
homologous	O
to	O
human	O
chromosome	O
11q	O
.	O

Fine	O
genetic	O
linkage	O
mapping	O
of	O
the	O
mouse	O
AT	S-DISO
region	O
was	O
performed	O
using	O
the	O
interspecific	O
backcross	O
mice	O
.	O

Atm	O
,	O
Acat1	O
,	O
and	O
Npat	O
,	O
which	O
is	O
a	O
new	O
gene	O
isolated	O
from	O
the	O
AT	O
region	O
,	O
and	O
12	O
flanking	O
microsatellite	O
DNA	O
markers	O
were	O
examined	O
.	O

No	O
recombinations	O
were	O
found	O
among	O
the	O
Atm	O
,	O
Npat	O
,	O
Acat1	O
,	O
and	O
D9Mit6	O
loci	O
,	O
and	O
these	O
loci	O
were	O
mapped	O
2	O
.	O

0	O
cM	O
distal	O
to	O
D9Mit99	O
and	O
1	O
.	O

3	O
cM	O
proximal	O
to	O
D9Mit102	O
.	O

Comparison	O
of	O
the	O
linkage	O
map	O
of	O
mouse	O
chromosome	O
9	O
(	O
MMU9	O
)	O
and	O
that	O
of	O
human	O
chromosome	O
11	O
(	O
HSA11	O
)	O
indicates	O
that	O
there	O
is	O
a	O
chromosomal	O
rearrangement	O
due	O
to	O
an	O
inversion	O
between	O
Ets1	O
and	O
Atm	O
-	O
Npat	O
-	O
Acat1	O
and	O
that	O
the	O
inversion	O
of	O
MMU9	O
originated	O
from	O
the	O
chromosomal	O
breakage	O
at	O
the	O
boundary	O
between	O
Gria4	O
and	O
Atm	O
-	O
Npat	O
-	O
Acat1	O
on	O
HSA11	O
.	O

This	O
type	O
of	O
inversion	O
appeared	O
to	O
be	O
conserved	O
in	O
the	O
three	O
rodent	O
species	O
,	O
mouse	O
,	O
rat	O
,	O
and	O
Syrian	O
hamster	O
,	O
using	O
additional	O
comparative	O
mapping	O
data	O
with	O
the	O
Rck	O
gene	O

An	O
animal	O
model	O
for	O
Norrie	B-DISO
disease	E-DISO
(	O
ND	S-DISO
)	O
:	O
gene	O
targeting	O
of	O
the	O
mouse	O
ND	S-DISO
gene	O
.	O

In	O
order	O
to	O
elucidate	O
the	O
cellular	O
and	O
molecular	O
processes	O
which	O
are	O
involved	O
in	O
Norrie	B-DISO
disease	E-DISO
(	O
ND	S-DISO
)	O
,	O
we	O
have	O
used	O
gene	O
targeting	O
technology	O
to	O
generate	O
ND	S-DISO
mutant	O
mice	O
.	O

The	O
murine	O
homologue	O
of	O
the	O
ND	S-DISO
gene	O
was	O
cloned	O
and	O
shown	O
to	O
encode	O
a	O
polypeptide	O
that	O
shares	O
94	O
%	O
of	O
the	O
amino	O
acid	O
sequence	O
with	O
its	O
human	O
counterpart	O
.	O

RNA	O
in	O
situ	O
hybridization	O
revealed	O
expression	O
in	O
retina	O
,	O
brain	O
and	O
the	O
olfactory	O
bulb	O
and	O
epithelium	O
of	O
2	O
week	O
old	O
mice	O
.	O

Hemizygous	O
mice	O
carrying	O
a	O
replacement	O
mutation	O
in	O
exon	O
2	O
of	O
the	O
ND	S-DISO
gene	O
developed	O
retrolental	O
structures	O
in	O
the	O
vitreous	O
body	O
and	O
showed	O
an	O
overall	O
disorganization	O
of	O
the	O
retinal	O
ganglion	O
cell	O
layer	O
.	O

The	O
outer	O
plexiform	O
layer	O
disappears	O
occasionally	O
,	O
resulting	O
in	O
a	O
juxtaposed	O
inner	O
and	O
outer	O
nuclear	O
layer	O
.	O

At	O
the	O
same	O
regions	O
,	O
the	O
outer	O
segments	O
of	O
the	O
photoreceptor	O
cell	O
layer	O
are	O
no	O
longer	O
present	O
.	O

These	O
ocular	O
findings	O
are	O
consistent	O
with	O
observations	O
in	O
ND	S-DISO
patients	O
and	O
the	O
generated	O
mouse	O
line	O
provides	O
a	O
faithful	O
model	O
for	O
study	O
of	O
early	O
pathogenic	O
events	O
in	O
this	O
severe	O
X	B-DISO
-	I-DISO
linked	I-DISO
recessive	I-DISO
neurological	I-DISO
disorder	E-DISO
.	O
.	O

The	O
hybrid	O
PAX3	O
-	O
FKHR	O
fusion	O
protein	O
of	O
alveolar	B-DISO
rhabdomyosarcoma	E-DISO
transforms	O
fibroblasts	O
in	O
culture	O
.	O

Pediatric	B-DISO
alveolar	I-DISO
rhabdomyosarcoma	E-DISO
is	O
characterized	O
by	O
a	O
chromosomal	O
translocation	O
that	O
fuses	O
parts	O
of	O
the	O
PAX3	O
and	O
FKHR	O
genes	O
.	O

PAX3	O
codes	O
for	O
a	O
transcriptional	O
regulator	O
that	O
controls	O
developmental	O
programs	O
,	O
and	O
FKHR	O
codes	O
for	O
a	O
forkhead	O
-	O
winged	O
helix	O
protein	O
,	O
also	O
a	O
likely	O
transcription	O
factor	O
.	O

The	O
PAX3	O
-	O
FKHR	O
fusion	O
product	O
retains	O
the	O
DNA	O
binding	O
domains	O
of	O
the	O
PAX3	O
protein	O
and	O
the	O
putative	O
activator	O
domain	O
of	O
the	O
FKHR	O
protein	O
.	O

The	O
PAX3	O
-	O
FKHR	O
protein	O
has	O
been	O
shown	O
to	O
function	O
as	O
a	O
transcriptional	O
activator	O
.	O

Using	O
the	O
RCAS	O
retroviral	O
vector	O
,	O
we	O
have	O
introduced	O
the	O
PAX3	O
-	O
FKHR	O
gene	O
into	O
chicken	O
embryo	O
fibroblasts	O
.	O

Expression	O
of	O
the	O
PAX3	O
-	O
FKHR	O
protein	O
in	O
these	O
cells	O
leads	O
to	O
transformation	O
the	O
cells	O
become	O
enlarged	O
,	O
grow	O
tightly	O
packed	O
and	O
in	O
multiple	O
layers	O
,	O
and	O
acquire	O
the	O
ability	O
for	O
anchorage	O
-	O
independent	O
growth	O
.	O

This	O
cellular	O
transformation	O
in	O
vitro	O
will	O
facilitate	O
studies	O
on	O
the	O
mechanism	O
of	O
PAX3	O
-	O
FKHR	O
-	O
induced	O
oncogenesis	O
.	O
.	O

Somatic	O
-	O
cell	O
selection	O
is	O
a	O
major	O
determinant	O
of	O
the	O
blood	O
-	O
cell	O
phenotype	O
in	O
heterozygotes	O
for	O
glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
mutations	O
causing	O
severe	O
enzyme	B-DISO
deficiency	E-DISO
.	O

X	O
-	O
chromosome	O
inactivation	O
in	O
mammals	O
is	O
regarded	O
as	O
an	O
essentially	O
random	O
process	O
,	O
but	O
the	O
resulting	O
somatic	O
-	O
cell	O
mosaicism	O
creates	O
the	O
opportunity	O
for	O
cell	O
selection	O
.	O

In	O
most	O
people	O
with	O
red	O
-	O
blood	O
-	O
cell	O
glucose	B-DISO
-	I-DISO
6	I-DISO
-	I-DISO
phosphate	I-DISO
dehydrogenase	I-DISO
(	I-DISO
G6PD	I-DISO
)	I-DISO
deficiency	E-DISO
,	O
the	O
enzyme	O
-	O
deficient	O
phenotype	O
is	O
only	O
moderately	O
expressed	O
in	O
nucleated	O
cells	O
.	O

However	O
,	O
in	O
a	O
small	O
subset	O
of	O
hemizygous	O
males	O
who	O
suffer	O
from	O
chronic	B-DISO
nonspherocytic	I-DISO
hemolytic	I-DISO
anemia	E-DISO
,	O
the	O
underlying	O
mutations	O
(	O
designated	O
class	O
I	O
)	O
cause	O
more	O
-	O
severe	O
G6PD	B-DISO
deficiency	E-DISO
,	O
and	O
this	O
might	O
provide	O
an	O
opportunity	O
for	O
selection	O
in	O
heterozygous	O
females	O
during	O
development	O
.	O

In	O
order	O
to	O
test	O
this	O
possibility	O
we	O
have	O
analyzed	O
four	O
heterozygotes	O
for	O
class	O
I	O
G6PD	O
mutations	O
two	O
with	O
G6PD	O
Portici	O
(	O
1178G	O
-	O
-	O
>	O
A	O
)	O
and	O
two	O
with	O
G6PD	O
Bari	O
(	O
1187C	O
-	O
-	O
>	O
T	O
)	O
.	O

We	O
found	O
that	O
in	O
fractionated	O
blood	O
cell	O
types	O
(	O
including	O
erythroid	O
,	O
myeloid	O
,	O
and	O
lymphoid	O
cell	O
lineages	O
)	O
there	O
was	O
a	O
significant	O
excess	O
of	O
G6PD	O
-	O
normal	O
cells	O
.	O

The	O
significant	O
concordance	O
that	O
we	O
have	O
observed	O
in	O
the	O
degree	O
of	O
imbalance	O
in	O
the	O
different	O
blood	O
-	O
cell	O
lineages	O
indicates	O
that	O
a	O
selective	O
mechanism	O
is	O
likely	O
to	O
operate	O
at	O
the	O
level	O
of	O
pluripotent	O
blood	O
stem	O
cells	O
.	O

Thus	O
,	O
it	O
appears	O
that	O
severe	O
G6PD	B-DISO
deficiency	E-DISO
affects	O
adversely	O
the	O
proliferation	O
or	O
the	O
survival	O
of	O
nucleated	O
blood	O
cells	O
and	O
that	O
this	O
phenotypic	O
characteristic	O
is	O
critical	O
during	O
hematopoiesis	O
.	O
.	O

Analysis	O
of	O
meiotic	O
segregation	O
,	O
using	O
single	O
-	O
sperm	O
typing	O
:	O
meiotic	O
drive	O
at	O
the	O
myotonic	B-DISO
dystrophy	E-DISO
locus	O
.	O

Meiotic	O
drive	O
at	O
the	O
myotonic	B-DISO
dystrophy	E-DISO
(	O
DM	S-DISO
)	O
locus	O
has	O
recently	O
been	O
suggested	O
as	O
being	O
responsible	O
for	O
maintaining	O
the	O
frequency	O
,	O
in	O
the	O
human	O
population	O
,	O
of	O
DM	S-DISO
chromosomes	O
capable	O
of	O
expansion	O
to	O
the	O
disease	O
state	O
.	O

In	O
order	O
to	O
test	O
this	O
hypothesis	O
,	O
we	O
have	O
studied	O
samples	O
of	O
single	O
sperm	O
from	O
three	O
individuals	O
heterozygous	O
at	O
the	O
DM	S-DISO
locus	O
,	O
each	O
with	O
one	O
allele	O
larger	O
and	O
one	O
allele	O
smaller	O
than	O
19	O
CTG	O
repeats	O
.	O

To	O
guard	O
against	O
the	O
possible	O
problem	O
of	O
differential	O
PCR	O
amplification	O
rates	O
based	O
on	O
the	O
lengths	O
of	O
the	O
alleles	O
,	O
the	O
sperm	O
were	O
also	O
typed	O
at	O
another	O
closely	O
linked	O
marker	O
whose	O
allele	O
size	O
was	O
unrelated	O
to	O
the	O
allele	O
size	O
at	O
the	O
DM	S-DISO
locus	O
.	O

Using	O
statistical	O
models	O
specifically	O
designed	O
to	O
study	O
single	O
-	O
sperm	O
segregation	O
data	O
,	O
we	O
find	O
no	O
evidence	O
of	O
meiotic	O
segregation	O
distortion	O
.	O

The	O
upper	O
limit	O
of	O
the	O
two	O
-	O
sided	O
95	O
%	O
confidence	O
interval	O
for	O
the	O
estimate	O
of	O
the	O
common	O
segregation	O
probability	O
for	O
the	O
three	O
donors	O
is	O
at	O
or	O
below	O
.	O

515	O
for	O
all	O
models	O
considered	O
,	O
and	O
no	O
statistically	O
significant	O
difference	O
from	O
.	O

5	O
is	O
detected	O
in	O
any	O
of	O
the	O
models	O
.	O

This	O
suggests	O
that	O
any	O
greater	O
amount	O
of	O
segregation	O
distortion	O
at	O
the	O
myotonic	B-DISO
dystrophy	E-DISO
locus	O
must	O
result	O
from	O
events	O
following	O
sperm	O
ejaculation	O
.	O

LPP	O
,	O
the	O
preferred	O
fusion	O
partner	O
gene	O
of	O
HMGIC	O
in	O
lipomas	S-DISO
,	O
is	O
a	O
novel	O
member	O
of	O
the	O
LIM	O
protein	O
gene	O
family	O
.	O

A	O
major	O
cytogenetic	O
subgroup	O
of	O
lipomas	S-DISO
is	O
characterized	O
by	O
recurrent	O
chromosome	O
aberrations	O
,	O
mainly	O
translocations	O
,	O
that	O
involve	O
chromosome	O
segment	O
12q13	O
-	O
q15	O
.	O

Multiple	O
chromosomes	O
have	O
been	O
found	O
as	O
the	O
translocation	O
partners	O
of	O
chromosome	O
12	O
but	O
3q27	O
-	O
q28	O
is	O
preferentially	O
involved	O
.	O

In	O
previous	O
studies	O
,	O
it	O
has	O
been	O
shown	O
that	O
the	O
high	O
mobility	O
group	O
(	O
HMG	O
)	O
protein	O
gene	O
HMGIC	O
at	O
12q15	O
is	O
consistently	O
rearranged	O
as	O
a	O
consequence	O
of	O
these	O
translocations	O
.	O

Here	O
,	O
we	O
report	O
the	O
identification	O
and	O
characterization	O
of	O
the	O
chromosome	O
3	O
-	O
derived	O
translocation	O
partner	O
gene	O
,	O
which	O
we	O
have	O
designated	O
LPP	O
(	O
lipoma	S-DISO
preferred	O
partner	O
gene	O
)	O
.	O

Using	O
3	O
-	O
RACE	O
analysis	O
of	O
HMGIC	O
fusion	O
transcripts	O
in	O
lipoma	S-DISO
cell	O
line	O
Li	O
-	O
501	O
/	O
SV40	O
,	O
ectopic	O
genetic	O
sequences	O
were	O
obtained	O
,	O
which	O
by	O
CASH	O
(	O
chromosome	O
assignment	O
using	O
somatic	O
cell	O
hybrids	O
)	O
and	O
FISH	O
(	O
fluorescence	O
in	O
situ	O
hybridization	O
)	O
analysis	O
were	O
found	O
to	O
originate	O
from	O
chromosome	O
segment	O
3q27	O
-	O
q28	O
.	O

In	O
Northern	O
blot	O
analysis	O
,	O
an	O
mRNA	O
of	O
over	O
10	O
kb	O
was	O
detected	O
by	O
these	O
ectopic	O
sequences	O
in	O
a	O
variety	O
of	O
human	O
tissues	O
but	O
not	O
in	O
brain	O
and	O
peripheral	O
blood	O
leukocytes	O
.	O

Upon	O
partial	O
cDNA	O
cloning	O
,	O
features	O
of	O
the	O
genetic	O
organization	O
of	O
LPP	O
were	O
established	O
.	O

The	O
gene	O
was	O
found	O
to	O
span	O
a	O
genomic	O
region	O
of	O
over	O
400	O
kb	O
.	O

Nucleotide	O
sequence	O
analysis	O
of	O
a	O
composite	O
cDNA	O
of	O
LPP	O
revealed	O
an	O
open	O
reading	O
frame	O
of	O
1836	O
nucleotides	O
encoding	O
a	O
proline	O
-	O
rich	O
protein	O
containing	O
a	O
leucine	O
-	O
zipper	O
motif	O
in	O
its	O
amino	O
-	O
terminal	O
region	O
and	O
three	O
LIM	O
domains	O
in	O
its	O
carboxy	O
-	O
terminal	O
region	O
.	O

The	O
LPP	O
-	O
encoded	O
protein	O
should	O
be	O
classified	O
as	O
a	O
novel	O
member	O
of	O
the	O
group	O
3	O
proteins	O
of	O
the	O
LIM	O
protein	O
gene	O
family	O
.	O

Using	O
reverse	O
transcriptase	O
combined	O
with	O
polymerase	O
chain	O
reactions	O
in	O
the	O
analysis	O
of	O
a	O
number	O
of	O
lipoma	S-DISO
cell	O
lines	O
and	O
primary	B-DISO
lipomas	E-DISO
,	O
it	O
appeared	O
that	O
LPP	O
is	O
frequently	O
rearranged	O
also	O
in	O
cases	O
without	O
a	O
cytogenetically	O
detectable	O
involvement	O
of	O
3q27	O
-	O
q28	O
.	O

Two	O
alternative	O
HMGIC	O
/	O
LPP	O
hybrid	O
transcripts	O
have	O
been	O
detected	O
;	O
the	O
difference	O
between	O
them	O
is	O
mainly	O
the	O
presence	O
of	O
either	O
two	O
or	O
three	O
LIM	O
domains	O
in	O
the	O
predicted	O
HMGI	O
-	O
C	O
/	O
LPP	O
fusion	O
proteins	O
.	O
.	O

Absence	O
of	O
disease	O
phenotype	O
and	O
intergenerational	O
stability	O
of	O
the	O
CAG	O
repeat	O
in	O
transgenic	O
mice	O
expressing	O
the	O
human	O
Huntington	B-DISO
disease	E-DISO
transcript	O
.	O

The	O
mutation	O
underlying	O
Huntington	B-DISO
disease	E-DISO
(	O
HD	S-DISO
)	O
is	O
CAG	O
expansion	O
in	O
the	O
first	O
exon	O
of	O
the	O
HD	S-DISO
gene	O
.	O

In	O
order	O
to	O
investigate	O
the	O
role	O
of	O
CAG	O
expansion	O
in	O
the	O
pathogenesis	O
of	O
HD	S-DISO
,	O
we	O
have	O
produced	O
transgenic	O
mice	O
containing	O
the	O
full	O
length	O
human	O
HD	S-DISO
cDNA	O
with	O
44	O
CAG	O
repeats	O
.	O

By	O
1	O
year	O
,	O
these	O
mice	O
have	O
no	O
behavioral	B-DISO
abnormalities	E-DISO
and	O
morphometric	O
analysis	O
at	O
6	O
(	O
one	O
animal	O
)	O
and	O
9	O
(	O
two	O
animals	O
)	O
months	O
age	O
revealed	O
no	O
changes	O
.	O

Despite	O
high	O
levels	O
of	O
mRNA	O
expression	O
,	O
there	O
was	O
no	O
evidence	O
of	O
the	O
HD	S-DISO
gene	O
product	O
in	O
any	O
of	O
these	O
transgenic	O
mice	O
.	O

In	O
vitro	O
transfection	O
studies	O
indicated	O
that	O
the	O
inclusion	O
of	O
120	O
bp	O
of	O
the	O
5	O
UTR	O
in	O
the	O
cDNA	O
construct	O
and	O
the	O
presence	O
of	O
a	O
frameshift	O
mutation	O
at	O
nucleotide	O
2349	O
prevented	O
expression	O
of	O
the	O
HD	S-DISO
cDNA	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
pathogenesis	O
of	O
HD	S-DISO
is	O
not	O
mediated	O
through	O
DNA	O
-	O
protein	O
interaction	O
and	O
that	O
presence	O
of	O
the	O
RNA	O
transcript	O
with	O
an	O
expanded	O
CAG	O
repeat	O
is	O
insufficient	O
to	O
cause	O
the	O
disease	O
.	O

Rather	O
,	O
translation	O
of	O
the	O
CAG	O
is	O
crucial	O
for	O
the	O
pathogenesis	O
of	O
HD	S-DISO
.	O

In	O
contrast	O
to	O
that	O
seen	O
in	O
humans	O
,	O
the	O
CAG	O
repeat	O
in	O
these	O
mice	O
was	O
remarkably	O
stable	O
in	O
97	O
meioses	O
.	O

This	O
suggests	O
that	O
genomic	O
sequences	O
may	O
play	O
a	O
critical	O
role	O
in	O
influencing	O
repeat	O
instability	O
.	O
.	O

FISH	O
studies	O
in	O
a	O
patient	O
with	O
sporadic	B-DISO
aniridia	E-DISO
and	O
t	O
(	O
7	O
;	O
11	O
)	O
(	O
q31	O
.	O
2	O
;	O
p13	O
)	O
.	O

A	O
2	O
year	O
old	O
female	O
presenting	O
with	O
bilateral	B-DISO
sporadic	I-DISO
aniridia	E-DISO
was	O
found	O
to	O
have	O
an	O
apparently	O
balanced	O
reciprocal	O
translocation	O
with	O
a	O
chromosome	O
11	O
breakpoint	O
within	O
band	O
p13	O
.	O

Fluorescence	O
in	O
situ	O
hybridisation	O
(	O
FISH	O
)	O
studies	O
with	O
distal	O
11p13	O
specific	O
cosmids	O
showed	O
that	O
the	O
chromosome	O
11	O
breakpoint	O
lay	O
between	O
the	O
aniridia	S-DISO
(	O
PAX6	O
)	O
locus	O
and	O
a	O
region	O
approximately	O
100	O
kb	O
distal	O
to	O
PAX6	O
defined	O
by	O
the	O
cosmid	O
FO2121	O
.	O

Although	O
this	O
patient	O
did	O
not	O
have	O
a	O
detectable	O
deletion	O
within	O
PAX6	O
,	O
her	O
aniridia	S-DISO
may	O
have	O
resulted	O
from	O
a	O
disruption	O
of	O
the	O
distal	O
chromatin	O
domain	O
containing	O
either	O
enhancers	O
or	O
regulators	O
for	O
PAX6	O
.	O

This	O
case	O
may	O
therefore	O
be	O
another	O
example	O
of	O
aniridia	S-DISO
caused	O
by	O
a	O
position	O
effect	O
as	O
recently	O
described	O
in	O
two	O
familial	B-DISO
aniridia	E-DISO
patients	O
in	O
which	O
the	O
phenotype	O
cosegregated	O
with	O
chromosome	B-DISO
abnormalities	E-DISO
with	O
11p13	O
breakpoints	O
.	O
.	O

Muscle	O
expression	O
of	O
glucose	B-DISO
-	I-DISO
6	I-DISO
-	I-DISO
phosphate	I-DISO
dehydrogenase	I-DISO
deficiency	E-DISO
in	O
different	O
variants	O
.	O

Muscle	O
expression	O
of	O
G6PD	B-DISO
deficiency	E-DISO
has	O
been	O
investigated	O
in	O
Mediterranean	O
,	O
Seattle	O
-	O
like	O
and	O
A	O
-	O
variants	O
.	O

G6PD	O
activity	O
was	O
detected	O
in	O
samples	O
obtained	O
from	O
biopsies	O
on	O
the	O
quadriceps	O
muscle	O
of	O
seven	O
males	O
and	O
one	O
female	O
.	O

The	O
type	O
of	O
genetic	O
variant	O
was	O
determined	O
by	O
molecular	O
analysis	O
of	O
DNA	O
,	O
extracted	O
from	O
blood	O
samples	O
.	O

All	O
variants	O
showed	O
the	O
enzyme	O
defect	O
in	O
muscle	O
.	O

A	O
statistically	O
significant	O
relationship	O
was	O
found	O
in	O
the	O
activity	O
of	O
G6PD	O
between	O
erythrocytes	O
and	O
muscle	O
of	O
the	O
male	O
subjects	O
(	O
r	O
=	O
0	O
.	O
968	O
;	O
p	O
=	O
0	O
.	O
00008	O
)	O
.	O

The	O
equation	O
for	O
the	O
best	O
fit	O
line	O
was	O
Y	O
=	O
0	O
.	O

390X	O
+	O
0	O
.	O

198	O
198	O
.	O

The	O
results	O
suggest	O
that	O
,	O
for	O
a	O
given	O
variant	O
,	O
the	O
extent	O
of	O
the	O
enzyme	O
defect	O
in	O
muscle	O
may	O
be	O
determined	O
,	O
using	O
this	O
equation	O
,	O
from	O
the	O
G6PD	O
activity	O
of	O
erythrocytes	O

Gene	O
therapy	O
for	O
phenylketonuria	S-DISO
.	O

Classical	O
phenylketonuria	S-DISO
(	O
PKU	S-DISO
)	O
is	O
an	O
autosomal	B-DISO
recessive	I-DISO
disorder	E-DISO
caused	O
by	O
a	O
deficiency	B-DISO
of	I-DISO
hepatic	I-DISO
phenylalanine	I-DISO
hydroxylase	E-DISO
(	O
PAH	O
)	O
.	O

Limitations	O
of	O
the	O
current	O
dietary	O
treatment	O
for	O
PKU	S-DISO
have	O
led	O
to	O
the	O
development	O
of	O
potential	O
treatments	O
based	O
on	O
somatic	O
gene	O
transfer	O
.	O

Three	O
different	O
vector	O
systems	O
have	O
been	O
examined	O
.	O

Vectors	O
derived	O
from	O
a	O
recombinant	O
retrovirus	O
or	O
a	O
DNA	O
/	O
protein	O
complex	O
can	O
efficiently	O
transduce	O
the	O
PAH	O
cDNA	O
into	O
PAH	B-DISO
-	I-DISO
deficient	E-DISO
hepatocytes	O
in	O
vitro	O
,	O
but	O
the	O
application	O
of	O
these	O
vector	O
systems	O
is	O
presently	O
limited	O
by	O
their	O
low	O
transduction	O
efficiency	O
in	O
vivo	O
.	O

In	O
contrast	O
,	O
a	O
vector	O
derived	O
from	O
a	O
recombinant	O
adenovirus	O
can	O
restore	O
10	O
%	O
-	O
80	O
%	O
of	O
normal	O
hepatic	O
PAH	O
activity	O
into	O
PAH	B-DISO
-	I-DISO
deficient	E-DISO
mice	O
,	O
which	O
completely	O
normalizes	O
serum	O
phenylalanine	O
levels	O
.	O

This	O
treatment	O
is	O
transient	O
and	O
cannot	O
be	O
effectively	O
re	O
-	O
administered	O
due	O
to	O
the	O
presence	O
of	O
neutralizing	O
antibodies	O
directed	O
against	O
the	O
recombinant	O
adenoviral	O
vector	O
.	O

However	O
,	O
these	O
findings	O
suggest	O
that	O
PKU	S-DISO
can	O
be	O
completely	O
corrected	O
by	O
somatic	O
gene	O
therapy	O
,	O
and	O
provide	O
some	O
direction	O
for	O
the	O
future	O
development	O
of	O
adenoviral	O
vectors	O
.	O
.	O

Exon	O
-	O
intron	O
structure	O
of	O
the	O
human	O
neuronal	O
nicotinic	O
acetylcholine	O
receptor	O
alpha	O
4	O
subunit	O
(	O
CHRNA4	O
)	O
.	O

The	O
human	O
neuronal	O
nicotinic	O
acetylcholine	O
receptor	O
alpha	O
4	O
subunit	O
gene	O
(	O
CHRNA4	O
)	O
is	O
located	O
in	O
the	O
candidate	O
region	O
for	O
three	O
different	O
phenotypes	O
benign	B-DISO
familial	I-DISO
neonatal	I-DISO
convulsions	E-DISO
,	O
autosomal	B-DISO
dominant	I-DISO
nocturnal	I-DISO
frontal	I-DISO
lobe	I-DISO
epilepsy	E-DISO
,	O
and	O
low	O
-	O
voltage	O
EEG	O
.	O

Recently	O
,	O
a	O
missense	O
mutation	O
in	O
transmembrane	O
domain	O
2	O
of	O
CHRNA4	O
was	O
found	O
to	O
be	O
associated	O
with	O
autosomal	B-DISO
dominant	I-DISO
nocturnal	I-DISO
frontal	I-DISO
lobe	I-DISO
epilepsy	E-DISO
in	O
one	O
extended	O
pedigree	O
.	O

We	O
have	O
determined	O
the	O
genomic	O
organization	O
of	O
CHRNA4	O
,	O
which	O
consists	O
of	O
six	O
exons	O
distributed	O
over	O
approximately	O
17	O
kb	O
of	O
genomic	O
DNA	O
.	O

The	O
nucleotide	O
sequence	O
obtained	O
from	O
the	O
genomic	O
regions	O
adjacent	O
to	O
the	O
exon	O
boundaries	O
enabled	O
us	O
to	O
develop	O
a	O
set	O
of	O
primer	O
pairs	O
for	O
PCR	O
amplification	O
of	O
the	O
complete	O
coding	O
region	O
.	O

The	O
sequence	O
analysis	O
provides	O
the	O
basis	O
for	O
a	O
comprehensive	O
mutation	O
screening	O
of	O
CHRNA4	O
in	O
the	O
above	O
-	O
mentioned	O
phenotypes	O
and	O
possibly	O
in	O
other	O
types	O
of	O
idiopathic	B-DISO
epilepsies	E-DISO
.	O
.	O

Ashkenazi	O
Jewish	O
population	O
frequencies	O
for	O
common	O
mutations	O
in	O
BRCA1	O
and	O
BRCA2	O
.	O

BRCA1	O
and	O
BRCA2	O
are	O
the	O
two	O
major	O
identified	O
causes	O
of	O
inherited	B-DISO
breast	I-DISO
cancer	E-DISO
,	O
with	O
mutations	O
in	O
either	O
gene	O
conferring	O
up	O
to	O
80	O
-	O
90	O
%	O
lifetime	O
risk	O
of	O
breast	B-DISO
cancer	E-DISO
in	O
carrier	O
females	O
.	O

Mutations	O
in	O
BRCA1	O
account	O
for	O
approximately	O
45	O
%	O
of	O
familial	B-DISO
breast	I-DISO
cancer	E-DISO
and	O
90	O
%	O
of	O
inherited	B-DISO
breast	I-DISO
/	I-DISO
ovarian	I-DISO
cancer	E-DISO
,	O
whereas	O
mutations	O
in	O
BRCA2	O
account	O
for	O
a	O
comparable	O
percentage	O
of	O
inherited	B-DISO
breast	I-DISO
cancer	E-DISO
cases	O
.	O

Over	O
85	O
distinct	O
BRCA1	O
mutations	O
and	O
a	O
growing	O
list	O
of	O
BRCA2	O
mutations	O
have	O
been	O
identified	O
,	O
with	O
the	O
majority	O
resulting	O
in	O
protein	O
truncation	O
.	O

A	O
specific	O
BRCA1	O
mutation	O
,	O
185delAG	O
,	O
has	O
a	O
reported	O
increased	O
carrier	O
frequency	O
of	O
approximately	O
0	O
.	O

9	O
%	O
in	O
the	O
Ashkenazi	O
Jewish	O
population	O
,	O
but	O
is	O
also	O
found	O
in	O
rare	O
non	O
-	O
Jewish	O
patients	O
with	O
a	O
different	O
haplotype	O
.	O

The	O
6174delT	O
mutation	O
in	O
BRCA2	O
was	O
recently	O
identified	O
as	O
a	O
frequent	O
mutation	O
in	O
8	O
out	O
of	O
107	O
Ashkenazi	O
Jewish	O
women	O
diagnosed	O
with	O
breast	B-DISO
cancer	E-DISO
by	O
age	O
50	O
(	O
ref	O
.	O
8	O
)	O
,	O
as	O
well	O
as	O
in	O
three	O
Ashkenazi	O
male	B-DISO
breast	I-DISO
cancer	E-DISO
patients	O
.	O

We	O
have	O
conducted	O
a	O
large	O
-	O
scale	O
population	O
study	O
to	O
investigate	O
the	O
prevalence	O
of	O
specific	O
BRCA1	O
and	O
BRCA2	O
mutations	O
in	O
Ashkenazi	O
Jewish	O
individuals	O
who	O
were	O
unselected	O
for	O
breast	B-DISO
cancer	E-DISO
.	O

BRCA1	O
mutation	O
screening	O
on	O
approximately	O
3	O
,	O
000	O
Ashkenazi	O
Jewish	O
samples	O
determined	O
a	O
carrier	O
frequency	O
of	O
1	O
.	O

09	O
%	O
for	O
the	O
185delAG	O
mutation	O
and	O
0	O
.	O

13	O
%	O
for	O
the	O
5382insC	O
mutation	O
.	O

BRCA2	O
analysis	O
on	O
3	O
,	O
085	O
individuals	O
from	O
the	O
same	O
population	O
showed	O
a	O
carrier	O
frequency	O
of	O
1	O
.	O

52	O
%	O
for	O
the	O
6174delT	O
mutation	O
.	O

This	O
expanded	O
population	O
-	O
based	O
study	O
confirms	O
that	O
the	O
BRCA1	O
185delAG	O
mutation	O
and	O
the	O
BRCA2	O
6174delT	O
mutation	O
constitute	O
the	O
two	O
most	O
frequent	O
mutation	O
alleles	O
predisposing	O
to	O
hereditary	B-DISO
breast	I-DISO
cancer	E-DISO
among	O
the	O
Ashkenazim	O
,	O
and	O
suggests	O
a	O
relatively	O
lower	O
penetrance	O
for	O
the	O
6174delT	O
mutation	O
in	O
BRCA2	O

Dual	O
roles	O
of	O
ATM	O
in	O
the	O
cellular	O
response	O
to	O
radiation	O
and	O
in	O
cell	O
growth	O
control	O
.	O

The	O
gene	O
mutated	O
in	O
ataxia	B-DISO
-	I-DISO
telangiectasia	E-DISO
(	O
AT	S-DISO
)	O
patients	O
,	O
denoted	O
ATM	O
,	O
encodes	O
a	O
putative	O
protein	O
or	O
lipid	O
kinase	O
.	O

To	O
elucidate	O
the	O
functions	O
of	O
ATM	O
,	O
we	O
disrupted	O
the	O
mouse	O
ATM	O
gene	O
through	O
homologous	O
recombination	O
in	O
mice	O
.	O

Consistent	O
with	O
cellular	O
defects	O
of	O
AT	S-DISO
patients	O
,	O
the	O
ATM	O
-	O
/	O
-	O
cells	O
are	O
hypersensitive	O
to	O
gamma	O
-	O
irradiation	O
and	O
defective	O
in	O
cell	O
-	O
cycle	O
arrest	O
following	O
radiation	O
,	O
correlating	O
with	O
a	O
defective	O
up	O
-	O
regulation	O
of	O
p53	O
.	O

In	O
addition	O
,	O
ATM	O
-	O
/	O
-	O
mouse	O
thymocytes	O
are	O
more	O
resistant	O
to	O
apoptosis	O
induced	O
by	O
gamma	O
-	O
irradiation	O
than	O
normal	O
thymocytes	O
.	O

ATM	O
-	O
/	O
-	O
fibroblasts	O
are	O
inefficient	O
in	O
G1	O
to	O
S	O
-	O
phase	O
progression	O
following	O
serum	O
stimulation	O
and	O
senesce	O
after	O
only	O
a	O
few	O
passages	O
in	O
culture	O
.	O

They	O
have	O
an	O
increased	O
constitutive	O
level	O
of	O
p21CP1	O
/	O
WAF1	O
.	O

The	O
ATM	O
protein	O
is	O
therefore	O
critical	O
both	O
for	O
cellular	O
responses	O
to	O
ionizing	O
radiation	O
and	O
for	O
normal	O
cell	O
-	O
cycle	O
progression	O
.	O

ATM	O
+	O
/	O
-	O
fibroblasts	O
and	O
thymocytes	O
showed	O
intermediately	O
defective	O
responses	O
to	O
irradiation	O
but	O
no	O
growth	O
defect	O
,	O
suggesting	O
that	O
the	O
increased	O
cancer	S-DISO
risk	O
of	O
AT	S-DISO
heterozygotes	O
could	O
be	O
attributable	O
to	O
poor	O
checkpoint	O
function	O
.	O
.	O

Targeted	O
disruption	O
of	O
ATM	O
leads	O
to	O
growth	B-DISO
retardation	E-DISO
,	O
chromosomal	B-DISO
fragmentation	I-DISO
during	I-DISO
meiosis	E-DISO
,	O
immune	B-DISO
defects	E-DISO
,	O
and	O
thymic	B-DISO
lymphoma	E-DISO
.	O

ATM	O
,	O
the	O
gene	O
mutated	O
in	O
the	O
inherited	B-DISO
human	I-DISO
disease	E-DISO
ataxia	B-DISO
-	I-DISO
telangiectasia	E-DISO
,	O
is	O
a	O
member	O
of	O
a	O
family	O
of	O
kinases	O
involved	O
in	O
DNA	O
metabolism	O
and	O
cell	O
-	O
cycle	O
checkpoint	O
control	O
.	O

To	O
help	O
clarify	O
the	O
physiological	O
roles	O
of	O
the	O
ATM	O
protein	O
,	O
we	O
disrupted	O
the	O
ATM	O
gene	O
in	O
mice	O
through	O
homologous	O
recombination	O
.	O

Initial	O
evaluation	O
of	O
the	O
ATM	O
knockout	O
animals	O
indicates	O
that	O
inactivation	O
of	O
the	O
mouse	O
ATM	O
gene	O
recreates	O
much	O
of	O
the	O
phenotype	O
of	O
ataxia	B-DISO
-	I-DISO
telangiectasia	E-DISO
.	O

The	O
homozygous	O
mutant	O
(	O
ATM	O
-	O
/	O
-	O
)	O
mice	O
are	O
viable	O
,	O
growth	O
-	O
retarded	O
,	O
and	O
infertile	O
.	O

The	O
infertility	S-DISO
of	O
ATM	O
-	O
/	O
-	O
mice	O
results	O
from	O
meiotic	O
failure	O
.	O

Meiosis	O
is	O
arrested	O
at	O
the	O
zygotene	O
/	O
pachytene	O
stage	O
of	O
prophase	O
I	O
as	O
a	O
result	O
of	O
abnormal	O
chromosomal	O
synapsis	O
and	O
subsequent	O
chromosome	O
fragmentation	O
.	O

Immune	B-DISO
defects	E-DISO
also	O
are	O
evident	O
in	O
ATM	O
-	O
/	O
-	O
mice	O
,	O
including	O
reduced	O
numbers	O
of	O
B220	O
+	O
CD43	O
-	O
pre	O
-	O
B	O
cells	O
,	O
thymocytes	O
,	O
and	O
peripheral	O
T	O
cells	O
,	O
as	O
well	O
as	O
functional	O
impairment	O
of	O
T	O
-	O
cell	O
-	O
dependent	O
immune	O
responses	O
.	O

The	O
cerebella	O
of	O
ATM	O
-	O
/	O
-	O
mice	O
appear	O
normal	O
by	O
histologic	O
examination	O
at	O
3	O
to	O
4	O
months	O
and	O
the	O
mice	O
have	O
no	O
gross	O
behavioral	B-DISO
abnormalities	E-DISO
.	O

The	O
majority	O
of	O
mutant	O
mice	O
rapidly	O
develop	O
thymic	B-DISO
lymphomas	E-DISO
and	O
die	O
before	O
4	O
months	O
of	O
age	O
.	O

These	O
findings	O
indicate	O
that	O
the	O
ATM	O
gene	O
product	O
plays	O
an	O
essential	O
role	O
in	O
a	O
diverse	O
group	O
of	O
cellular	O
processes	O
,	O
including	O
meiosis	O
,	O
the	O
normal	O
growth	O
of	O
somatic	O
tissues	O
,	O
immune	O
development	O
,	O
and	O
tumor	S-DISO
suppression	O
.	O
.	O

Cloning	O
and	O
characterization	O
of	O
human	O
very	O
-	O
long	O
-	O
chain	O
acyl	O
-	O
CoA	O
dehydrogenase	O
cDNA	O
,	O
chromosomal	O
assignment	O
of	O
the	O
gene	O
and	O
identification	O
in	O
four	O
patients	O
of	O
nine	O
different	O
mutations	O
within	O
the	O
VLCAD	O
gene	O
.	O

Very	O
-	O
long	O
-	O
chain	O
acyl	O
-	O
CoA	O
dehydrogenase	O
(	O
VLCAD	O
)	O
is	O
one	O
of	O
four	O
straight	O
-	O
chain	O
acyl	O
-	O
CoA	O
dehydrogenase	O
(	O
ACD	O
)	O
enzymes	O
,	O
which	O
are	O
all	O
nuclear	O
encoded	O
mitochondrial	O
flavoproteins	O
catalyzing	O
the	O
initial	O
step	O
in	O
fatty	O
acid	O
beta	O
-	O
oxidation	O
.	O

We	O
have	O
used	O
the	O
very	O
fast	O
,	O
Rapid	O
Amplification	O
of	O
cDNA	O
Ends	O
(	O
RACE	O
)	O
based	O
strategy	O
to	O
obtain	O
the	O
sequence	O
of	O
cDNAs	O
encoding	O
human	O
VLCAD	O
from	O
placenta	O
and	O
fibroblasts	O
.	O

Alignment	O
of	O
the	O
predicted	O
amino	O
acid	O
sequence	O
of	O
human	O
VLCAD	O
with	O
those	O
of	O
the	O
other	O
human	O
ACD	O
enzymes	O
revealed	O
extensive	O
sequence	O
homology	O
.	O

Moreover	O
,	O
human	O
VLCAD	O
and	O
human	O
acyl	O
-	O
CoA	O
oxidase	O
showed	O
extensive	O
sequence	O
homology	O
corroborating	O
the	O
notion	O
that	O
these	O
genes	O
are	O
evolutionarily	O
related	O
.	O

Southern	O
blot	O
analysis	O
of	O
genomic	O
DNA	O
from	O
hybrid	O
cell	O
lines	O
was	O
used	O
to	O
localize	O
the	O
VLCAD	O
gene	O
to	O
human	O
chromosome	O
17p11	O
.	O

2	O
-	O
p11	O
.	O

13105	O
.	O

Using	O
Northern	O
and	O
Western	O
blot	O
analysis	O
to	O
investigate	O
the	O
tissue	O
specific	O
distribution	O
of	O
VLCAD	O
mRNA	O
and	O
protein	O
in	O
several	O
human	O
tissues	O
we	O
showed	O
that	O
VLCAD	O
is	O
most	O
abundant	O
in	O
heart	O
and	O
skeletal	O
muscle	O
.	O

This	O
agrees	O
well	O
with	O
the	O
fact	O
that	O
cardiac	O
and	O
muscle	O
symptoms	O
are	O
characteristic	O
for	O
patients	O
with	O
VLCAD	B-DISO
deficiency	E-DISO
.	O

Northern	O
blot	O
analysis	O
and	O
sequencing	O
of	O
cloned	O
PCR	O
amplified	O
VLCAD	O
cDNA	O
from	O
four	O
unrelated	O
patients	O
with	O
VLCAD	B-DISO
deficiency	E-DISO
showed	O
that	O
VLCAD	O
mRNA	O
was	O
undetectable	O
in	O
one	O
patient	O
and	O
that	O
the	O
other	O
three	O
have	O
mutations	O
in	O
both	O
VLCAD	O
alleles	O
.	O

Western	O
blot	O
analysis	O
of	O
patient	O
fibroblasts	O
showed	O
that	O
the	O
identified	O
mutations	O
result	O
in	O
severely	O
reduced	O
amounts	O
of	O
VLCAD	O
protein	O
.	O

Molecular	O
bases	O
of	O
combined	B-DISO
subtotal	I-DISO
deficiencies	I-DISO
of	I-DISO
C6	I-DISO
and	I-DISO
C7	E-DISO
:	O
their	O
effects	O
in	O
combination	O
with	O
other	O
C6	B-DISO
and	I-DISO
C7	I-DISO
deficiencies	E-DISO
.	O

Combined	B-DISO
subtotal	I-DISO
deficiency	I-DISO
of	I-DISO
C6	I-DISO
and	I-DISO
C7	E-DISO
,	O
in	O
which	O
both	O
proteins	O
are	O
expressed	O
at	O
very	O
low	O
levels	O
,	O
has	O
been	O
observed	O
in	O
homozygous	O
form	O
in	O
two	O
families	O
.	O

A	O
defect	O
at	O
the	O
5	O
splice	O
donor	O
site	O
of	O
intron	O
15	O
of	O
the	O
C6	O
gene	O
explains	O
the	O
low	O
molecular	O
weight	O
of	O
the	O
C6	O
protein	O
and	O
is	O
probably	O
responsible	O
for	O
its	O
low	O
expressed	O
concentration	O
.	O

The	O
C7	O
defect	O
is	O
more	O
enigmatic	O
the	O
protein	O
is	O
of	O
normal	O
molecular	O
weight	O
,	O
low	O
circulating	O
concentration	O
,	O
and	O
altered	O
isoelectric	O
point	O
.	O

An	O
Arg	O
>	O
Ser	O
codon	O
substitution	O
in	O
exon	O
11	O
is	O
the	O
only	O
molecular	O
alteration	O
within	O
the	O
mature	O
C7	O
protein	O
.	O

These	O
defects	O
are	O
associated	O
with	O
a	O
characteristic	O
set	O
of	O
polymorphic	O
DNA	O
markers	O
in	O
the	O
C6	O
/	O
C7	O
region	O
,	O
forming	O
a	O
distinct	O
haplotype	O
.	O

The	O
haplotype	O
has	O
been	O
found	O
in	O
combination	O
with	O
a	O
number	O
of	O
other	O
haplotypes	O
containing	O
defective	O
genes	O
that	O
lead	O
either	O
to	O
C6	B-DISO
or	I-DISO
C7	I-DISO
deficiency	E-DISO
,	O
but	O
with	O
different	O
consequences	O
.	O

Where	O
it	O
is	O
combined	O
with	O
a	O
C6	B-DISO
-	I-DISO
deficient	E-DISO
gene	O
,	O
the	O
serum	O
C7	O
levels	O
can	O
be	O
surprisingly	O
high	O
,	O
possibly	O
because	O
there	O
is	O
no	O
C6	O
generating	O
C56	O
to	O
consume	O
the	O
C7	O
.	O

In	O
contrast	O
,	O
where	O
the	O
C7	O
genes	O
are	O
both	O
defective	O
(	O
but	O
still	O
partially	O
functional	O
)	O
,	O
there	O
may	O
be	O
a	O
profound	O
deficit	O
of	O
circulating	O
C7	O
because	O
there	O
is	O
ample	O
C6	O
to	O
produce	O
C56	O
and	O
consume	O
the	O
already	O
small	O
amount	O
of	O
C7	O
.	O

Each	O
molecular	O
defect	O
has	O
also	O
been	O
found	O
in	O
isolation	O
and	O
has	O
the	O
expected	O
effect	O
.	O
.	O

Genetic	O
bases	O
of	O
human	O
complement	B-DISO
C7	I-DISO
deficiency	E-DISO
.	O

Complement	B-DISO
C7	I-DISO
deficiency	E-DISO
(	O
C7D	S-DISO
)	O
is	O
associated	O
frequently	O
with	O
recurrent	O
bacterial	B-DISO
infections	E-DISO
,	O
especially	O
meningitis	S-DISO
caused	O
by	O
Neisseria	B-DISO
meningitidis	E-DISO
.	O

We	O
report	O
in	O
this	O
work	O
the	O
molecular	O
bases	O
of	O
C7D	S-DISO
in	O
two	O
unrelated	O
Japanese	O
males	O
.	O

We	O
used	O
exon	O
-	O
specific	O
PCR	O
/	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
analysis	O
as	O
a	O
screening	O
step	O
for	O
mutations	O
.	O

Subsequent	O
direct	O
sequencing	O
of	O
the	O
target	O
exons	O
identified	O
homozygous	O
mutations	O
in	O
exon	O
16	O
of	O
case	O
1	O
and	O
in	O
exon	O
15	O
of	O
case	O
2	O
.	O

The	O
mutation	O
of	O
case	O
1	O
was	O
a	O
homozygous	O
T	O
to	O
A	O
transversion	O
at	O
nucleotide	O
2250	O
,	O
the	O
third	O
nucleotide	O
of	O
the	O
codon	O
TGT	O
for	O
Cys728	O
,	O
leading	O
to	O
a	O
stop	O
codon	O
TGA	O
(	O
C728X	O
)	O
.	O

In	O
case	O
2	O
,	O
a	O
homozygous	O
2	O
-	O
bp	O
deletion	O
(	O
2137delTG	O
/	O
2138delGT	O
/	O
2139delTG	O
)	O
caused	O
a	O
frameshift	O
,	O
generating	O
a	O
premature	O
termination	O
codon	O
4	O
to	O
6	O
nucleotides	O
downstream	O
.	O

Family	O
study	O
in	O
case	O
1	O
confirmed	O
the	O
genetic	O
nature	O
of	O
the	O
defect	O
.	O

Moreover	O
,	O
we	O
detected	O
a	O
novel	O
polymorphism	O
in	O
intron	O
11	O
that	O
presumably	O
is	O
linked	O
to	O
the	O
mutation	O
responsible	O
for	O
C7D	S-DISO
in	O
case	O
1	O
.	O

Our	O
results	O
indicate	O
that	O
the	O
pathogenesis	O
of	O
C7D	S-DISO
is	O
heterogeneous	O
like	O
most	O
of	O
the	O
other	O
deficiencies	B-DISO
of	I-DISO
complement	I-DISO
components	E-DISO
.	O
.	O

HPRT	B-DISO
-	I-DISO
APRT	I-DISO
-	I-DISO
deficient	E-DISO
mice	O
are	O
not	O
a	O
model	O
for	O
lesch	B-DISO
-	I-DISO
nyhan	I-DISO
syndrome	E-DISO
.	O

Complete	B-DISO
hypoxanthine	I-DISO
-	I-DISO
guanine	I-DISO
phosphoribosyl	I-DISO
-	I-DISO
transferase	I-DISO
(	I-DISO
HPRT	I-DISO
)	I-DISO
deficiency	E-DISO
in	O
humans	O
results	O
in	O
the	O
Lesch	B-DISO
-	I-DISO
Nyhan	I-DISO
syndrome	E-DISO
which	O
is	O
characterized	O
,	O
among	O
other	O
features	O
,	O
by	O
compulsive	O
self	O
-	O
injurious	O
behavior	O
.	O

HPRT	B-DISO
-	I-DISO
deficient	E-DISO
mice	O
generated	O
using	O
mouse	O
embryonic	O
stem	O
cells	O
exhibit	O
none	O
of	O
the	O
behavioral	O
symptoms	O
associated	O
with	O
the	O
Lesch	B-DISO
-	I-DISO
Nyhan	I-DISO
syndrome	E-DISO
.	O

Administration	O
of	O
drugs	O
that	O
inhibit	O
adenine	O
phosphoribosyltransferase	O
(	O
APRT	O
)	O
in	O
HPRT	B-DISO
-	I-DISO
deficient	E-DISO
mice	O
has	O
produced	O
the	O
suggestion	O
that	O
deficiency	B-DISO
of	I-DISO
APRT	E-DISO
in	O
combination	O
with	O
HPRT	B-DISO
-	I-DISO
deficiency	E-DISO
in	O
mice	O
may	O
lead	O
to	O
self	O
-	O
mutilation	O
behavior	O
[	O
C	O
.	O
L	O
.	O
Wu	O
and	O
D	O
.	O
W	O
.	O
Melton	O
(	O
1993	O
)	O
Nature	O
Genet	O
.	O
3	O
,	O
235	O
-	O
240	O
]	O
.	O

To	O
test	O
this	O
proposition	O
,	O
we	O
bred	O
HPRT	B-DISO
-	I-DISO
APRT	I-DISO
-	I-DISO
deficient	E-DISO
mice	O
.	O

Although	O
the	O
doubly	O
-	O
deficient	O
mice	O
excrete	O
adenine	O
and	O
its	O
highly	O
insoluble	O
derivative	O
,	O
2	O
,	O
8	O
-	O
dihydroxyadenine	O
,	O
which	O
are	O
also	O
associated	O
with	O
human	O
APRT	B-DISO
deficiency	E-DISO
,	O
additional	O
abnormalities	O
or	O
any	O
self	O
-	O
injurious	O
behavior	O
were	O
not	O
detected	O
.	O

Thus	O
,	O
APRT	B-DISO
-	I-DISO
HPRT	I-DISO
-	I-DISO
deficient	E-DISO
mice	O
,	O
which	O
are	O
devoid	O
of	O
any	O
purine	O
salvage	O
pathways	O
,	O
show	O
no	O
novel	O
phenotype	O
and	O
are	O
not	O
a	O
model	O
for	O
the	O
behavioral	B-DISO
abnormalities	E-DISO
associated	O
with	O
the	O
Lesch	B-DISO
-	I-DISO
Nyhan	I-DISO
syndrome	E-DISO
as	O
previously	O
suggested	O

Somatic	O
alterations	O
of	O
the	O
DPC4	O
gene	O
in	O
human	O
colorectal	B-DISO
cancers	E-DISO
in	O
vivo	O
.	O

BACKGROUND	O
&	O
AIMS	O
The	O
chromosome	O
region	O
18q21	O
has	O
been	O
shown	O
to	O
be	O
frequently	O
deleted	O
in	O
colorectal	B-DISO
cancers	E-DISO
,	O
and	O
such	O
frequent	O
allelic	O
loss	O
is	O
a	O
hallmark	O
of	O
the	O
presence	O
of	O
a	O
tumor	O
-	O
suppressor	O
gene	O
.	O

The	O
DPC4	O
gene	O
,	O
which	O
is	O
located	O
at	O
18q21	O
,	O
has	O
been	O
identified	O
as	O
a	O
tumor	O
-	O
suppressor	O
gene	O
from	O
examination	O
of	O
pancreatic	B-DISO
cancers	E-DISO
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	O
if	O
it	O
might	O
also	O
be	O
altered	O
in	O
colorectal	B-DISO
cancers	E-DISO
.	O

METHODS	O
Mutation	O
analyses	O
of	O
the	O
DPC4	O
gene	O
were	O
performed	O
on	O
complementary	O
DNA	O
samples	O
from	O
31	O
primary	O
colorectal	B-DISO
cancer	E-DISO
specimens	O
using	O
a	O
combination	O
of	O
polymerase	O
chain	O
reaction	O
,	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
,	O
and	O
DNA	O
sequencing	O
.	O

RESULTS	O
Four	O
missense	O
mutations	O
producing	O
amino	O
acid	O
substitutions	O
and	O
a	O
somatic	O
12	O
-	O
base	O
pair	O
deletion	O
in	O
the	O
coding	O
region	O
of	O
the	O
DPC4	O
gene	O
were	O
detected	O
in	O
the	O
31	O
cancers	S-DISO
(	O
16	O
%	O
;	O
5	O
of	O
31	O
)	O
.	O

CONCLUSIONS	O
The	O
DPC4	O
gene	O
may	O
play	O
a	O
role	O
as	O
a	O
tumor	O
-	O
suppressor	O
gene	O
in	O
a	O
fraction	O
of	O
colorectal	B-DISO
cancers	E-DISO
;	O
however	O
,	O
while	O
allelic	O
loss	O
at	O
18q21	O
is	O
very	O
often	O
seen	O
in	O
colorectal	B-DISO
cancers	E-DISO
,	O
only	O
a	O
minority	O
show	O
DPC4	O
mutations	O
,	O
suggesting	O
that	O
there	O
might	O
be	O
another	O
tumor	O
-	O
suppressor	O
gene	O
in	O
this	O
chromosome	O
region	O
.	O
.	O

Pleiotropic	O
defects	O
in	O
ataxia	B-DISO
-	I-DISO
telangiectasia	E-DISO
protein	O
-	O
deficient	O
mice	O
.	O

We	O
have	O
generated	O
a	O
mouse	O
model	O
for	O
ataxia	B-DISO
-	I-DISO
telangiectasia	E-DISO
by	O
using	O
gene	O
targeting	O
to	O
generate	O
mice	O
that	O
do	O
not	O
express	O
the	O
Atm	O
protein	O
.	O

Atm	O
-	O
deficient	O
mice	O
are	O
retarded	O
in	O
growth	O
,	O
do	O
not	O
produce	O
mature	O
sperm	O
,	O
and	O
exhibit	O
severe	O
defects	O
in	O
T	O
cell	O
maturation	O
while	O
going	O
on	O
to	O
develop	O
thymomas	S-DISO
.	O

Atm	O
-	O
deficient	O
fibroblasts	O
grow	O
poorly	O
in	O
culture	O
and	O
display	O
a	O
high	O
level	O
of	O
double	O
-	O
stranded	O
chromosome	O
breaks	O
.	O

Atm	O
-	O
deficient	O
thymocytes	O
undergo	O
spontaneous	O
apoptosis	O
in	O
vitro	O
significantly	O
more	O
than	O
controls	O
.	O

Atm	O
-	O
deficient	O
mice	O
then	O
exhibit	O
many	O
of	O
the	O
same	O
symptoms	O
found	O
in	O
ataxia	B-DISO
-	I-DISO
telangiectasia	E-DISO
patients	O
and	O
in	O
cells	O
derived	O
from	O
them	O
.	O

Furthermore	O
,	O
we	O
demonstrate	O
that	O
the	O
Atm	O
protein	O
exists	O
as	O
two	O
discrete	O
molecular	O
species	O
,	O
and	O
that	O
loss	O
of	O
one	O
or	O
of	O
both	O
of	O
these	O
can	O
lead	O
to	O
the	O
development	O
of	O
the	O
disease	O
.	O
.	O

The	O
DCC	O
protein	O
and	O
prognosis	O
in	O
colorectal	B-DISO
cancer	E-DISO
.	O

BACKGROUND	O
Allelic	O
loss	O
of	O
chromosome	O
18q	O
predicts	O
a	O
poor	O
outcome	O
in	O
patients	O
with	O
stage	B-DISO
II	I-DISO
colorectal	I-DISO
cancer	E-DISO
.	O

Although	O
the	O
specific	O
gene	O
inactivated	O
by	O
this	O
allelic	O
loss	O
has	O
not	O
been	O
elucidated	O
,	O
the	O
DCC	O
(	O
deleted	O
in	O
colorectal	B-DISO
cancer	E-DISO
)	O
gene	O
is	O
a	O
candidate	O
.	O

We	O
investigated	O
whether	O
the	O
expression	O
of	O
the	O
DCC	O
protein	O
in	O
tumor	S-DISO
cells	O
is	O
a	O
prognostic	O
marker	O
in	O
colorectal	B-DISO
carcinoma	E-DISO
.	O

METHODS	O
The	O
expression	O
of	O
DCC	O
was	O
evaluated	O
immunohistochemically	O
in	O
132	O
paraffin	O
-	O
embedded	O
samples	O
from	O
patients	O
with	O
curatively	O
resected	O
stage	B-DISO
II	I-DISO
and	I-DISO
III	I-DISO
colorectal	I-DISO
carcinomas	E-DISO
.	O

The	O
Cox	O
proportional	O
-	O
hazards	O
model	O
was	O
used	O
to	O
adjust	O
for	O
covariates	O
including	O
age	O
,	O
sex	O
,	O
tumor	S-DISO
site	O
,	O
degree	O
of	O
tumor	S-DISO
differentiation	O
,	O
and	O
use	O
of	O
adjuvant	O
therapy	O
.	O

RESULTS	O
The	O
expression	O
of	O
DCC	O
was	O
a	O
strong	O
positive	O
predictive	O
factor	O
for	O
survival	O
in	O
both	O
stage	B-DISO
II	I-DISO
and	I-DISO
stage	I-DISO
III	I-DISO
colorectal	I-DISO
carcinomas	E-DISO
.	O

In	O
patients	O
with	O
stage	O
II	O
disease	O
whose	O
tumors	S-DISO
expressed	O
DCC	O
,	O
the	O
five	O
-	O
year	O
survival	O
rate	O
was	O
94	O
.	O

3	O
percent	O
,	O
whereas	O
in	O
patients	O
with	O
DCC	B-DISO
-	I-DISO
negative	I-DISO
tumors	E-DISO
,	O
the	O
survival	O
rate	O
was	O
61	O
.	O

6	O
percent	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

In	O
patients	O
with	O
stage	B-DISO
III	I-DISO
disease	E-DISO
,	O
the	O
respective	O
survival	O
rates	O
were	O
59	O
.	O

3	O
percent	O
and	O
33	O
.	O

2	O
percent	O
(	O
P	O
=	O
0	O
.	O
03	O
)	O
.	O

CONCLUSIONS	O
DCC	O
is	O
a	O
prognostic	O
marker	O
in	O
patients	O
with	O
stage	B-DISO
II	I-DISO
or	I-DISO
stage	I-DISO
III	I-DISO
colorectal	I-DISO
cancer	E-DISO
.	O

In	O
stage	B-DISO
II	I-DISO
colorectal	I-DISO
carcinomas	E-DISO
,	O
the	O
absence	O
of	O
DCC	O
identifies	O
a	O
subgroup	O
of	O
patients	O
with	O
lesions	O
that	O
behave	O
like	O
stage	B-DISO
III	I-DISO
cancers	E-DISO
.	O

These	O
findings	O
may	O
thus	O
have	O
therapeutic	O
implications	O
in	O
this	O
group	O
of	O
patients	O

Association	O
of	O
anxiety	B-DISO
-	I-DISO
related	I-DISO
traits	E-DISO
with	O
a	O
polymorphism	O
in	O
the	O
serotonin	O
transporter	O
gene	O
regulatory	O
region	O
.	O

Transporter	O
-	O
facilitated	O
uptake	O
of	O
serotonin	O
(	O
5	O
-	O
hydroxytryptamine	O
or	O
5	O
-	O
HT	O
)	O
has	O
been	O
implicated	O
in	O
anxiety	S-DISO
in	O
humans	O
and	O
animal	O
models	O
and	O
is	O
the	O
site	O
of	O
action	O
of	O
widely	O
used	O
uptake	O
-	O
inhibiting	O
antidepressant	O
and	O
antianxiety	O
drugs	O
.	O

Human	O
5	O
-	O
HT	O
transporter	O
(	O
5	O
-	O
HTT	O
)	O
gene	O
transcription	O
is	O
modulated	O
by	O
a	O
common	O
polymorphism	O
in	O
its	O
upstream	O
regulatory	O
region	O
.	O

The	O
short	O
variant	O
of	O
the	O
polymorphism	O
reduces	O
the	O
transcriptional	O
efficiency	O
of	O
the	O
5	O
-	O
HTT	O
gene	O
promoter	O
,	O
resulting	O
in	O
decreased	O
5	O
-	O
HTT	O
expression	O
and	O
5	O
-	O
HT	O
uptake	O
in	O
lymphoblasts	O
.	O

Association	O
studies	O
in	O
two	O
independent	O
samples	O
totaling	O
505	O
individuals	O
revealed	O
that	O
the	O
5	O
-	O
HTT	O
polymorphism	O
accounts	O
for	O
3	O
to	O
4	O
percent	O
of	O
total	O
variation	O
and	O
7	O
to	O
9	O
percent	O
of	O
inherited	O
variance	O
in	O
anxiety	B-DISO
-	I-DISO
related	I-DISO
personality	I-DISO
traits	E-DISO
in	O
individuals	O
as	O
well	O
as	O
sibships	O
.	O
.	O

Phenotypic	O
and	O
genotypic	O
overlap	O
between	O
atelosteogenesis	B-DISO
type	I-DISO
2	E-DISO
and	O
diastrophic	B-DISO
dysplasia	E-DISO
.	O

Mutations	O
in	O
the	O
diastrophic	B-DISO
dysplasia	E-DISO
sulfate	O
transporter	O
gene	O
DTDST	O
have	O
been	O
associated	O
with	O
a	O
family	O
of	O
chondrodysplasias	S-DISO
that	O
comprises	O
,	O
in	O
order	O
of	O
increasing	O
severity	O
,	O
diastrophic	B-DISO
dysplasia	E-DISO
(	O
DTD	S-DISO
)	O
,	O
atelosteogenesis	B-DISO
type	I-DISO
2	E-DISO
(	O
AO2	S-DISO
)	O
,	O
and	O
achondrogenesis	B-DISO
type	I-DISO
1B	E-DISO
(	O
ACG1B	S-DISO
)	O
.	O

To	O
learn	O
more	O
about	O
the	O
molecular	O
basis	O
of	O
DTDST	B-DISO
chondrodysplasias	E-DISO
and	O
about	O
genotype	O
-	O
phenotype	O
correlations	O
,	O
we	O
studied	O
fibroblast	O
cultures	O
of	O
three	O
new	O
patients	O
one	O
with	O
AO	B-DISO
-	I-DISO
2	E-DISO
,	O
one	O
with	O
DTD	S-DISO
,	O
and	O
one	O
with	O
an	O
intermediate	O
phenotype	O
(	O
AO2	S-DISO
/	O
DTD	S-DISO
)	O
.	O

Reduced	O
incorporation	O
of	O
inorganic	O
sulfate	O
into	O
macromolecules	O
was	O
found	O
in	O
all	O
three	O
.	O

Each	O
of	O
the	O
three	O
patients	O
was	O
found	O
to	O
be	O
heterozygous	O
for	O
a	O
c862t	O
transition	O
predicting	O
a	O
R279W	O
substitution	O
in	O
the	O
third	O
extracellular	O
loop	O
of	O
DTDST	O
.	O

In	O
two	O
patients	O
(	O
DTD	S-DISO
and	O
AO2	S-DISO
/	O
DTD	S-DISO
)	O
,	O
no	O
other	O
structural	O
mutation	O
was	O
found	O
,	O
but	O
polymerase	O
chain	O
reaction	O
amplification	O
and	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
analysis	O
of	O
fibroblast	O
cDNA	O
showed	O
reduced	O
mRNA	O
levels	O
of	O
the	O
wild	O
-	O
type	O
DTDST	O
allele	O
these	O
two	O
patients	O
may	O
be	O
compound	O
heterozygotes	O
for	O
the	O
"	O
Finnish	O
"	O
mutation	O
(	O
as	O
yet	O
uncharacterized	O
at	O
the	O
DNA	O
level	O
)	O
,	O
which	O
causes	O
reduced	O
expression	O
of	O
DTDST	O
.	O

The	O
third	O
patient	O
(	O
with	O
AO2	S-DISO
)	O
had	O
the	O
R279W	O
mutation	O
compounded	O
with	O
a	O
novel	O
mutation	O
,	O
the	O
deletion	O
of	O
cytosine	O
418	O
(	O
delta	O
c418	O
)	O
,	O
predicting	O
a	O
frameshift	O
with	O
premature	O
termination	O
.	O

Also	O
the	O
delta	O
c418	O
allele	O
was	O
underrepresented	O
in	O
the	O
cDNA	O
,	O
in	O
accordance	O
with	O
previous	O
observations	O
that	O
premature	O
stop	O
codons	O
reduce	O
mRNA	O
levels	O
.	O

The	O
presence	O
of	O
the	O
DTDST	O
R279W	O
mutation	O
in	O
a	O
total	O
of	O
11	O
patients	O
with	O
AO2	S-DISO
or	O
DTD	S-DISO
emphasizes	O
the	O
overlap	O
between	O
these	O
conditions	O
.	O

This	O
mutation	O
has	O
not	O
been	O
found	O
so	O
far	O
in	O
8	O
analyzed	O
ACG1B	S-DISO
patients	O
,	O
suggesting	O
that	O
it	O
allows	O
some	O
residual	O
activity	O
of	O
the	O
sulfate	O
transporter	O
.	O
.	O

Identification	O
of	O
WASP	O
mutations	O
,	O
mutation	O
hotspots	O
and	O
genotype	O
-	O
phenotype	O
disparities	O
in	O
24	O
patients	O
with	O
the	O
Wiskott	B-DISO
-	I-DISO
Aldrich	I-DISO
syndrome	E-DISO
.	O

The	O
Wiskott	B-DISO
-	I-DISO
Aldrich	I-DISO
syndrome	E-DISO
(	O
WAS	S-DISO
)	O
,	O
an	O
X	B-DISO
-	I-DISO
linked	I-DISO
immunodeficiency	I-DISO
disease	E-DISO
caused	O
by	O
mutation	O
in	O
the	O
recently	O
isolated	O
gene	O
encoding	O
WAS	S-DISO
protein	O
(	O
WASP	O
)	O
,	O
is	O
known	O
to	O
be	O
associated	O
with	O
extensive	O
clinical	O
heterogeneity	O
.	O

Cumulative	O
mutation	O
data	O
have	O
revealed	O
that	O
WASP	O
genotypes	O
are	O
also	O
highly	O
variable	O
among	O
WAS	S-DISO
patients	O
,	O
but	O
the	O
relationship	O
of	O
phenotype	O
with	O
genotype	O
in	O
this	O
disease	O
remains	O
unclear	O
.	O

To	O
address	O
this	O
issue	O
we	O
characterized	O
WASP	O
mutations	O
in	O
24	O
unrelated	O
WAS	S-DISO
patients	O
,	O
including	O
18	O
boys	O
with	O
severe	O
classical	O
WAS	S-DISO
and	O
6	O
boys	O
expressing	O
mild	O
forms	O
of	O
the	O
disease	O
,	O
and	O
then	O
examined	O
the	O
degree	O
of	O
correlation	O
of	O
these	O
as	O
well	O
as	O
all	O
previously	O
published	O
WASP	O
mutations	O
with	O
disease	O
severity	O
.	O

By	O
analysis	O
of	O
these	O
compiled	O
mutation	O
data	O
,	O
we	O
demonstrated	O
clustering	O
of	O
WASP	O
mutations	O
within	O
the	O
four	O
most	O
N	O
-	O
terminal	O
exons	O
of	O
the	O
gene	O
and	O
also	O
identified	O
several	O
sites	O
within	O
this	O
region	O
as	O
hotspots	O
for	O
WASP	O
mutation	O
.	O

These	O
characteristics	O
were	O
observed	O
,	O
however	O
,	O
in	O
both	O
severe	O
and	O
mild	O
cases	O
of	O
the	O
disease	O
.	O

Similarly	O
,	O
while	O
the	O
cumulative	O
data	O
revealed	O
a	O
predominance	O
of	O
missense	O
mutations	O
among	O
the	O
WASP	O
gene	O
lesions	O
observed	O
in	O
boys	O
with	O
isolated	B-DISO
thrombocytopenia	E-DISO
,	O
missense	O
mutations	O
were	O
not	O
exclusively	O
associated	O
with	O
milder	O
WAS	S-DISO
phenotypes	O
,	O
but	O
also	O
comprised	O
a	O
substantial	O
portion	O
(	O
38	O
%	O
)	O
of	O
the	O
WASP	O
gene	O
defects	O
found	O
in	O
patients	O
with	O
severe	O
disease	O
.	O

These	O
findings	O
,	O
as	O
well	O
as	O
the	O
detection	O
of	O
identical	O
WASP	O
mutations	O
in	O
patients	O
with	O
disparate	O
phenotypes	O
,	O
reveal	O
a	O
lack	O
of	O
phenotype	O
concordance	O
with	O
genotype	O
in	O
WAS	S-DISO
and	O
thus	O
imply	O
that	O
phenotypic	O
outcome	O
in	O
this	O
disease	O
cannot	O
be	O
reliably	O
predicted	O
solely	O
on	O
the	O
basis	O
of	O
WASP	O
genotypes	O
.	O
.	O

Germline	O
mutations	O
in	O
the	O
3	O
'	O
part	O
of	O
APC	S-DISO
exon	O
15	O
do	O
not	O
result	O
in	O
truncated	O
proteins	O
and	O
are	O
associated	O
with	O
attenuated	O
adenomatous	B-DISO
polyposis	I-DISO
coli	E-DISO
.	O

Familial	B-DISO
adenomatous	I-DISO
polyposis	E-DISO
(	O
FAP	S-DISO
)	O
is	O
an	O
inherited	O
predisposition	O
to	O
colorectal	B-DISO
cancer	E-DISO
characterized	O
by	O
the	O
development	O
of	O
numerous	O
adenomatous	B-DISO
polyps	E-DISO
predominantly	O
in	O
the	O
colorectal	O
region	O
.	O

Germline	O
mutations	O
in	O
the	O
adenomatous	B-DISO
polyposis	I-DISO
coli	E-DISO
(	O
APC	S-DISO
)	O
gene	O
are	O
responsible	O
for	O
most	O
cases	O
of	O
FAP	S-DISO
.	O

Mutations	O
at	O
the	O
5	O
end	O
of	O
APC	S-DISO
are	O
known	O
to	O
be	O
associated	O
with	O
a	O
relatively	O
mild	O
form	O
of	O
the	O
disease	O
,	O
called	O
attenuated	B-DISO
adenomatous	I-DISO
polyposis	I-DISO
coli	E-DISO
(	O
AAPC	S-DISO
)	O
.	O

We	O
identified	O
a	O
frameshift	O
mutation	O
in	O
the	O
3	O
part	O
of	O
exon	O
15	O
,	O
resulting	O
in	O
a	O
stop	O
codon	O
at	O
1862	O
,	O
in	O
a	O
large	O
Dutch	O
kindred	O
with	O
AAPC	S-DISO
.	O

Western	O
blot	O
analysis	O
of	O
lymphoblastoid	O
cell	O
lines	O
derived	O
from	O
affected	O
family	O
members	O
from	O
this	O
kindred	O
,	O
as	O
well	O
as	O
from	O
a	O
previously	O
reported	O
Swiss	O
family	O
carrying	O
a	O
frameshift	O
mutation	O
at	O
codon	O
1987	O
and	O
displaying	O
a	O
similar	O
attenuated	O
phenotype	O
,	O
showed	O
only	O
the	O
wild	O
-	O
type	O
APC	S-DISO
protein	O
.	O

Our	O
study	O
indicates	O
that	O
chain	O
-	O
terminating	O
mutations	O
located	O
in	O
the	O
3	O
part	O
of	O
APC	S-DISO
do	O
not	O
result	O
in	O
detectable	O
truncated	O
polypeptides	O
and	O
we	O
hypothesize	O
that	O
this	O
is	O
likely	O
to	O
be	O
the	O
basis	O
for	O
the	O
observed	O
AAPC	S-DISO
phenotype	O
.	O
.	O

Complete	O
genomic	O
sequence	O
and	O
analysis	O
of	O
117	O
kb	O
of	O
human	O
DNA	O
containing	O
the	O
gene	O
BRCA1	O
.	O

Over	O
100	O
distinct	O
disease	O
-	O
associated	O
mutations	O
have	O
been	O
identified	O
in	O
the	O
breast	B-DISO
-	I-DISO
ovarian	I-DISO
cancer	E-DISO
susceptibility	O
gene	O
BRCA1	O
.	O

Loss	O
of	O
the	O
wild	O
-	O
type	O
allele	O
in	O
>	O
90	O
%	O
of	O
tumors	S-DISO
from	O
patients	O
with	O
inherited	O
BRCA1	O
mutations	O
indicates	O
tumor	S-DISO
suppressive	O
function	O
.	O

The	O
low	O
incidence	O
of	O
somatic	O
mutations	O
suggests	O
that	O
BRCA1	O
inactivation	O
in	O
sporadic	O
tumors	S-DISO
occurs	O
by	O
alternative	O
mechanisms	O
,	O
such	O
as	O
interstitial	O
chromosomal	O
deletion	O
or	O
reduced	O
transcription	O
.	O

To	O
identify	O
possible	O
features	O
of	O
the	O
BRCA1	O
genomic	O
region	O
that	O
may	O
contribute	O
to	O
chromosomal	O
instability	O
as	O
well	O
as	O
potential	O
transcriptional	O
regulatory	O
elements	O
,	O
a	O
117	O
,	O
143	O
-	O
bp	O
DNA	O
sequence	O
encompassing	O
BRCA1	O
was	O
obtained	O
by	O
random	O
sequencing	O
of	O
four	O
cosmids	O
identified	O
from	O
a	O
human	O
chromosome	O
17	O
specific	O
library	O
.	O

The	O
24	O
exons	O
of	O
BRCA1	O
span	O
an	O
81	O
-	O
kb	O
region	O
that	O
has	O
an	O
unusually	O
high	O
density	O
of	O
Alu	O
repetitive	O
DNA	O
(	O
41	O
.	O
5	O
%	O
)	O
,	O
but	O
relatively	O
low	O
density	O
(	O
4	O
.	O
8	O
%	O
)	O
of	O
other	O
repetitive	O
sequences	O
.	O

BRCA1	O
intron	O
lengths	O
range	O
in	O
size	O
from	O
403	O
bp	O
to	O
9	O
.	O

2	O
kb	O
and	O
contain	O
the	O
intragenic	O
microsatellite	O
markers	O
D17S1323	O
,	O
D17S1322	O
,	O
and	O
D17S855	O
,	O
which	O
localize	O
to	O
introns	O
12	O
,	O
19	O
,	O
and	O
20	O
,	O
respectively	O
.	O

In	O
addition	O
to	O
BRCA1	O
,	O
the	O
contig	O
contains	O
two	O
complete	O
genes	O
Rho7	O
,	O
a	O
member	O
of	O
the	O
rho	O
family	O
of	O
GTP	O
binding	O
proteins	O
,	O
and	O
VAT1	O
,	O
an	O
abundant	O
membrane	O
protein	O
of	O
cholinergic	O
synaptic	O
vesicles	O
.	O

Partial	O
sequences	O
of	O
the	O
1A1	O
-	O
3B	O
B	O
-	O
box	O
protein	O
pseudogene	O
and	O
IFP	O
35	O
,	O
an	O
interferon	O
induced	O
leucine	O
zipper	O
protein	O
,	O
reside	O
within	O
the	O
contig	O
.	O

An	O
L21	O
ribosomal	O
protein	O
pseudogene	O
is	O
embedded	O
in	O
BRCA1	O
intron	O
13	O
.	O

The	O
order	O
of	O
genes	O
on	O
the	O
chromosome	O
is	O
centromere	O
-	O
1FP	O
35	O
-	O
VAT1	O
-	O
Rho7	O
-	O
BRCA1	O
-	O
1A1	O
-	O
3B	O
-	O
telomere	O

Identification	O
of	O
a	O
RING	O
protein	O
that	O
can	O
interact	O
in	O
vivo	O
with	O
the	O
BRCA1	O
gene	O
product	O
.	O

The	O
hereditary	B-DISO
breast	I-DISO
and	I-DISO
ovarian	I-DISO
cancer	E-DISO
gene	O
,	O
BRCA1	O
,	O
encodes	O
a	O
large	O
polypeptide	O
that	O
contains	O
the	O
cysteine	O
-	O
rich	O
RING	O
motif	O
,	O
a	O
zinc	O
-	O
binding	O
domain	O
found	O
in	O
a	O
variety	O
of	O
regulatory	O
proteins	O
.	O

Here	O
we	O
describe	O
a	O
novel	O
protein	O
that	O
interacts	O
in	O
vivo	O
with	O
the	O
N	O
-	O
terminal	O
region	O
of	O
BRCA1	O
.	O

This	O
BRCA1	O
-	O
associated	O
RING	O
domain	O
(	O
BARD1	O
)	O
protein	O
contains	O
an	O
N	O
-	O
terminal	O
RING	O
motif	O
,	O
three	O
tandem	O
ankyrin	O
repeats	O
,	O
and	O
a	O
C	O
-	O
terminal	O
sequence	O
with	O
significant	O
homology	O
to	O
the	O
phylogenetically	O
conserved	O
BRCT	O
domains	O
that	O
lie	O
near	O
the	O
C	O
terminus	O
of	O
BRCA1	O
.	O

The	O
BARD1	O
/	O
BRCA1	O
interaction	O
is	O
disrupted	O
by	O
BRCA1	O
missense	O
mutations	O
that	O
segregate	O
with	O
breast	B-DISO
cancer	E-DISO
susceptibility	O
,	O
indicating	O
that	O
BARD1	O
may	O
be	O
involved	O
in	O
mediating	O
tumour	S-DISO
suppression	O
by	O
BRCA1	O
.	O
.	O

Detection	O
of	O
heterozygous	O
mutations	O
in	O
BRCA1	O
using	O
high	O
density	O
oligonucleotide	O
arrays	O
and	O
two	O
-	O
colour	O
fluorescence	O
analysis	O
.	O

The	O
ability	O
to	O
scan	O
a	O
large	O
gene	O
rapidly	O
and	O
accurately	O
for	O
all	O
possible	O
heterozygous	O
mutations	O
in	O
large	O
numbers	O
of	O
patient	O
samples	O
will	O
be	O
critical	O
for	O
the	O
future	O
of	O
medicine	O
.	O

We	O
have	O
designed	O
high	O
-	O
density	O
arrays	O
consisting	O
of	O
over	O
96	O
,	O
600	O
oligonucleotides	O
20	O
-	O
nucleotides	O
(	O
nt	O
)	O
in	O
length	O
to	O
screen	O
for	O
a	O
wide	O
range	O
of	O
heterozygous	O
mutations	O
in	O
the	O
3	O
.	O

45	O
-	O
kilobases	O
(	O
kb	O
)	O
exon	O
11	O
of	O
the	O
hereditary	B-DISO
breast	I-DISO
and	I-DISO
ovarian	I-DISO
cancer	E-DISO
gene	O
BRCA1	O
.	O

Reference	O
and	O
test	O
samples	O
were	O
co	O
-	O
hybridized	O
to	O
these	O
arrays	O
and	O
differences	O
in	O
hybridization	O
patterns	O
quantitated	O
by	O
two	O
-	O
colour	O
analysis	O
.	O

Fourteen	O
of	O
fifteen	O
patient	O
samples	O
with	O
known	O
mutations	O
were	O
accurately	O
diagnosed	O
,	O
and	O
no	O
false	O
positive	O
mutations	O
were	O
identified	O
in	O
20	O
control	O
samples	O
.	O

Eight	O
single	O
nucleotide	O
polymorphisms	O
were	O
also	O
readily	O
detected	O
.	O

DNA	O
chip	O
-	O
based	O
assays	O
may	O
provide	O
a	O
valuable	O
new	O
technology	O
for	O
high	O
-	O
throughput	O
cost	O
-	O
efficient	O
detection	O
of	O
genetic	O
alterations	O
.	O

Autosomal	O
dominant	O
primary	O
hyperparathyroidism	B-DISO
and	I-DISO
jaw	I-DISO
tumor	I-DISO
syndrome	E-DISO
associated	O
with	O
renal	B-DISO
hamartomas	E-DISO
and	O
cystic	B-DISO
kidney	I-DISO
disease	E-DISO
:	O
linkage	O
to	O
1q21	O
-	O
q32	O
and	O
loss	O
of	O
the	O
wild	O
type	O
allele	O
in	O
renal	B-DISO
hamartomas	E-DISO
.	O

Hereditary	B-DISO
hyperparathyroidism	I-DISO
-	I-DISO
jaw	I-DISO
tumor	I-DISO
syndrome	E-DISO
(	O
HPT	B-DISO
-	I-DISO
JT	E-DISO
)	O
is	O
an	O
autosomal	B-DISO
dominant	I-DISO
disease	E-DISO
(	O
OMIM	O
145001	O
)	O
that	O
has	O
recently	O
been	O
mapped	O
to	O
chromosomal	O
region	O
1q21	O
-	O
q32	O
(	O
HRPT2	O
)	O
.	O

Here	O
we	O
report	O
two	O
families	O
with	O
HPT	B-DISO
-	I-DISO
JT	I-DISO
syndrome	E-DISO
in	O
which	O
adult	B-DISO
renal	I-DISO
hamartomas	E-DISO
or	O
cystic	B-DISO
kidney	I-DISO
disease	E-DISO
were	O
prominent	O
associated	O
features	O
,	O
possibly	O
representing	O
a	O
new	O
phenotypic	O
variant	O
of	O
the	O
HPT	B-DISO
-	I-DISO
JT	I-DISO
syndrome	E-DISO
.	O

In	O
the	O
first	O
family	O
,	O
renal	B-DISO
lesions	E-DISO
were	O
present	O
in	O
five	O
out	O
of	O
six	O
affected	O
individuals	O
,	O
whereas	O
HPT	S-DISO
and	O
JT	S-DISO
were	O
seen	O
in	O
four	O
and	O
two	O
cases	O
,	O
respectively	O
.	O

In	O
the	O
second	O
family	O
,	O
JT	S-DISO
was	O
found	O
in	O
three	O
of	O
the	O
five	O
affected	O
individuals	O
and	O
two	O
affected	O
members	O
also	O
exhibited	O
polycystic	B-DISO
kidney	I-DISO
disease	E-DISO
.	O

The	O
possibility	O
of	O
the	O
latter	O
cosegregating	O
as	O
a	O
separate	O
autosomal	O
dominant	O
gene	O
can	O
not	O
be	O
ruled	O
out	O
.	O

A	O
sex	O
-	O
dependent	O
penetrance	O
of	O
primary	B-DISO
HPT	E-DISO
,	O
resulting	O
in	O
predominantly	O
male	O
-	O
affected	O
cases	O
was	O
evident	O
in	O
the	O
two	O
families	O
.	O

Twenty	O
microsatellite	O
markers	O
in	O
the	O
HRPT2	O
region	O
were	O
typed	O
,	O
in	O
addition	O
to	O
markers	O
in	O
the	O
multiple	B-DISO
endocrine	I-DISO
neoplasia	I-DISO
(	I-DISO
MEN	I-DISO
)	I-DISO
types	I-DISO
1	I-DISO
and	I-DISO
2	E-DISO
regions	O
at	O
11q13	O
and	O
10q11	O
.	O

The	O
disease	O
in	O
these	O
two	O
kindreds	O
was	O
linked	O
to	O
five	O
markers	O
in	O
the	O
1q21	O
-	O
q32	O
region	O
(	O
logarithm	O
-	O
of	O
-	O
odds	O
scores	O
3	O
.	O
2	O
-	O
4	O
2	O
-	O
4	O
.	O
2	O
)	O
,	O
whereas	O
linkage	O
to	O
the	O
MEN1	S-DISO
and	O
MEN2	S-DISO
regions	O
was	O
excluded	O
.	O

Meiotic	O
recombinations	O
detected	O
in	O
affected	O
individuals	O
placed	O
the	O
locus	O
telomeric	O
of	O
D1S215	O
,	O
thus	O
narrowing	O
the	O
HRPT2	O
region	O
from	O
>	O
60	O
to	O
approximately	O
34	O
centimorgans	O
.	O

Loss	O
of	O
heterozygosity	O
was	O
studied	O
in	O
seven	O
renal	B-DISO
hamartomas	E-DISO
from	O
two	O
affected	O
individuals	O
in	O
the	O
first	O
family	O
,	O
as	O
well	O
as	O
in	O
a	O
jaw	B-DISO
tumor	E-DISO
and	O
a	O
parathyroid	B-DISO
tumor	E-DISO
from	O
the	O
second	O
family	O
.	O

All	O
renal	B-DISO
hamartomas	E-DISO
showed	O
loss	O
of	O
heterozygosity	O
at	O
the	O
1q21	O
-	O
q32	O
region	O
.	O

The	O
losses	O
invariably	O
involved	O
the	O
wild	O
type	O
allele	O
derived	O
from	O
the	O
unaffected	O
parent	O
,	O
suggesting	O
the	O
inactivation	O
of	O
a	O
tumor	S-DISO
suppressor	O
gene	O
in	O
this	O
region	O

Independent	O
origin	O
of	O
single	O
and	O
double	O
mutations	O
in	O
the	O
human	O
glucose	O
6	O
-	O
phosphate	O
dehydrogenase	O
gene	O
.	O

The	O
vast	O
majority	O
of	O
both	O
polymorphic	O
and	O
sporadic	O
G6PD	O
variants	O
are	O
due	O
to	O
single	O
missense	O
mutations	O
.	O

In	O
the	O
four	O
polymorphic	O
variants	O
that	O
have	O
two	O
point	O
mutations	O
,	O
one	O
of	O
the	O
mutations	O
is	O
always	O
376	O
A	O
-	O
-	O
>	O
G	O
(	O
126	O
Asn	O
-	O
-	O
>	O
Asp	O
)	O
,	O
which	O
on	O
its	O
own	O
gives	O
rise	O
to	O
the	O
nondeficient	O
polymorphic	O
variant	O
,	O
G6PD	O
A	O
.	O

In	O
a	O
study	O
of	O
G6PD	B-DISO
deficient	E-DISO
patients	O
who	O
presented	O
with	O
clinical	O
favism	S-DISO
in	O
Spain	O
,	O
we	O
have	O
found	O
a	O
new	O
polymorphic	O
variant	O
that	O
we	O
have	O
called	O
G6PD	O
Malaga	O
,	O
whose	O
only	O
abnormality	O
is	O
a	O
542	O
A	O
-	O
-	O
>	O
T	O
(	O
181	O
Asp	O
-	O
-	O
>	O
Val	O
)	O
mutation	O
.	O

This	O
is	O
the	O
same	O
mutation	O
as	O
previously	O
found	O
in	O
association	O
with	O
the	O
mutation	O
of	O
G6PD	O
A	O
in	O
the	O
double	O
mutant	O
,	O
G6PD	O
Santamaria	O
.	O

G6PD	O
Malaga	O
is	O
associated	O
with	O
enzyme	B-DISO
deficiency	E-DISO
(	O
class	O
III	O
)	O
,	O
and	O
the	O
enzymic	O
properties	O
of	O
G6PD	O
Malaga	O
and	O
G6PD	O
Santamaria	O
are	O
quite	O
similar	O
,	O
indicating	O
that	O
in	O
this	O
case	O
the	O
effects	O
of	O
the	O
two	O
mutations	O
are	O
additive	O
rather	O
than	O
synergistic	O
.	O

G6PD	O
Santamaria	O
might	O
have	O
been	O
produced	O
by	O
recombination	O
between	O
G6PD	O
A	O
and	O
G6PD	O
Malaga	O
;	O
however	O
haplotype	O
analysis	O
,	O
including	O
the	O
use	O
of	O
a	O
new	O
silent	O
polymorphism	O
,	O
suggests	O
that	O
the	O
same	O
542	O
A	O
-	O
-	O
>	O
T	O
mutation	O
has	O
taken	O
place	O
independently	O
in	O
a	O
G6PD	O
B	O
gene	O
to	O
give	O
G6PD	O
Malaga	O
and	O
in	O
a	O
G6PD	O
A	O
gene	O
to	O
give	O
G6PD	O
Santamaria	O
.	O

These	O
findings	O
help	O
to	O
outline	O
the	O
relationship	O
and	O
evolution	O
of	O
mutations	O
in	O
the	O
human	O
G6PD	O
locus	O
.	O
.	O

BRCA1	O
R841W	O
:	O
a	O
strong	O
candidate	O
for	O
a	O
common	O
mutation	O
with	O
moderate	O
phenotype	O
.	O

BRCA1	O
mutations	O
cause	O
increased	O
risk	O
for	O
breast	B-DISO
and	I-DISO
ovarian	I-DISO
cancer	E-DISO
,	O
frequently	O
of	O
early	O
onset	O
.	O

Many	O
different	O
mutations	O
occur	O
in	O
BRCA1	O
,	O
including	O
several	O
examples	O
of	O
recurrent	O
mutations	O
,	O
each	O
of	O
which	O
accounts	O
for	O
a	O
significant	O
number	O
of	O
families	O
with	O
heritable	O
cancer	S-DISO
predisposition	O
.	O

These	O
common	O
mutations	O
have	O
an	O
etiological	O
role	O
in	O
many	O
breast	B-DISO
and	I-DISO
ovarian	I-DISO
cancer	E-DISO
cases	O
and	O
provide	O
the	O
opportunity	O
to	O
examine	O
genotype	O
-	O
phenotype	O
correlations	O
and	O
genotype	O
-	O
environment	O
interactions	O
in	O
individuals	O
with	O
the	O
identical	O
BRCA1	O
lesion	O
.	O

We	O
report	O
a	O
novel	O
missense	O
change	O
in	O
BRCA1	O
,	O
2640	O
C	O
-	O
-	O
>	O
T	O
(	O
R841W	O
)	O
,	O
found	O
in	O
3	O
cases	O
from	O
a	O
subject	O
group	O
of	O
305	O
breast	B-DISO
and	I-DISO
79	I-DISO
ovarian	I-DISO
cancer	E-DISO
cases	O
from	O
Orange	O
County	O
,	O
CA	O
.	O

These	O
are	O
consecutive	O
,	O
population	O
-	O
based	O
cases	O
not	O
selected	O
for	O
age	O
or	O
family	O
history	O
.	O

In	O
all	O
three	O
cases	O
,	O
there	O
is	O
a	O
strong	O
family	O
history	O
of	O
breast	B-DISO
,	I-DISO
ovarian	I-DISO
,	I-DISO
or	I-DISO
other	I-DISO
cancers	E-DISO
possibly	O
related	O
to	O
a	O
BRCA1	O
defect	O
and	O
family	O
members	O
showed	O
a	O
high	O
concordance	O
of	O
cancer	S-DISO
incidence	O
with	O
the	O
presence	O
of	O
R841W	O
.	O

The	O
age	O
of	O
cancer	S-DISO
onset	O
was	O
not	O
always	O
distinct	O
from	O
typical	O
sporadic	O
cases	O
.	O

Testing	O
of	O
a	O
sample	O
of	O
413	O
unrelated	O
individuals	O
to	O
examine	O
the	O
hypothesis	O
that	O
R841W	O
might	O
be	O
a	O
rare	O
polymorphism	O
detected	O
one	O
additional	O
instance	O
in	O
a	O
woman	O
with	O
breast	B-DISO
cancer	E-DISO
diagnosed	O
at	O
age	O
77	O
years	O
,	O
and	O
cancer	S-DISO
in	O
one	O
parent	O
.	O

R841W	O
is	O
likely	O
to	O
be	O
an	O
etiologically	O
significant	O
lesion	O
with	O
involvement	O
in	O
close	O
to	O
1	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
of	O
0	O
-	O
1	O
.	O
7	O
%	O
)	O
of	O
all	O
breast	B-DISO
and	I-DISO
ovarian	I-DISO
cancers	E-DISO
in	O
this	O
population	O
.	O

Ataxia	B-DISO
-	I-DISO
telangiectasia	E-DISO
:	O
founder	O
effect	O
among	O
north	O
African	O
Jews	O
.	O

The	O
ATM	O
gene	O
is	O
responsible	O
for	O
the	O
autosomal	B-DISO
recessive	I-DISO
disorder	E-DISO
ataxia	B-DISO
-	I-DISO
telangiectasia	E-DISO
(	O
A	B-DISO
-	I-DISO
T	E-DISO
)	O
,	O
characterized	O
by	O
cerebellar	B-DISO
degeneration	E-DISO
,	O
immunodeficiency	S-DISO
and	O
cancer	B-DISO
predisposition	E-DISO
.	O

A	B-DISO
-	I-DISO
T	E-DISO
carriers	O
were	O
reported	O
to	O
be	O
moderately	O
cancer	B-DISO
-	I-DISO
prone	E-DISO
.	O

A	O
wide	O
variety	O
of	O
A	B-DISO
-	I-DISO
T	E-DISO
mutations	O
,	O
most	O
of	O
which	O
are	O
unique	O
to	O
single	O
families	O
,	O
were	O
identified	O
in	O
various	O
ethnic	O
groups	O
,	O
precluding	O
carrier	O
screening	O
with	O
mutation	O
-	O
specific	O
assays	O
.	O

However	O
,	O
a	O
single	O
mutation	O
was	O
observed	O
in	O
32	O
/	O
33	O
defective	O
ATM	O
alleles	O
in	O
Jewish	O
A	B-DISO
-	I-DISO
T	E-DISO
families	O
of	O
North	O
African	O
origin	O
,	O
coming	O
from	O
various	O
regions	O
of	O
Morocco	O
and	O
Tunisia	O
.	O

This	O
mutation	O
,	O
103C	O
-	O
-	O
>	O
T	O
,	O
results	O
in	O
a	O
stop	O
codon	O
at	O
position	O
35	O
of	O
the	O
ATM	O
protein	O
.	O

In	O
keeping	O
with	O
the	O
nature	O
of	O
this	O
mutation	O
,	O
various	O
antibodies	O
directed	O
against	O
the	O
ATM	O
protein	O
failed	O
to	O
defect	O
this	O
protein	O
in	O
patient	O
cells	O
.	O

A	O
rapid	O
carrier	O
detection	O
assay	O
detected	O
this	O
mutation	O
in	O
three	O
out	O
of	O
488	O
ATM	O
alleles	O
of	O
Jewish	O
Moroccan	O
or	O
Tunisian	O
origin	O
.	O

This	O
founder	O
effect	O
provides	O
a	O
unique	O
opportunity	O
for	O
population	O
-	O
based	O
screening	O
for	O
A	B-DISO
-	I-DISO
T	E-DISO
carriers	O
in	O
a	O
large	O
Jewish	O
community	O
.	O
.	O

Mutation	O
analysis	O
of	O
BRCA1	O
and	O
BRCA2	O
in	O
a	O
male	B-DISO
breast	I-DISO
cancer	E-DISO
population	O
.	O

A	O
population	O
-	O
based	O
series	O
of	O
54	O
male	B-DISO
breast	I-DISO
cancer	E-DISO
cases	O
from	O
Southern	O
California	O
were	O
analyzed	O
for	O
germ	O
-	O
line	O
mutations	O
in	O
the	O
inherited	B-DISO
breast	I-DISO
/	I-DISO
ovarian	I-DISO
cancer	E-DISO
genes	O
,	O
BRCA1	O
and	O
BRCA2	O
.	O

Nine	O
(	O
17	O
%	O
)	O
of	O
the	O
patients	O
had	O
a	O
family	O
history	O
of	O
breast	B-DISO
and	I-DISO
/	I-DISO
or	I-DISO
ovarian	I-DISO
cancer	E-DISO
in	O
at	O
least	O
one	O
first	O
-	O
degree	O
relative	O
.	O

A	O
further	O
seven	O
(	O
13	O
%	O
)	O
of	O
the	O
patients	O
reported	O
breast	B-DISO
/	I-DISO
ovarian	I-DISO
cancer	E-DISO
in	O
at	O
least	O
one	O
second	O
-	O
degree	O
relative	O
and	O
in	O
no	O
first	O
-	O
degree	O
relatives	O
.	O

No	O
germ	O
-	O
line	O
BRCA1	O
mutations	O
were	O
found	O
.	O

Two	O
male	B-DISO
breast	I-DISO
cancer	E-DISO
patients	O
(	O
4	O
%	O
of	O
the	O
total	O
)	O
were	O
found	O
to	O
carry	O
novel	O
truncating	O
mutations	O
in	O
the	O
BRCA2	O
gene	O
.	O

Only	O
one	O
of	O
the	O
two	O
male	B-DISO
breast	I-DISO
cancer	E-DISO
patients	O
carrying	O
a	O
BRCA2	O
mutation	O
had	O
a	O
family	O
history	O
of	O
cancer	S-DISO
,	O
with	O
one	O
case	O
of	O
ovarian	B-DISO
cancer	E-DISO
in	O
a	O
first	O
-	O
degree	O
relative	O
.	O

The	O
remaining	O
eight	O
cases	O
(	O
89	O
%	O
)	O
of	O
male	B-DISO
breast	I-DISO
cancer	E-DISO
with	O
a	O
family	O
history	O
of	O
breast	B-DISO
/	I-DISO
ovarian	I-DISO
cancer	E-DISO
in	O
first	O
-	O
degree	O
relatives	O
remain	O
unaccounted	O
for	O
by	O
mutations	O
in	O
either	O
the	O
BRCA1	O
gene	O
or	O
the	O
BRCA2	O
gene	O
.	O
.	O

Molecular	O
basis	O
for	O
Duarte	B-DISO
and	I-DISO
Los	I-DISO
Angeles	I-DISO
variant	I-DISO
galactosemia	E-DISO
.	O

Human	O
orythrocytes	O
that	O
are	O
homozygous	O
for	O
the	O
Duarte	B-DISO
enzyme	I-DISO
variant	I-DISO
of	I-DISO
galactosemia	E-DISO
(	O
D	O
/	O
D	O
)	O
have	O
a	O
characteristic	O
isoform	O
on	O
isoelectric	O
focusing	O
and	O
50	O
%	O
reduction	O
in	O
galactose	O
-	O
1	O
-	O
phosphate	O
uridyltransferase	O
(	O
GALT	O
)	O
enzyme	O
activity	O
.	O

The	O
Duarte	O
biochemical	O
phenotype	O
has	O
a	O
molecular	O
genotype	O
of	O
N314D	O
/	O
N314D	O
.	O

The	O
characteristic	O
Duarte	O
isoform	O
is	O
also	O
associated	O
with	O
a	O
variant	O
called	O
the	O
"	O
Los	O
Angeles	O
(	O
LA	O
)	O
phenotype	O
,	O
"	O
which	O
has	O
increased	O
GALT	O
enzyme	O
activity	O
.	O

We	O
evaluated	O
GALT	O
enzyme	O
activity	O
and	O
screened	O
the	O
GALT	O
genes	O
of	O
145	O
patients	O
with	O
one	O
or	O
more	O
N314D	O
-	O
containing	O
alleles	O
.	O

We	O
found	O
seven	O
with	O
the	O
LA	O
biochemical	O
phenotype	O
,	O
and	O
all	O
had	O
a	O
1721C	O
-	O
-	O
>	O
T	O
transition	O
in	O
exon	O
7	O
in	O
cis	O
with	O
the	O
N314D	O
missense	O
mutation	O
.	O

The	O
1721C	O
-	O
-	O
>	O
T	O
transition	O
is	O
a	O
neutral	O
polymorphism	O
for	O
leucine	O
at	O
amino	O
acid	O
218	O
(	O
L218L	O
)	O
.	O

In	O
pedigree	O
analyses	O
,	O
this	O
1721C	O
-	O
-	O
>	O
T	O
transition	O
segregated	O
with	O
the	O
LA	O
phenotype	O
of	O
increased	O
GALT	O
activity	O
in	O
three	O
different	O
biochemical	O
phenotypes	O
(	O
LA	O
/	O
N	O
,	O
LA	O
/	O
G	O
,	O
and	O
LA	O
/	O
D	O
)	O
.	O

To	O
determine	O
the	O
mechanism	O
for	O
increased	O
activity	O
of	O
the	O
LA	O
variant	O
,	O
we	O
compared	O
GALT	O
mRNA	O
,	O
protein	O
abundance	O
,	O
and	O
enzyme	O
thermal	O
stability	O
in	O
lymphoblast	O
cell	O
lines	O
of	O
D	O
and	O
LA	O
phenotypes	O
with	O
comparable	O
genotypes	O
.	O

GALT	O
protein	O
abundance	O
was	O
increased	O
in	O
LA	O
compared	O
to	O
D	O
alleles	O
,	O
but	O
mRNA	O
was	O
similar	O
among	O
all	O
genotypes	O
.	O

When	O
LA	O
/	O
D	O
and	O
D	O
/	O
D	O
GALT	O
biochemical	O
phenotypes	O
were	O
compared	O
to	O
N	O
/	O
N	O
GALT	O
phenotypes	O
,	O
both	O
had	O
50	O
%	O
,	O
as	O
compared	O
to	O
21	O
%	O
,	O
reduction	O
in	O
GALT	O
activity	O
in	O
the	O
wild	O
type	O
(	O
N	O
/	O
N	O
)	O
after	O
exposure	O
at	O
identical	O
initial	O
enzyme	O
activity	O
to	O
50	O
degrees	O
C	O
for	O
15	O
min	O
.	O

We	O
conclude	O
that	O
the	O
codon	O
change	O
N314D	O
in	O
cis	O
with	O
the	O
base	O
-	O
pair	O
transition	O
1721C	O
-	O
-	O
>	O
T	O
produces	O
the	O
LA	B-DISO
variant	I-DISO
of	I-DISO
galactosemia	E-DISO
and	O
that	O
this	O
nucleotide	O
change	O
increases	O
GALT	O
activity	O
by	O
increasing	O
GALT	O
protein	O
abundance	O
without	O
increasing	O
transcription	O
or	O
decreasing	O
thermal	O
lability	O
.	O

A	O
favorable	O
codon	O
bias	O
for	O
the	O
mutated	O
codon	O
with	O
consequently	O
increased	O
translation	O
rates	O
is	O
postulated	O
as	O
the	O
mechanism	O
.	O
.	O

The	O
TSG101	O
tumor	S-DISO
susceptibility	O
gene	O
is	O
located	O
in	O
chromosome	O
11	O
band	O
p15	O
and	O
is	O
mutated	O
in	O
human	O
breast	B-DISO
cancer	E-DISO
.	O

Recent	O
work	O
has	O
identified	O
a	O
mouse	O
gene	O
(	O
tsg101	O
)	O
whose	O
inactivation	O
in	O
fibroblasts	O
results	O
in	O
cellular	O
transformation	O
and	O
the	O
ability	O
to	O
produce	O
metastatic	B-DISO
tumors	E-DISO
in	O
nude	O
mice	O
.	O

Here	O
,	O
we	O
report	O
that	O
the	O
human	O
homolog	O
,	O
TSG101	O
,	O
which	O
we	O
isolated	O
and	O
mapped	O
to	O
chromosome	O
11	O
,	O
bands	O
15	O
.	O

1	O
-	O
15	O
1	O
-	O
15	O
.	O

2	O
,	O
a	O
region	O
proposed	O
to	O
contain	O
tumor	S-DISO
suppressor	O
gene	O
(	O
s	O
)	O
,	O
is	O
mutated	O
at	O
high	O
frequency	O
in	O
human	O
breast	B-DISO
cancer	E-DISO
.	O

In	O
7	O
of	O
15	O
uncultured	O
primary	O
human	O
breast	B-DISO
carcinomas	E-DISO
,	O
intragenic	O
deletions	O
were	O
shown	O
in	O
TSG101	O
genomic	O
DNA	O
and	O
transcripts	O
by	O
gel	O
and	O
sequence	O
analysis	O
,	O
and	O
mutations	O
affecting	O
two	O
TSG101	O
alleles	O
were	O
identified	O
in	O
four	O
of	O
these	O
cancers	S-DISO
.	O

No	O
TSG101	O
defects	O
were	O
found	O
in	O
matched	O
normal	O
breast	O
tissue	O
from	O
the	O
breast	B-DISO
cancer	E-DISO
patients	O
.	O

These	O
findings	O
strongly	O
implicate	O
TSG101	O
mutations	O
in	O
human	O
breast	B-DISO
cancer	E-DISO

Moderate	O
intergenerational	O
and	O
somatic	O
instability	O
of	O
a	O
55	O
-	O
CTG	O
repeat	O
in	O
transgenic	O
mice	O
.	O

Myotonic	B-DISO
dystrophy	E-DISO
(	O
DM	S-DISO
)	O
is	O
associated	O
with	O
the	O
expansion	O
of	O
a	O
(	O
CTG	O
)	O
n	O
trinucleotide	O
repeat	O
in	O
the	O
3	O
untranslated	O
region	O
(	O
UTR	O
)	O
of	O
the	O
DM	S-DISO
protein	O
kinase	O
gene	O
(	O
DMPK	O
)	O
.	O

The	O
(	O
CTG	O
)	O
n	O
repeat	O
is	O
polymorphic	O
and	O
varies	O
in	O
size	O
between	O
5	O
and	O
37	O
repeats	O
in	O
unaffected	O
individuals	O
whereas	O
in	O
affected	O
patients	O
there	O
are	O
between	O
50	O
and	O
4	O
,	O
000	O
CTGs	O
.	O

The	O
size	O
of	O
the	O
(	O
CTG	O
)	O
n	O
repeat	O
,	O
which	O
increases	O
through	O
generations	O
,	O
generally	O
correlates	O
with	O
clinical	O
severity	O
and	O
age	O
of	O
onset	O
.	O

The	O
instability	O
of	O
the	O
CTG	O
repeat	O
appears	O
to	O
depend	O
on	O
its	O
size	O
as	O
well	O
as	O
on	O
the	O
sex	O
of	O
the	O
transmitting	O
parent	O
.	O

Moreover	O
,	O
mitotic	O
instability	O
analysis	O
of	O
different	O
human	O
DM	S-DISO
tissues	O
shows	O
length	O
mosaicism	O
between	O
different	O
cell	O
lineages	O
.	O

The	O
molecular	O
mechanisms	O
of	O
triplet	O
instability	O
remain	O
elusive	O
.	O

To	O
investigate	O
the	O
role	O
of	O
genomic	O
sequences	O
in	O
instability	O
,	O
we	O
produced	O
transgenic	O
mice	O
containing	O
a	O
45	O
-	O
kb	O
genomic	O
segment	O
with	O
a	O
55	O
-	O
CTG	O
repeat	O
cloned	O
from	O
a	O
mildly	O
affected	O
patient	O
.	O

In	O
contrast	O
to	O
other	O
mouse	O
models	O
containing	O
CAG	O
repeats	O
within	O
cDNAs	O
,	O
these	O
mice	O
showed	O
both	O
intergenerational	O
and	O
somatic	O
repeat	O
instability	O
.	O
.	O

Missense	O
mutations	O
in	O
the	O
Fas	O
gene	O
resulting	O
in	O
autoimmune	B-DISO
lymphoproliferative	I-DISO
syndrome	E-DISO
:	O
a	O
molecular	O
and	O
immunological	O
analysis	O
.	O

Programmed	O
cell	O
death	O
(	O
or	O
apoptosis	O
)	O
is	O
a	O
physiological	O
process	O
essential	O
to	O
the	O
normal	O
development	O
and	O
homeostatic	O
maintenance	O
of	O
the	O
immune	O
system	O
.	O

The	O
Fas	O
/	O
Apo	O
-	O
1	O
receptor	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
regulation	O
of	O
apoptosis	O
,	O
as	O
demonstrated	O
by	O
lymphoproliferation	O
in	O
MRL	O
-	O
lpr	O
/	O
lpr	O
mice	O
and	O
by	O
the	O
recently	O
described	O
autoimmune	B-DISO
lymphoproliferative	I-DISO
syndrome	E-DISO
(	O
ALPS	S-DISO
)	O
in	O
humans	O
,	O
both	O
of	O
which	O
are	O
due	O
to	O
mutations	O
in	O
the	O
Fas	O
gene	O
.	O

We	O
describe	O
a	O
novel	O
family	O
with	O
ALPS	S-DISO
in	O
which	O
three	O
affected	O
siblings	O
carry	O
two	O
distinct	O
missense	O
mutations	O
on	O
both	O
the	O
Fas	O
gene	O
alleles	O
and	O
show	O
lack	O
of	O
Fas	O
-	O
induced	O
apoptosis	O
.	O

The	O
children	O
share	O
common	O
clinical	O
features	O
including	O
splenomegaly	S-DISO
and	O
lymphadenopathy	S-DISO
,	O
but	O
only	O
one	O
developed	O
severe	O
autoimmune	B-DISO
manifestations	E-DISO
.	O

In	O
all	O
three	O
siblings	O
,	O
we	O
demonstrated	O
the	O
presence	O
of	O
anergic	O
CD3	O
+	O
CD4	O
-	O
CD8	O
-	O
(	O
double	O
negative	O
,	O
[	O
DN	O
]	O
)	O
T	O
cells	O
;	O
moreover	O
,	O
a	O
chronic	O
lymphocyte	O
activation	O
was	O
found	O
,	O
as	O
demonstrated	O
by	O
the	O
presence	O
of	O
high	O
levels	O
of	O
HLA	O
-	O
DR	O
expression	O
on	O
peripheral	O
CD3	O
+	O
cells	O
and	O
by	O
the	O
presence	O
of	O
high	O
levels	O
of	O
serum	O
activation	O
markers	O
such	O
as	O
soluble	O
interleukin	O
-	O
2	O
receptor	O
(	O
slL	O
-	O
2R	O
)	O
and	O
soluble	O
CD30	O
(	O
sCD30	O
)	O
.	O
.	O

The	O
ataxia	B-DISO
-	I-DISO
telangiectasia	E-DISO
gene	O
product	O
,	O
a	O
constitutively	O
expressed	O
nuclear	O
protein	O
that	O
is	O
not	O
up	O
-	O
regulated	O
following	O
genome	O
damage	O
.	O

The	O
product	O
of	O
the	O
ataxia	B-DISO
-	I-DISO
telangiectasia	E-DISO
gene	O
(	O
ATM	O
)	O
was	O
identified	O
by	O
using	O
an	O
antiserum	O
developed	O
to	O
a	O
peptide	O
corresponding	O
to	O
the	O
deduced	O
amino	O
acid	O
sequence	O
.	O

The	O
ATM	O
protein	O
is	O
a	O
single	O
,	O
high	O
-	O
molecular	O
weight	O
protein	O
predominantly	O
confined	O
to	O
the	O
nucleus	O
of	O
human	O
fibroblasts	O
,	O
but	O
is	O
present	O
in	O
both	O
nuclear	O
and	O
microsomal	O
fractions	O
from	O
human	O
lymphoblast	O
cells	O
and	O
peripheral	O
blood	O
lymphocytes	O
.	O

ATM	O
protein	O
levels	O
and	O
localization	O
remain	O
constant	O
throughout	O
all	O
stages	O
of	O
the	O
cell	O
cycle	O
.	O

Truncated	O
ATM	O
protein	O
was	O
not	O
detected	O
in	O
lymphoblasts	O
from	O
ataxia	B-DISO
-	I-DISO
telangiectasia	E-DISO
patients	O
homozygous	O
for	O
mutations	O
leading	O
to	O
premature	O
protein	O
termination	O
.	O

Exposure	O
of	O
normal	O
human	O
cells	O
to	O
gamma	O
-	O
irradiation	O
and	O
the	O
radiomimetic	O
drug	O
neocarzinostatin	O
had	O
no	O
effect	O
on	O
ATM	O
protein	O
levels	O
,	O
in	O
contrast	O
to	O
a	O
noted	O
rise	O
in	O
p53	O
levels	O
over	O
the	O
same	O
time	O
interval	O
.	O

These	O
findings	O
are	O
consistent	O
with	O
a	O
role	O
for	O
the	O
ATM	O
protein	O
in	O
ensuring	O
the	O
fidelity	O
of	O
DNA	O
repair	O
and	O
cell	O
cycle	O
regulation	O
following	O
genome	O
damage	O
.	O
.	O

Type	O
III	O
collagen	O
is	O
crucial	O
for	O
collagen	O
I	O
fibrillogenesis	O
and	O
for	O
normal	O
cardiovascular	O
development	O
.	O

Type	O
III	O
collagen	O
is	O
a	O
fibrillar	O
forming	O
collagen	O
comprising	O
three	O
alpha1	O
(	O
III	O
)	O
chains	O
and	O
is	O
expressed	O
in	O
early	O
embryos	O
and	O
throughout	O
embryogenesis	O
.	O

In	O
the	O
adult	O
,	O
type	O
III	O
collagen	O
is	O
a	O
major	O
component	O
of	O
the	O
extracellular	O
matrix	O
in	O
a	O
variety	O
of	O
internal	O
organs	O
and	O
skin	O
.	O

Mutations	O
in	O
the	O
COL3A1	O
gene	O
have	O
been	O
implicated	O
as	O
a	O
cause	O
of	O
type	B-DISO
IV	I-DISO
Ehlers	I-DISO
-	I-DISO
Danlos	I-DISO
syndrome	E-DISO
,	O
a	O
disease	O
leading	O
to	O
aortic	B-DISO
rupture	E-DISO
in	O
early	O
adult	O
life	O
.	O

To	O
directly	O
study	O
the	O
role	O
of	O
Col3a1	O
in	O
development	O
and	O
disease	O
,	O
we	O
have	O
inactivated	O
the	O
Col3a1	O
gene	O
in	O
embryonic	O
stem	O
cells	O
by	O
homologous	O
recombination	O
.	O

The	O
mutated	O
allele	O
was	O
transmitted	O
through	O
the	O
mouse	O
germ	O
line	O
and	O
homozygous	O
mutant	O
animals	O
were	O
derived	O
from	O
heterozygous	O
intercrosses	O
.	O

About	O
10	O
%	O
of	O
the	O
homozygous	O
mutant	O
animals	O
survived	O
to	O
adulthood	O
but	O
have	O
a	O
much	O
shorter	O
life	O
span	O
compared	O
with	O
wild	O
-	O
type	O
mice	O
.	O

The	O
major	O
cause	O
of	O
death	O
of	O
mutant	O
mice	O
was	O
rupture	O
of	O
the	O
major	O
blood	O
vessels	O
,	O
similar	O
to	O
patients	O
with	O
type	B-DISO
IV	I-DISO
Ehlers	I-DISO
-	I-DISO
Danlos	I-DISO
syndrome	E-DISO
.	O

Ultrastructural	O
analysis	O
of	O
tissues	O
from	O
mutant	O
mice	O
revealed	O
that	O
type	O
III	O
collagen	O
is	O
essential	O
for	O
normal	O
collagen	O
I	O
fibrillogenesis	O
in	O
the	O
cardiovascular	O
system	O
and	O
other	O
organs	O
.	O
.	O

Nonsense	O
mutation	O
in	O
exon	O
3	O
of	O
the	O
proteolipid	O
protein	O
gene	O
(	O
PLP	O
)	O
in	O
a	O
family	O
with	O
an	O
unusual	O
form	O
of	O
Pelizaeus	B-DISO
-	I-DISO
Merzbacher	I-DISO
disease	E-DISO
.	O

We	O
report	O
a	O
G	O
-	O
-	O
>	O
A	O
transition	O
at	O
nucleotide	O
431	O
of	O
the	O
proteolipid	O
protein	O
gene	O
(	O
PLP	O
)	O
results	O
in	O
a	O
nonsense	O
codon	O
in	O
a	O
family	O
with	O
an	O
unusual	O
form	O
of	O
Pelizaeus	B-DISO
-	I-DISO
Merzbacher	I-DISO
disease	E-DISO
(	O
PMD	S-DISO
)	O
.	O

The	O
mutation	O
,	O
which	O
creates	O
a	O
second	O
AluI	O
restriction	O
site	O
,	O
results	O
in	O
a	O
nonsense	O
mutation	O
in	O
PLP	O
.	O

The	O
clinical	O
picture	O
resembles	O
somewhat	O
that	O
of	O
X	B-DISO
-	I-DISO
linked	I-DISO
spastic	I-DISO
paraplegia	E-DISO
(	O
SPG	S-DISO
)	O
.	O

It	O
differs	O
from	O
this	O
and	O
both	O
the	O
classical	O
and	O
connatal	O
forms	O
of	O
PMD	S-DISO
in	O
that	O
it	O
is	O
relatively	O
mild	O
in	O
form	O
,	O
onset	O
is	O
delayed	O
beyond	O
age	O
2	O
years	O
,	O
nystagmus	S-DISO
is	O
absent	O
,	O
tremors	S-DISO
are	O
prominent	O
,	O
mental	B-DISO
retardation	E-DISO
is	O
not	O
severe	O
,	O
some	O
patients	O
show	O
dementia	S-DISO
or	O
personality	B-DISO
disorders	E-DISO
,	O
the	O
disease	O
is	O
progressive	O
rather	O
than	O
static	O
in	O
some	O
,	O
and	O
several	O
females	O
show	O
signs	O
of	O
disease	O
.	O

The	O
nonsense	O
mutation	O
,	O
which	O
is	O
in	O
exon	O
3B	O
,	O
should	O
block	O
the	O
synthesis	O
of	O
normal	O
PLP	O
but	O
spare	O
DM20	O
,	O
the	O
isoform	O
whose	O
persistence	O
has	O
been	O
associated	O
with	O
mild	O
forms	O
of	O
PLP	B-DISO
-	I-DISO
associated	I-DISO
disease	E-DISO
in	O
both	O
humans	O
and	O
mice	O
.	O
.	O

Common	O
BRCA1	O
variants	O
and	O
susceptibility	O
to	O
breast	B-DISO
and	I-DISO
ovarian	I-DISO
cancer	E-DISO
in	O
the	O
general	O
population	O
.	O

Most	O
multiple	O
case	O
families	O
of	O
young	O
onset	O
breast	B-DISO
cancer	E-DISO
and	O
ovarian	B-DISO
cancer	E-DISO
are	O
thought	O
to	O
be	O
due	O
to	O
highly	O
penetrant	O
mutations	O
in	O
the	O
predisposing	O
genes	O
BRCA1	O
and	O
BRCA2	O
.	O

However	O
,	O
these	O
mutations	O
are	O
uncommon	O
in	O
the	O
population	O
and	O
they	O
probably	O
account	O
for	O
only	O
a	O
few	O
percent	O
of	O
all	O
breast	B-DISO
cancer	E-DISO
incidence	O
.	O

A	O
much	O
larger	O
fraction	O
of	O
breast	B-DISO
cancer	E-DISO
might	O
,	O
in	O
principle	O
,	O
be	O
due	O
to	O
common	O
variants	O
which	O
confer	O
more	O
modest	O
individual	O
risks	O
.	O

There	O
are	O
several	O
common	O
polymorphisms	O
in	O
the	O
BRCA1	O
gene	O
which	O
generate	O
amino	O
acid	O
substitutions	O
.	O

We	O
have	O
examined	O
the	O
frequency	O
of	O
four	O
of	O
these	O
polymorphisms	O
Gln356Arg	O
,	O
Pro871Leu	O
,	O
Glu1038Gly	O
and	O
Ser1613Gly	O
in	O
large	O
series	O
of	O
breast	B-DISO
and	I-DISO
ovarian	I-DISO
cancer	E-DISO
cases	O
and	O
matched	O
controls	O
.	O

Due	O
to	O
strong	O
linkage	O
disequilibrium	O
,	O
these	O
four	O
sites	O
generate	O
only	O
three	O
haplotypes	O
with	O
a	O
frequency	O
>	O
1	O
.	O

3	O
%	O
.	O

The	O
most	O
common	O
haplotypes	O
,	O
defined	O
by	O
the	O
alleles	O
Gln356Pro871Glu1038Ser1613	O
and	O
Gln356Leu871Gly1038Gly1613	O
,	O
have	O
frequencies	O
of	O
0	O
.	O

57	O
and	O
0	O
.	O

32	O
respectively	O
,	O
and	O
these	O
frequencies	O
do	O
not	O
differ	O
significantly	O
between	O
patient	O
and	O
control	O
groups	O
.	O

Thus	O
the	O
most	O
common	O
polymorphisms	O
of	O
the	O
BRCA1	O
gene	O
do	O
not	O
make	O
a	O
significant	O
contribution	O
to	O
breast	B-DISO
or	I-DISO
ovarian	I-DISO
cancer	E-DISO
risk	O
.	O

However	O
,	O
our	O
data	O
suggest	O
that	O
the	O
Arg356	O
allele	O
may	O
have	O
a	O
different	O
genotype	O
distribution	O
in	O
breast	B-DISO
cancer	E-DISO
patients	O
from	O
that	O
in	O
controls	O
(	O
Arg356	O
homozygotes	O
are	O
more	O
frequent	O
in	O
the	O
control	O
groups	O
,	O
P	O
=	O
0	O
.	O
01	O
)	O
,	O
indicating	O
that	O
it	O
may	O
be	O
protective	O
against	O
breast	B-DISO
cancer	E-DISO
.	O

If	O
this	O
finding	O
can	O
be	O
confirmed	O
,	O
it	O
may	O
provide	O
an	O
insight	O
into	O
the	O
structural	O
features	O
of	O
the	O
BRCA1	O
protein	O
that	O
are	O
important	O
for	O
its	O
function	O
.	O

Kniest	B-DISO
dysplasia	E-DISO
:	O
Dr	O
.	O
W	O
.	O

Kniest	O
,	O
his	O
patient	O
,	O
the	O
molecular	O
defect	O
.	O

Kniest	B-DISO
dysplasia	E-DISO
is	O
a	O
severe	O
chondrodysplasia	S-DISO
caused	O
by	O
the	O
defective	B-DISO
formation	I-DISO
of	I-DISO
type	I-DISO
II	I-DISO
collagen	E-DISO
.	O

We	O
report	O
about	O
Dr	O
.	O
Kniest	O
,	O
who	O
first	O
described	O
the	O
condition	O
in	O
1952	O
,	O
and	O
his	O
patient	O
,	O
who	O
,	O
at	O
the	O
age	O
of	O
50	O
years	O
is	O
severely	B-DISO
handicapped	E-DISO
with	O
short	B-DISO
stature	E-DISO
,	O
restricted	B-DISO
joint	I-DISO
mobility	E-DISO
,	O
and	O
blindness	S-DISO
but	O
is	O
mentally	O
alert	O
and	O
leads	O
an	O
active	O
life	O
.	O

Molecular	O
analysis	O
of	O
the	O
patients	O
DNA	O
showed	O
a	O
single	O
base	O
(	O
G	O
)	O
deletion	O
involving	O
the	O
GT	O
dinucleotide	O
at	O
the	O
start	O
of	O
intron	O
18	O
destroying	O
a	O
splice	O
site	O
of	O
the	O
COL2A1	O
gene	O
.	O

This	O
is	O
in	O
accordance	O
with	O
molecular	O
findings	O
in	O
other	O
patients	O
with	O
Kniest	B-DISO
dysplasia	E-DISO
and	O
confirms	O
,	O
in	O
the	O
original	O
patient	O
,	O
that	O
the	O
disorder	O
is	O
caused	O
by	O
small	O
inframe	O
deletions	O
often	O
due	O
to	O
exon	O
skipping	O
as	O
a	O
result	O
of	O
COL2A1	O
splice	O
site	O
mutations	O
.	O
.	O

Cloning	O
of	O
the	O
homogentisate	O
1	O
,	O
2	O
-	O
dioxygenase	O
gene	O
,	O
the	O
key	O
enzyme	O
of	O
alkaptonuria	S-DISO
in	O
mouse	O
.	O

We	O
determined	O
48	O
amino	O
acid	O
residues	O
from	O
five	O
peptides	O
from	O
the	O
homogeneous	O
monomer	O
of	O
homogentisate	O
1	O
,	O
2	O
-	O
dioxygenase	O
(	O
HGO	O
;	O
E	O
.	O
C	O
.	O
1	O
.	O
13	O
.	O
11	O
.	O
15	O
)	O
of	O
mouse	O
liver	O
.	O

After	O
digestion	O
with	O
trypsin	O
,	O
peptides	O
were	O
separated	O
by	O
reversed	O
phase	O
chromatography	O
and	O
amino	O
acid	O
sequenced	O
.	O

The	O
deduced	O
codon	O
sequence	O
of	O
three	O
peptides	O
was	O
used	O
to	O
derive	O
degenerated	O
oligomeres	O
.	O

By	O
combining	O
these	O
oligos	O
,	O
we	O
were	O
able	O
to	O
amplify	O
fragments	O
from	O
100	O
to	O
300	O
bases	O
(	O
b	O
)	O
from	O
mouse	O
liver	O
cDNA	O
by	O
polymerase	O
chain	O
reaction	O
after	O
reverse	O
transcription	O
(	O
RT	O
-	O
PCR	O
)	O
.	O

A	O
fragment	O
of	O
200	O
b	O
was	O
cloned	O
and	O
used	O
as	O
a	O
probe	O
to	O
screen	O
a	O
mouse	O
liver	O
cDNA	O
library	O
.	O

One	O
clone	O
from	O
this	O
library	O
contained	O
the	O
complete	O
cDNA	O
-	O
insert	O
for	O
HGO	O
as	O
determined	O
by	O
sequencing	O
.	O

The	O
cDNA	O
encodes	O
for	O
a	O
protein	O
of	O
50	O
kDa	O
,	O
as	O
predicted	O
.	O

The	O
cDNA	O
of	O
mouse	O
HGO	O
has	O
an	O
overall	O
identity	O
of	O
41	O
%	O
to	O
the	O
corresponding	O
gene	O
hmgA	O
from	O
Aspergillus	O
.	O

Sequence	O
similarities	O
to	O
human	O
expressed	O
sequence	O
tags	O
(	O
EST	O
)	O
clones	O
ranged	O
from	O
70	O
%	O
to	O
20	O
%	O
.	O

The	O
positions	O
of	O
122	O
conserved	O
amino	O
acids	O
could	O
be	O
determined	O
by	O
multiple	O
sequence	O
alignment	O
.	O

We	O
identified	O
one	O
first	O
intron	O
of	O
928	O
b	O
in	O
the	O
mouse	O
gene	O
.	O

The	O
gene	O
for	O
HGO	O
seems	O
to	O
be	O
expressed	O
in	O
various	O
tissues	O
,	O
as	O
shown	O
by	O
RT	O
-	O
PCR	O
on	O
different	O
cDNAs	O
.	O

FISH	O
experiments	O
with	O
the	O
whole	O
murine	O
cDNA	O
as	O
probe	O
clearly	O
revealed	O
signals	O
at	O
the	O
human	O
chromosomal	O
band	O
3q13	O
.	O

3	O
-	O
q21	O
.	O

This	O
corresponds	O
well	O
to	O
the	O
previous	O
assignment	O
of	O
the	O
locus	O
for	O
the	O
human	O
alkaptonuria	S-DISO
gene	O
(	O
AKU	O
)	O
to	O
the	O
same	O
chromosomal	O
region	O
by	O
multipoint	O
linkage	O
analysis	O
.	O

We	O
therefore	O
conclude	O
that	O
the	O
HGO	O
cDNA	O
encodes	O
the	O
gene	O
responsible	O
for	O
alkaptonuria	S-DISO
.	O

PTEN	O
,	O
a	O
putative	O
protein	O
tyrosine	O
phosphatase	O
gene	O
mutated	O
in	O
human	O
brain	B-DISO
,	I-DISO
breast	I-DISO
,	I-DISO
and	I-DISO
prostate	I-DISO
cancer	E-DISO
.	O

Mapping	O
of	O
homozygous	O
deletions	O
on	O
human	O
chromosome	O
10q23	O
has	O
led	O
to	O
the	O
isolation	O
of	O
a	O
candidate	O
tumor	S-DISO
suppressor	O
gene	O
,	O
PTEN	O
,	O
that	O
appears	O
to	O
be	O
mutated	O
at	O
considerable	O
frequency	O
in	O
human	O
cancers	S-DISO
.	O

In	O
preliminary	O
screens	O
,	O
mutations	O
of	O
PTEN	O
were	O
detected	O
in	O
31	O
%	O
(	O
13	O
/	O
42	O
)	O
of	O
glioblastoma	S-DISO
cell	O
lines	O
and	O
xenografts	O
,	O
100	O
%	O
(	O
4	O
/	O
4	O
)	O
of	O
prostate	B-DISO
cancer	E-DISO
cell	O
lines	O
,	O
6	O
%	O
(	O
4	O
/	O
65	O
)	O
of	O
breast	B-DISO
cancer	E-DISO
cell	O
lines	O
and	O
xenografts	O
,	O
and	O
17	O
%	O
(	O
3	O
/	O
18	O
)	O
of	O
primary	B-DISO
glioblastomas	E-DISO
.	O

The	O
predicted	O
PTEN	O
product	O
has	O
a	O
protein	O
tyrosine	O
phosphatase	O
domain	O
and	O
extensive	O
homology	O
to	O
tensin	O
,	O
a	O
protein	O
that	O
interacts	O
with	O
actin	O
filaments	O
at	O
focal	O
adhesions	O
.	O

These	O
homologies	O
suggest	O
that	O
PTEN	O
may	O
suppress	O
tumor	S-DISO
cell	O
growth	O
by	O
antagonizing	O
protein	O
tyrosine	O
kinases	O
and	O
may	O
regulate	O
tumor	S-DISO
cell	O
invasion	O
and	O
metastasis	S-DISO
through	O
interactions	O
at	O
focal	O
adhesions	O
.	O
.	O

Heterogeneity	O
in	O
Schwartz	B-DISO
-	I-DISO
Jampel	I-DISO
chondrodystrophic	I-DISO
myotonia	E-DISO
.	O

The	O
Schwartz	B-DISO
-	I-DISO
Jampel	I-DISO
syndrome	E-DISO
(	O
SJS	S-DISO
;	O
chondrodystrophic	B-DISO
myotonia	E-DISO
;	O
McK	O
255	O
,	O
800	O
)	O
is	O
a	O
recessively	B-DISO
inherited	I-DISO
condition	E-DISO
defined	O
by	O
myotonia	S-DISO
,	O
short	B-DISO
stature	E-DISO
,	O
and	O
bone	B-DISO
dysplasia	E-DISO
.	O

Genetic	O
linkage	O
between	O
SJS	S-DISO
and	O
chromosomal	O
region	O
1q36	O
-	O
34	O
has	O
been	O
observed	O
in	O
several	O
families	O
,	O
but	O
the	O
gene	O
has	O
not	O
yet	O
been	O
identified	O
.	O

We	O
studied	O
the	O
clinical	O
and	O
radiological	O
features	O
in	O
81	O
patients	O
from	O
the	O
literature	O
and	O
5	O
own	O
patients	O
trying	O
to	O
identify	O
distinct	O
subgroups	O
.	O

In	O
addition	O
,	O
we	O
tested	O
genetic	O
linkage	O
to	O
the	O
SJS	S-DISO
locus	O
on	O
chromosome	O
1	O
in	O
one	O
family	O
with	O
two	O
affected	O
sibs	O
.	O

We	O
found	O
that	O
a	O
group	O
of	O
patients	O
have	O
mild	O
skeletal	O
changes	O
which	O
may	O
be	O
secondary	O
consequences	O
of	O
myotonia	S-DISO
,	O
while	O
another	O
group	O
of	O
patients	O
appear	O
to	O
have	O
primary	O
bone	B-DISO
dysplasia	E-DISO
with	O
myotonia	S-DISO
.	O

Within	O
this	O
latter	O
group	O
,	O
there	O
are	O
differences	O
in	O
age	O
of	O
manifestation	O
,	O
clinical	O
course	O
and	O
pattern	O
of	O
bone	O
changes	O
.	O

We	O
tentatively	O
isolate	O
three	O
different	O
types	O
of	O
SJS	B-DISO
type	I-DISO
1A	E-DISO
,	O
usually	O
recognized	O
in	O
childhood	O
,	O
with	O
moderate	O
bone	B-DISO
dysplasia	E-DISO
,	O
corresponding	O
to	O
the	O
original	O
descriptions	O
of	O
Schwartz	O
,	O
Jampel	O
and	O
Aberfeld	O
;	O
type	O
1B	O
,	O
similar	O
to	O
type	O
1A	O
but	O
recognizable	O
at	O
birth	O
,	O
with	O
more	O
pronounced	O
bone	B-DISO
dysplasia	E-DISO
resembling	O
Kniest	B-DISO
dysplasia	E-DISO
;	O
and	O
type	O
2	O
,	O
manifest	O
at	O
birth	O
,	O
with	O
increased	O
mortality	O
and	O
bone	B-DISO
dysplasia	E-DISO
resembling	O
Pyle	B-DISO
disease	E-DISO
.	O

Genetic	O
analysis	O
of	O
the	O
family	O
with	O
two	O
sibs	O
affected	O
by	O
SJS	B-DISO
type	I-DISO
2	E-DISO
showed	O
evidence	O
against	O
linkage	O
to	O
chromosome	O
1p36	O
-	O
34	O
.	O

CONCLUSIONS	O
SJS	S-DISO
is	O
clinically	O
and	O
radiologically	O
heterogeneous	O
.	O

The	O
causes	O
of	O
heterogeneity	O
are	O
not	O
known	O
yet	O
but	O
are	O
likely	O
to	O
include	O
both	O
different	O
mutations	O
at	O
the	O
SJS	S-DISO
locus	O
on	O
chromosome	O
1	O
and	O
the	O
presence	O
of	O
a	O
second	O
SJS	S-DISO
locus	O
.	O

A	O
tentative	O
clinico	O
-	O
radiological	O
classification	O
can	O
be	O
useful	O
for	O
the	O
characterization	O
of	O
patients	O
and	O
the	O
development	O
of	O
genotype	O
-	O
phenotype	O
correlations	O
.	O
.	O

A	O
clinical	O
overview	O
of	O
WT1	O
gene	O
mutations	O
.	O

Mutations	O
in	O
the	O
WT1	O
gene	O
were	O
anticipated	O
to	O
explain	O
the	O
genetic	O
basis	O
of	O
the	O
childhood	O
kidney	B-DISO
cancer	E-DISO
,	O
Wilms	B-DISO
tumour	E-DISO
(	O
WT	S-DISO
)	O
.	O

Six	O
years	O
on	O
,	O
we	O
review	O
100	O
reports	O
of	O
intragenic	O
WT1	O
mutations	O
and	O
examine	O
the	O
accompanying	O
clinical	O
phenotypes	O
.	O

While	O
only	O
5	O
%	O
of	O
sporadic	B-DISO
Wilms	I-DISO
tumours	E-DISO
have	O
intragenic	O
WT1	O
mutations	O
,	O
>	O
90	O
%	O
of	O
patients	O
with	O
the	O
Denys	B-DISO
-	I-DISO
Drash	I-DISO
syndrome	E-DISO
(	O
renal	B-DISO
nephropathy	E-DISO
,	O
gonadal	B-DISO
anomaly	E-DISO
,	O
predisposition	B-DISO
to	I-DISO
WT	E-DISO
)	O
carry	O
constitutional	O
intragenic	O
WT1	O
mutations	O
.	O

WT1	O
mutations	O
have	O
also	O
been	O
reported	O
in	O
juvenile	B-DISO
granulosa	I-DISO
cell	I-DISO
tumour	E-DISO
,	O
non	B-DISO
-	I-DISO
asbestos	I-DISO
related	I-DISO
mesothelioma	E-DISO
,	O
desmoplastic	B-DISO
small	I-DISO
round	I-DISO
cell	I-DISO
tumour	E-DISO
and	O
,	O
most	O
recently	O
,	O
acute	B-DISO
myeloid	I-DISO
leukemia	E-DISO
.	O
.	O

A	O
mutation	O
in	O
autosomal	B-DISO
dominant	I-DISO
myotonia	I-DISO
congenita	E-DISO
affects	O
pore	O
properties	O
of	O
the	O
muscle	O
chloride	O
channel	O
.	O

Autosomal	B-DISO
dominant	I-DISO
myotonia	I-DISO
congenita	E-DISO
is	O
an	O
inherited	B-DISO
disorder	I-DISO
of	I-DISO
skeletal	I-DISO
muscle	E-DISO
caused	O
by	O
mutations	O
in	O
a	O
voltage	O
-	O
gated	O
Cl	O
-	O
channel	O
gene	O
(	O
CLCN1	O
,	O
7q35	O
)	O
.	O

Here	O
,	O
we	O
report	O
that	O
a	O
mutation	O
predicting	O
the	O
substitution	O
of	O
Gly	O
230	O
by	O
glutamic	O
acid	O
(	O
G230E	O
)	O
between	O
segments	O
D3	O
and	O
D4	O
dramatically	O
alters	O
the	O
pore	O
properties	O
of	O
a	O
recombinant	O
human	O
muscle	O
Cl	O
-	O
channel	O
(	O
hCIC	O
-	O
1	O
)	O
expressed	O
in	O
a	O
mammalian	O
cell	O
line	O
(	O
tsA201	O
)	O
.	O

The	O
G230E	O
mutation	O
causes	O
substantial	O
changes	O
in	O
anion	O
and	O
cation	O
selectivity	O
as	O
well	O
as	O
a	O
fundamental	O
change	O
in	O
rectification	O
of	O
the	O
current	O
-	O
voltage	O
relationship	O
.	O

Whereas	O
wild	O
-	O
type	O
channels	O
are	O
characterized	O
by	O
pronounced	O
inward	O
rectification	O
and	O
a	O
Cl	O
>	O
thiocyanate	O
>	O
Br	O
>	O
NO	O
(	O
3	O
)	O
>	O
I	O
>	O
CH	O
(	O
3	O
)	O
SO	O
(	O
3	O
)	O
selectivity	O
,	O
G230E	O
exhibits	O
outward	O
rectification	O
at	O
positive	O
potentials	O
and	O
a	O
thiocyanate	O
>	O
NO	O
(	O
3	O
)	O
>	O
I	O
>	O
Br	O
>	O
Cl	O
>	O
CH	O
(	O
3	O
)	O
SO	O
(	O
3	O
)	O
selectivity	O
.	O

Furthermore	O
,	O
the	O
cation	O
-	O
to	O
-	O
anion	O
permeability	O
ratio	O
of	O
the	O
mutant	O
is	O
much	O
greater	O
than	O
that	O
of	O
the	O
wild	O
-	O
type	O
channel	O
.	O

Voltage	O
-	O
dependent	O
blocks	O
by	O
intracellular	O
and	O
extracellular	O
iodide	O
help	O
to	O
distinguish	O
two	O
distinct	O
ion	O
binding	O
sites	O
within	O
the	O
hClC	O
-	O
1	O
conduction	O
pathway	O
.	O

Both	O
binding	O
sites	O
are	O
preserved	O
in	O
the	O
mutant	O
but	O
have	O
decreased	O
affinities	O
for	O
iodide	O
.	O

These	O
findings	O
suggest	O
that	O
Gly	O
230	O
is	O
critical	O
for	O
normal	O
ion	O
conductance	O
in	O
hClC	O
-	O
1	O
and	O
that	O
this	O
residue	O
resides	O
within	O
the	O
channel	O
pore	O
.	O
.	O

The	O
incidence	O
of	O
PAX6	O
mutation	O
in	O
patients	O
with	O
simple	O
aniridia	S-DISO
:	O
an	O
evaluation	O
of	O
mutation	O
detection	O
in	O
12	O
cases	O
.	O

Twelve	O
aniridia	S-DISO
patients	O
,	O
five	O
with	O
a	O
family	O
history	O
and	O
seven	O
presumed	O
to	O
be	O
sporadic	O
,	O
were	O
exhaustively	O
screened	O
in	O
order	O
to	O
test	O
what	O
proportion	O
of	O
people	O
with	O
aniridia	S-DISO
,	O
uncomplicated	O
by	O
associated	O
anomalies	O
,	O
carry	O
mutations	O
in	O
the	O
human	O
PAX6	O
gene	O
.	O

Mutations	O
were	O
detected	O
in	O
90	O
%	O
of	O
the	O
cases	O
.	O

Three	O
mutation	O
detection	O
techniques	O
were	O
used	O
to	O
determine	O
if	O
one	O
method	O
was	O
superior	O
for	O
this	O
gene	O
.	O

The	O
protein	O
truncation	O
test	O
(	O
PTT	O
)	O
was	O
used	O
on	O
RT	O
-	O
PCR	O
products	O
,	O
SSCP	O
on	O
genomic	O
PCR	O
amplifications	O
,	O
and	O
chemical	O
cleavage	O
of	O
mismatch	O
on	O
both	O
RT	O
-	O
PCR	O
and	O
genomic	O
amplifications	O
.	O

For	O
RT	O
-	O
PCR	O
products	O
,	O
only	O
the	O
translated	O
portion	O
of	O
the	O
gene	O
was	O
screened	O
.	O

On	O
genomic	O
products	O
exons	O
1	O
to	O
13	O
(	O
including	O
740	O
bp	O
of	O
the	O
3	O
untranslated	O
sequence	O
and	O
all	O
intron	O
/	O
exon	O
boundaries	O
)	O
were	O
screened	O
,	O
as	O
was	O
a	O
neuroretina	O
specific	O
enhancer	O
in	O
intron	O
4	O
.	O

Ten	O
of	O
the	O
possible	O
12	O
mutations	O
in	O
the	O
five	O
familial	O
cases	O
and	O
five	O
of	O
the	O
sporadic	O
patients	O
were	O
found	O
,	O
all	O
of	O
which	O
conformed	O
to	O
a	O
functional	O
outcome	O
of	O
haploinsufficiency	O
.	O

Five	O
were	O
splice	O
site	O
mutations	O
(	O
one	O
in	O
the	O
donor	O
site	O
of	O
intron	O
4	O
,	O
two	O
in	O
the	O
donor	O
site	O
of	O
intron	O
6	O
,	O
one	O
in	O
each	O
of	O
the	O
acceptor	O
sites	O
of	O
introns	O
8	O
and	O
9	O
)	O
and	O
five	O
were	O
nonsense	O
mutations	O
in	O
exons	O
8	O
,	O
9	O
,	O
10	O
,	O
11	O
,	O
and	O
12	O
.	O

SSCP	O
analysis	O
of	O
individually	O
amplified	O
exons	O
,	O
with	O
which	O
nine	O
of	O
the	O
10	O
mutations	O
were	O
seen	O
,	O
was	O
the	O
most	O
useful	O
detection	O
method	O
for	O
PAX6	O
.	O
.	O

Insulin	O
gene	O
region	O
contributes	O
to	O
genetic	O
susceptibility	O
to	O
,	O
but	O
may	O
not	O
to	O
low	O
incidence	O
of	O
,	O
insulin	B-DISO
-	I-DISO
dependent	I-DISO
diabetes	I-DISO
mellitus	E-DISO
in	O
Japanese	O
.	O

In	O
the	O
Caucasian	O
population	O
,	O
it	O
has	O
been	O
demonstrated	O
that	O
the	O
insulin	O
gene	O
(	O
INS	O
)	O
region	O
contains	O
the	O
insulin	B-DISO
-	I-DISO
dependent	I-DISO
diabetes	I-DISO
mellitus	E-DISO
locus	O
(	O
IDDM2	O
)	O
.	O

In	O
the	O
Japanese	O
population	O
,	O
however	O
,	O
there	O
has	O
been	O
no	O
report	O
demonstrating	O
the	O
contribution	O
of	O
IDDM2	O
to	O
the	O
pathogenesis	O
of	O
IDDM	S-DISO
.	O

We	O
conducted	O
an	O
association	O
study	O
of	O
IDDM	S-DISO
in	O
a	O
large	O
number	O
of	O
Japanese	O
subjects	O
with	O
multiple	O
polymorphisms	O
in	O
INS	O
region	O
.	O

We	O
found	O
a	O
significant	O
association	O
of	O
the	O
INS	O
region	O
with	O
IDDM	S-DISO
.	O

Alleles	O
positively	O
associated	O
with	O
IDDM	S-DISO
in	O
INS	O
region	O
were	O
the	O
same	O
as	O
those	O
positively	O
-	O
associated	O
with	O
IDDM	S-DISO
in	O
Caucasian	O
population	O
,	O
although	O
positively	O
-	O
associated	O
alleles	O
are	O
very	O
common	O
(	O
allele	O
frequencies	O
>	O
0	O
.	O
9	O
)	O
in	O
the	O
Japanese	O
general	O
population	O
.	O

These	O
data	O
suggest	O
that	O
IDDM2	O
is	O
involved	O
in	O
the	O
genetic	O
susceptibility	O
to	O
IDDM	S-DISO
in	O
Japanese	O
.	O

The	O
high	O
frequencies	O
of	O
disease	O
-	O
associated	O
alleles	O
in	O
the	O
general	O
population	O
suggest	O
that	O
IDDM2	O
locus	O
is	O
not	O
responsible	O
for	O
the	O
low	O
incidence	O
of	O
IDDM	S-DISO
in	O
Japanese	O
.	O

The	O
human	O
complement	O
C9	O
gene	O
:	O
identification	O
of	O
two	O
mutations	O
causing	O
deficiency	O
and	O
revision	O
of	O
the	O
gene	O
structure	O
.	O

The	O
ninth	O
component	O
of	O
human	O
complement	O
(	O
C9	O
)	O
is	O
the	O
last	O
of	O
the	O
terminal	O
complement	O
components	O
creating	O
the	O
membrane	O
attack	O
complex	O
.	O

C9	O
is	O
a	O
single	O
-	O
chain	O
serum	O
protein	O
that	O
is	O
encoded	O
by	O
a	O
gene	O
located	O
on	O
chromosome	O
5p	O
.	O

Deficiency	B-DISO
of	I-DISO
terminal	I-DISO
complement	I-DISO
components	E-DISO
is	O
generally	O
associated	O
with	O
recurrent	O
neisseria	B-DISO
infections	E-DISO
.	O

We	O
studied	O
a	O
previously	O
described	O
Swiss	O
family	O
with	O
inherited	B-DISO
C9	I-DISO
deficiency	E-DISO
.	O

To	O
identify	O
the	O
genetic	O
basis	O
of	O
C9	B-DISO
deficiency	E-DISO
,	O
we	O
developed	O
an	O
approach	O
using	O
exon	O
-	O
specific	O
PCR	O
and	O
direct	O
DNA	O
sequencing	O
.	O

As	O
a	O
cause	O
of	O
C9	B-DISO
deficiency	E-DISO
,	O
we	O
found	O
two	O
different	O
point	O
mutations	O
,	O
both	O
generating	O
TGA	O
stop	O
codons	O
in	O
the	O
coding	O
sequence	O
.	O

One	O
mutation	O
,	O
a	O
C	O
to	O
A	O
exchange	O
,	O
was	O
detected	O
in	O
exon	O
2	O
at	O
cDNA	O
position	O
166	O
,	O
the	O
other	O
,	O
a	O
C	O
to	O
T	O
exchange	O
,	O
was	O
located	O
in	O
exon	O
4	O
(	O
cDNA	O
position	O
464	O
)	O
.	O

In	O
family	O
studies	O
of	O
three	O
first	O
-	O
degree	O
relatives	O
with	O
heterozygous	O
C9	B-DISO
deficiency	E-DISO
,	O
we	O
demonstrated	O
that	O
the	O
two	O
mutations	O
are	O
segregating	O
independently	O
.	O

Therefore	O
,	O
these	O
mutations	O
are	O
sufficient	O
to	O
explain	O
the	O
complete	O
deficiency	O
of	O
both	O
the	O
probands	O
studied	O
.	O

DNA	O
sequencing	O
of	O
the	O
exon	O
-	O
intron	O
junctions	O
revealed	O
a	O
number	O
of	O
revisions	O
regarding	O
the	O
boundaries	O
between	O
exons	O
4	O
,	O
5	O
,	O
and	O
6	O
as	O
well	O
as	O
between	O
exons	O
10	O
and	O
11	O
.	O

No	O
additional	O
introns	O
were	O
detected	O
in	O
exons	O
6	O
and	O
10	O
.	O

Furthermore	O
,	O
DNA	O
marker	O
studies	O
were	O
conducted	O
using	O
known	O
polymorphisms	O
of	O
the	O
C6	O
,	O
C7	O
,	O
and	O
C9	O
genes	O
,	O
confirming	O
the	O
linkage	O
of	O
the	O
observed	O
C9	O
mutations	O
with	O
defined	O
haplotypes	O
.	O
.	O

BRCA1	O
mutations	O
in	O
women	O
attending	O
clinics	O
that	O
evaluate	O
the	O
risk	O
of	O
breast	B-DISO
cancer	E-DISO
.	O

BACKGROUND	O
To	O
define	O
the	O
incidence	O
of	O
BRCA1	O
mutations	O
among	O
patients	O
seen	O
in	O
clinics	O
that	O
evaluate	O
the	O
risk	O
of	O
breast	B-DISO
cancer	E-DISO
,	O
we	O
analyzed	O
DNA	O
samples	O
from	O
women	O
seen	O
in	O
this	O
setting	O
and	O
constructed	O
probability	O
tables	O
to	O
provide	O
estimates	O
of	O
the	O
likelihood	O
of	O
finding	O
a	O
BRCA1	O
mutation	O
in	O
individual	O
families	O
.	O

METHODS	O
Clinical	O
information	O
,	O
family	O
histories	O
,	O
and	O
blood	O
for	O
DNA	O
analysis	O
were	O
obtained	O
from	O
263	O
women	O
with	O
breast	B-DISO
cancer	E-DISO
.	O

Conformation	O
-	O
sensitive	O
gel	O
electrophoresis	O
and	O
DNA	O
sequencing	O
were	O
used	O
to	O
identify	O
BRCA1	O
mutations	O
.	O

RESULTS	O
BRCA1	O
mutations	O
were	O
identified	O
in	O
16	O
percent	O
of	O
women	O
with	O
a	O
family	O
history	O
of	O
breast	B-DISO
cancer	E-DISO
.	O

Only	O
7	O
percent	O
of	O
women	O
from	O
families	O
with	O
a	O
history	O
of	O
breast	B-DISO
cancer	E-DISO
but	O
not	O
ovarian	B-DISO
cancer	E-DISO
had	O
BRCA1	O
mutations	O
.	O

The	O
rates	O
were	O
higher	O
among	O
women	O
from	O
families	O
with	O
a	O
history	O
of	O
both	O
breast	B-DISO
and	I-DISO
ovarian	I-DISO
cancer	E-DISO
.	O

Among	O
family	O
members	O
,	O
an	O
average	O
age	O
of	O
less	O
than	O
55	O
years	O
at	O
the	O
diagnosis	O
of	O
breast	B-DISO
cancer	E-DISO
,	O
the	O
presence	O
of	O
ovarian	B-DISO
cancer	E-DISO
,	O
the	O
presence	O
of	O
breast	B-DISO
and	I-DISO
ovarian	I-DISO
cancer	E-DISO
in	O
the	O
same	O
woman	O
,	O
and	O
Ashkenazi	O
Jewish	O
ancestry	O
were	O
all	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
detecting	O
a	O
BRCA1	O
mutation	O
.	O

No	O
association	O
was	O
found	O
between	O
the	O
presence	O
of	O
bilateral	O
breast	B-DISO
cancer	E-DISO
or	O
the	O
number	O
of	O
breast	B-DISO
cancers	E-DISO
in	O
a	O
family	O
and	O
the	O
detection	O
of	O
a	O
BRCA1	O
mutation	O
,	O
or	O
between	O
the	O
position	O
of	O
the	O
mutation	O
in	O
the	O
BRCA1	O
gene	O
and	O
the	O
presence	O
of	O
ovarian	B-DISO
cancer	E-DISO
in	O
a	O
family	O
.	O

CONCLUSIONS	O
Among	O
women	O
with	O
breast	B-DISO
cancer	E-DISO
and	O
a	O
family	O
history	O
of	O
the	O
disease	O
,	O
the	O
percentage	O
with	O
BRCA1	O
coding	O
-	O
region	O
mutations	O
is	O
less	O
than	O
the	O
45	O
percent	O
predicted	O
by	O
genetic	O
-	O
linkage	O
analysis	O
.	O

These	O
results	O
suggest	O
that	O
even	O
in	O
a	O
referral	O
clinic	O
specializing	O
in	O
screening	O
women	O
from	O
high	O
-	O
risk	O
families	O
,	O
the	O
majority	O
of	O
tests	O
for	O
BRCA1	O
mutations	O
will	O
be	O
negative	O
and	O
therefore	O
uninformative	O
.	O
.	O

Mutations	O
in	O
the	O
arginine	O
-	O
rich	O
protein	O
gene	O
(	O
ARP	O
)	O
in	O
pancreatic	B-DISO
cancer	E-DISO
.	O

The	O
ARP	O
gene	O
encodes	O
a	O
highly	O
conserved	O
arginine	O
-	O
rich	O
protein	O
from	O
chromosomal	O
band	O
3p21	O
.	O

1	O
1	O
.	O

At	O
the	O
cytogenetic	O
level	O
this	O
region	O
is	O
frequently	O
deleted	O
in	O
a	O
variety	O
of	O
different	O
solid	B-DISO
tumors	E-DISO
,	O
although	O
not	O
in	O
pancreatic	B-DISO
cancer	E-DISO
.	O

We	O
have	O
reported	O
the	O
presence	O
of	O
a	O
specific	O
mutation	O
(	O
ATG50	O
-	O
-	O
>	O
AGG	O
)	O
or	O
deletion	O
of	O
codon	O
50	O
of	O
the	O
ARP	O
gene	O
in	O
different	O
tumor	B-DISO
types	E-DISO
(	O
Shridhar	O
et	O
al	O
.	O
,	O
1996	O
,	O
1996a	O
)	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
observed	O
mutations	O
involving	O
codon	O
50	O
in	O
11	O
of	O
37	O
pancreatic	B-DISO
tumors	E-DISO
.	O

The	O
frequency	O
of	O
codon	O
50	O
mutation	O
is	O
roughly	O
the	O
same	O
in	O
pancreatic	B-DISO
tumors	E-DISO
as	O
in	O
the	O
other	O
types	O
of	O
tumors	S-DISO
previously	O
examined	O
.	O

In	O
addition	O
,	O
we	O
have	O
detected	O
mutations	O
at	O
codon	O
51	O
in	O
multiple	O
PCR	O
subclones	O
in	O
two	O
other	O
pancreatic	B-DISO
tumors	E-DISO
.	O

Mutations	O
in	O
the	O
ARP	O
gene	O
are	O
thus	O
commonly	O
observed	O
in	O
pancreatic	B-DISO
cancer	E-DISO
,	O
as	O
well	O
as	O
many	O
other	O
cancers	S-DISO
.	O

Difficulties	O
in	O
the	O
ascertainment	O
of	O
C9	B-DISO
deficiency	E-DISO
:	O
lessons	O
to	O
be	O
drawn	O
from	O
a	O
compound	O
heterozygote	O
C9	B-DISO
-	I-DISO
deficient	E-DISO
subject	O
.	O

A	O
group	O
of	O
patients	O
with	O
long	O
-	O
surviving	O
mismatched	O
kidney	O
allografts	O
were	O
investigated	O
for	O
complement	O
function	O
using	O
haemolytic	O
assays	O
in	O
agarose	O
gels	O
.	O

One	O
patient	O
was	O
found	O
to	O
have	O
no	O
alternative	O
pathway	O
activity	O
but	O
a	O
low	O
normal	O
classical	O
pathway	O
.	O

Surprisingly	O
,	O
investigation	O
revealed	O
that	O
the	O
patients	O
complement	O
was	O
normal	O
for	O
all	O
components	O
except	O
C9	O
,	O
which	O
was	O
functionally	O
absent	O
.	O

The	O
patient	O
was	O
shown	O
to	O
be	O
heterozygous	O
for	O
DNA	O
markers	O
in	O
the	O
C6	O
,	O
C7	O
and	O
C9	O
region	O
of	O
chromosome	O
5	O
and	O
therefore	O
appears	O
to	O
be	O
a	O
compound	O
heterozygote	O
for	O
two	O
uncharacterized	O
C9	B-DISO
deficiency	E-DISO
genes	O
.	O

Serological	O
analysis	O
by	O
ELISA	O
revealed	O
that	O
he	O
has	O
trace	O
concentrations	O
of	O
a	O
non	O
-	O
functional	O
C9	O
molecule	O
.	O

Western	O
blot	O
analysis	O
was	O
not	O
sufficiently	O
sensitive	O
to	O
permit	O
detection	O
of	O
this	O
molecule	O
.	O

We	O
hypothesize	O
that	O
the	O
patient	O
is	O
heterozygous	O
for	O
a	O
complete	B-DISO
deficiency	I-DISO
of	I-DISO
C9	E-DISO
and	O
for	O
a	O
gene	O
directing	O
hyposynthesis	O
of	O
a	O
defective	O
C9	O
.	O

We	O
also	O
suggest	O
that	O
C9	B-DISO
deficiency	E-DISO
may	O
be	O
more	O
common	O
among	O
Caucasians	O
than	O
has	O
been	O
reported	O
.	O
.	O

Screening	O
for	O
ESR	O
mutations	O
in	O
breast	B-DISO
and	I-DISO
ovarian	I-DISO
cancer	E-DISO
patients	O
.	O

In	O
the	O
present	O
study	O
,	O
leukocyte	O
DNA	O
from	O
143	O
patients	O
with	O
familial	O
clustering	O
of	O
breast	B-DISO
and	I-DISO
/	I-DISO
or	I-DISO
ovarian	I-DISO
cancer	E-DISO
and	O
tumour	S-DISO
DNA	O
from	O
96	O
breast	B-DISO
carcinomas	E-DISO
were	O
screened	O
for	O
base	O
mutations	O
in	O
the	O
estrogen	O
receptor	O
gene	O
(	O
ESR	O
)	O
.	O

Three	O
patients	O
with	O
a	O
family	O
history	O
of	O
cancer	S-DISO
were	O
carrying	O
a	O
Gly160Cys	O
germline	O
substitution	O
.	O

This	O
alteration	O
was	O
also	O
detected	O
in	O
eight	O
(	O
four	O
females	O
and	O
four	O
males	O
)	O
of	O
729	O
controls	O
(	O
366	O
female	O
,	O
363	O
males	O
)	O
,	O
indicating	O
that	O
the	O
substitution	O
probably	O
represents	O
a	O
polymorphism	O
.	O

However	O
,	O
in	O
the	O
229	O
female	O
controls	O
in	O
whom	O
family	O
history	O
of	O
cancer	S-DISO
was	O
known	O
,	O
one	O
of	O
two	O
who	O
had	O
a	O
sister	O
with	O
breast	B-DISO
cancer	E-DISO
was	O
carrying	O
the	O
variant	O
allele	O
.	O

Hence	O
,	O
a	O
possible	O
clinical	O
significance	O
of	O
the	O
glycine	O
into	O
cysteine	O
cannot	O
be	O
completely	O
ruled	O
out	O
and	O
should	O
be	O
further	O
investigated	O
.	O

Somatic	O
mutations	O
were	O
not	O
detected	O
in	O
any	O
of	O
the	O
tumours	S-DISO
studied	O
,	O
and	O
the	O
present	O
data	O
do	O
not	O
provide	O
support	O
for	O
somatic	O
ESR	O
base	O
mutations	O
as	O
an	O
important	O
mechanism	O
for	O
hormonal	O
therapy	O
resistance	O
in	O
estrogen	B-DISO
receptor	I-DISO
-	I-DISO
positive	I-DISO
breast	I-DISO
carcinomas	E-DISO
.	O
.	O

Molecular	O
bases	O
of	O
C7	B-DISO
deficiency	E-DISO
:	O
three	O
different	O
defects	O
.	O

The	O
molecular	O
basis	O
of	O
C7	B-DISO
deficiency	E-DISO
has	O
been	O
investigated	O
in	O
two	O
Irish	O
families	O
and	O
a	O
number	O
of	O
Israeli	O
families	O
of	O
Moroccan	O
Sephardic	O
Jewish	O
origin	O
.	O

Exon	O
PCR	O
and	O
sequencing	O
revealed	O
a	O
heterozygous	O
point	O
mutation	O
at	O
the	O
3	O
splice	O
acceptor	O
site	O
of	O
intron	O
1	O
in	O
one	O
Irish	O
family	O
.	O

In	O
the	O
other	O
Irish	O
family	O
,	O
exons	O
7	O
and	O
8	O
failed	O
to	O
amplify	O
and	O
they	O
were	O
shown	O
to	O
be	O
deleted	O
.	O

Marker	O
haplotype	O
studies	O
of	O
the	O
C6	O
and	O
C7	O
gene	O
region	O
and	O
Southern	O
blots	O
show	O
that	O
the	O
Irish	O
family	O
with	O
the	O
splice	O
defect	O
also	O
segregate	O
for	O
the	O
deletion	O
,	O
which	O
is	O
not	O
easily	O
detected	O
in	O
heterozygotes	O
.	O

The	O
Israeli	O
C7	B-DISO
-	I-DISO
deficient	E-DISO
cases	O
all	O
share	O
a	O
C7	O
haplotype	O
and	O
are	O
homozygous	O
for	O
a	O
mis	O
-	O
sense	O
mutation	O
in	O
exon	O
9	O
.	O

However	O
,	O
one	O
individual	O
is	O
heterozygous	O
for	O
markers	O
at	O
adjacent	O
C6	O
loci	O
,	O
showing	O
that	O
there	O
has	O
been	O
an	O
intergenic	O
recombination	O
and	O
suggesting	O
that	O
the	O
deficiency	O
mutation	O
is	O
of	O
appreciable	O
antiquity	O
.	O
.	O

Molecular	O
heterogeneity	O
of	O
classical	B-DISO
and	I-DISO
Duarte	I-DISO
galactosemia	E-DISO
:	O
mutation	O
analysis	O
by	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
.	O

Classical	B-DISO
galactosemia	E-DISO
is	O
caused	O
by	O
one	O
common	O
missense	O
mutation	O
(	O
Q188R	O
)	O
and	O
by	O
several	O
rare	O
mutations	O
in	O
the	O
galactose	O
-	O
1	O
-	O
phosphate	O
uridyltransferase	O
(	O
GALT	O
)	O
gene	O
.	O

The	O
most	O
common	O
variant	O
of	O
GALT	O
,	O
the	O
Duarte	O
variant	O
,	O
occurs	O
as	O
two	O
types	O
,	O
Duarte	O
-	O
1	O
(	O
D	O
-	O
1	O
)	O
and	O
Duarte	O
-	O
2	O
(	O
D	O
-	O
2	O
)	O
,	O
both	O
of	O
which	O
carry	O
the	O
sequence	O
change	O
N314D	O
.	O

D	O
-	O
1	O
increases	O
,	O
whereas	O
D	O
-	O
2	O
decreases	O
GALT	O
activity	O
.	O

To	O
study	O
the	O
molecular	O
genetics	O
of	O
classical	B-DISO
and	I-DISO
Duarte	I-DISO
galactosemia	E-DISO
,	O
we	O
analyzed	O
the	O
GALT	O
mutations	O
in	O
30	O
families	O
with	O
classical	B-DISO
galactosemia	E-DISO
,	O
in	O
10	O
families	O
with	O
the	O
D	O
-	O
2	O
variant	O
and	O
in	O
3	O
individuals	O
carrying	O
the	O
D	O
-	O
1	O
allele	O
by	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
(	O
DGGE	O
)	O
.	O

DGGE	O
detected	O
59	O
of	O
the	O
60	O
classical	O
galactosemia	S-DISO
alleles	O
.	O

Q188R	O
accounted	O
for	O
60	O
%	O
,	O
K285N	O
accounted	O
for	O
28	O
%	O
of	O
these	O
alleles	O
.	O

Eight	O
novel	O
candidate	O
galactosemia	S-DISO
mutations	O
were	O
found	O
.	O

On	O
all	O
D	O
-	O
2	O
alleles	O
N314D	O
occurred	O
in	O
cis	O
with	O
two	O
intronic	O
sequence	O
changes	O
,	O
on	O
the	O
D	O
-	O
1	O
alleles	O
in	O
cis	O
with	O
a	O
neutral	O
mutation	O
in	O
exon	O
7	O
.	O

We	O
conclude	O
that	O
the	O
mutations	O
causing	O
galactosemia	S-DISO
are	O
highly	O
heterogeneous	O
and	O
that	O
K285N	O
is	O
a	O
second	O
common	O
galactosemia	S-DISO
mutation	O
in	O
our	O
population	O
.	O
.	O

Isolation	O
of	O
full	O
-	O
length	O
ATM	O
cDNA	O
and	O
correction	O
of	O
the	O
ataxia	B-DISO
-	I-DISO
telangiectasia	E-DISO
cellular	O
phenotype	O
.	O

A	O
gene	O
mutated	O
in	O
the	O
human	O
genetic	B-DISO
disorder	E-DISO
ataxia	B-DISO
-	I-DISO
telangiectasia	E-DISO
(	O
A	B-DISO
-	I-DISO
T	E-DISO
)	O
,	O
ATM	O
,	O
was	O
recently	O
identified	O
by	O
positional	O
cloning	O
.	O

ATM	O
is	O
a	O
member	O
of	O
the	O
phosphatidylinositol	O
-	O
3	O
-	O
kinase	O
superfamily	O
,	O
some	O
of	O
which	O
are	O
protein	O
kinases	O
and	O
appear	O
to	O
have	O
important	O
roles	O
in	O
cell	O
cycle	O
control	O
and	O
radiation	O
signal	O
transduction	O
.	O

We	O
describe	O
herein	O
,	O
to	O
our	O
knowledge	O
,	O
for	O
the	O
first	O
time	O
,	O
the	O
cloning	O
of	O
a	O
full	O
-	O
length	O
cDNA	O
for	O
ATM	O
and	O
correction	O
of	O
multiple	O
aspects	O
of	O
the	O
radio	O
-	O
sensitive	O
phenotype	O
of	O
A	B-DISO
-	I-DISO
T	E-DISO
cells	O
by	O
transfection	O
with	O
this	O
cDNA	O
.	O

Overexpression	O
of	O
ATM	O
cDNA	O
in	O
A	B-DISO
-	I-DISO
T	E-DISO
cells	O
enhanced	O
the	O
survival	O
of	O
these	O
cells	O
in	O
response	O
to	O
radiation	O
exposure	O
,	O
decreased	O
radiation	O
-	O
induced	O
chromosome	O
aberrations	O
,	O
reduced	O
radio	O
-	O
resistant	O
DNA	O
synthesis	O
,	O
and	O
partially	O
corrected	O
defective	O
cell	O
cycle	O
checkpoints	O
and	O
induction	O
of	O
stress	O
-	O
activated	O
protein	O
kinase	O
.	O

This	O
correction	O
of	O
the	O
defects	O
in	O
A	B-DISO
-	I-DISO
T	E-DISO
cells	O
provides	O
further	O
evidence	O
of	O
the	O
multiplicity	O
of	O
effector	O
functions	O
of	O
the	O
ATM	O
protein	O
and	O
suggests	O
possible	O
approaches	O
to	O
gene	O
therapy	O
.	O
.	O

Fusion	O
genes	O
resulting	O
from	O
alternative	O
chromosomal	O
translocations	O
are	O
overexpressed	O
by	O
gene	O
-	O
specific	O
mechanisms	O
in	O
alveolar	B-DISO
rhabdomyosarcoma	E-DISO
.	O

Chromosomal	O
translocations	O
identified	O
in	O
hematopoietic	B-DISO
and	I-DISO
solid	I-DISO
tumors	E-DISO
result	O
in	O
deregulated	O
expression	O
of	O
protooncogenes	O
or	O
creation	O
of	O
chimeric	O
proteins	O
with	O
tumorigenic	O
potential	O
.	O

In	O
the	O
pediatric	O
solid	B-DISO
tumor	E-DISO
alveolar	B-DISO
rhabdomyosarcoma	E-DISO
,	O
a	O
consistent	O
t	O
(	O
2	O
;	O
13	O
)	O
(	O
q35	O
;	O
q14	O
)	O
or	O
variant	O
t	O
(	O
1	O
;	O
13	O
)	O
(	O
p36	O
;	O
q14	O
)	O
translocation	O
generates	O
PAX3	O
-	O
FKHR	O
or	O
PAX7	O
-	O
FKHR	O
fusion	O
proteins	O
,	O
respectively	O
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
in	O
addition	O
to	O
functional	O
alterations	O
these	O
translocations	O
are	O
associated	O
with	O
fusion	O
product	O
overexpression	O
.	O

Furthermore	O
,	O
PAX3	O
-	O
FKHR	O
and	O
PAX7	O
-	O
FKHR	O
overexpression	O
occurs	O
by	O
distinct	O
mechanisms	O
.	O

Transcription	O
of	O
PAX3	O
-	O
FKHR	O
is	O
increased	O
relative	O
to	O
wild	O
-	O
type	O
PAX3	O
by	O
a	O
copy	O
number	O
-	O
independent	O
process	O
.	O

In	O
contrast	O
,	O
PAX7	O
-	O
FKHR	O
overexpression	O
results	O
from	O
fusion	O
gene	O
amplification	O
.	O

Thus	O
,	O
gene	O
-	O
specific	O
mechanisms	O
were	O
selected	O
to	O
overexpress	O
PAX3	O
-	O
FKHR	O
and	O
PAX7	O
-	O
FKHR	O
in	O
alveolar	B-DISO
rhabdomyosarcoma	E-DISO
,	O
presumably	O
due	O
to	O
differences	O
in	O
regulation	O
between	O
the	O
wild	O
-	O
type	O
loci	O
.	O

We	O
postulate	O
that	O
these	O
overexpression	O
mechanisms	O
ensure	O
a	O
critical	O
level	O
of	O
gene	O
product	O
for	O
the	O
oncogenic	O
effects	O
of	O
these	O
fusions	O
.	O
.	O

atm	O
and	O
p53	O
cooperate	O
in	O
apoptosis	O
and	O
suppression	O
of	O
tumorigenesis	O
,	O
but	O
not	O
in	O
resistance	O
to	O
acute	B-DISO
radiation	I-DISO
toxicity	E-DISO
.	O

Mutations	O
in	O
atm	O
and	O
p53	O
cause	O
the	O
human	O
cancer	B-DISO
-	I-DISO
associated	I-DISO
diseases	E-DISO
ataxia	B-DISO
-	I-DISO
telangiectasia	E-DISO
and	O
Li	B-DISO
-	I-DISO
Fraumeni	I-DISO
syndrome	E-DISO
,	O
respectively	O
.	O

The	O
two	O
genes	O
are	O
believed	O
to	O
interact	O
in	O
a	O
number	O
of	O
pathways	O
,	O
including	O
regulation	O
of	O
DNA	O
damage	O
-	O
induced	O
cell	O
-	O
cycle	O
checkpoints	O
,	O
apoptosis	O
and	O
radiation	O
sensitivity	O
,	O
and	O
cellular	O
proliferation	O
.	O

Atm	O
-	O
null	O
mice	O
,	O
as	O
well	O
as	O
those	O
null	O
for	O
p53	O
,	O
develop	O
mainly	O
T	B-DISO
-	I-DISO
cell	I-DISO
lymphomas	E-DISO
,	O
supporting	O
the	O
view	O
that	O
these	O
genes	O
have	O
similar	O
roles	O
in	O
thymocyte	O
development	O
.	O

To	O
study	O
the	O
interactions	O
of	O
these	O
two	O
genes	O
on	O
an	O
organismal	O
level	O
,	O
we	O
bred	O
mice	O
heterozygous	O
for	O
null	O
alleles	O
of	O
both	O
atm	O
and	O
p53	O
to	O
produce	O
all	O
genotypic	O
combinations	O
.	O

Mice	O
doubly	O
null	O
for	O
atm	O
and	O
p53	O
exhibited	O
a	O
dramatic	O
acceleration	O
of	O
tumour	S-DISO
formation	O
relative	O
to	O
singly	O
null	O
mice	O
,	O
indicating	O
that	O
both	O
genes	O
collaborate	O
in	O
a	O
significant	O
manner	O
to	O
prevent	O
tumorigenesis	O
.	O

With	O
respect	O
to	O
their	O
roles	O
in	O
apoptosis	O
,	O
loss	O
of	O
atm	O
rendered	O
thymocytes	O
only	O
partly	O
resistant	O
to	O
irradiation	O
-	O
induced	O
apoptosis	O
,	O
whereas	O
additional	O
loss	O
of	O
p53	O
engendered	O
complete	O
resistance	O
.	O

This	O
implies	O
that	O
the	O
irradiation	O
-	O
induced	O
atm	O
and	O
p53	O
apoptotic	O
pathways	O
are	O
not	O
completely	O
congruent	O
.	O

Finally	O
-	O
and	O
in	O
contrast	O
to	O
prior	O
predictions	O
-	O
atm	O
and	O
p53	O
do	O
not	O
appear	O
to	O
interact	O
in	O
acute	B-DISO
radiation	I-DISO
toxicity	E-DISO
,	O
suggesting	O
a	O
separate	O
atm	O
effector	O
pathway	O
for	O
this	O
DNA	O
damage	O
response	O
and	O
having	O
implications	O
for	O
the	O
prognosis	O
and	O
treatment	O
of	O
human	O
tumours	S-DISO
.	O
.	O

Trinucleotide	O
repeat	O
expansion	O
at	O
the	O
myotonic	B-DISO
dystrophy	E-DISO
locus	O
reduces	O
expression	O
of	O
DMAHP	O
.	O

Myotonic	B-DISO
dystrophy	E-DISO
,	O
or	O
dystrophia	B-DISO
myotonica	E-DISO
(	O
DM	S-DISO
)	O
,	O
is	O
an	O
autosomal	B-DISO
dominant	I-DISO
multisystem	I-DISO
disorder	E-DISO
caused	O
by	O
the	O
expansion	O
of	O
a	O
CTG	O
trinucleotide	O
repeat	O
in	O
the	O
3	O
untranslated	O
region	O
of	O
the	O
DMPK	O
protein	O
kinase	O
gene	O
on	O
chromosome	O
19q13	O
.	O

3	O
(	O
refs	O
1	O
-	O
3	O
)	O
.	O

Although	O
the	O
DM	S-DISO
mutation	O
was	O
identified	O
more	O
than	O
five	O
years	O
ago	O
,	O
the	O
pathogenic	O
mechanisms	O
underlying	O
this	O
most	O
prevalent	O
form	O
of	O
hereditary	O
adult	O
neuromuscular	B-DISO
disease	E-DISO
remain	O
elusive	O
.	O

Previous	O
work	O
from	O
our	O
laboratory	O
demonstrated	O
that	O
a	O
DNase	O
l	O
-	O
hypersensitive	O
site	O
located	O
adjacent	O
to	O
the	O
repeats	O
on	O
the	O
wild	O
-	O
type	O
allele	O
is	O
eliminated	O
by	O
repeat	O
expansion	O
,	O
indicating	O
that	O
large	O
CTG	O
-	O
repeat	O
arrays	O
may	O
be	O
associated	O
with	O
a	O
local	O
chromatin	O
environment	O
that	O
represses	O
gene	O
expression	O
.	O

Here	O
we	O
report	O
that	O
the	O
hypersensitive	O
site	O
contains	O
an	O
enhancer	O
element	O
that	O
regulates	O
transcription	O
of	O
the	O
adjacent	O
DMAHP	O
homeobox	O
gene	O
.	O

Analysis	O
of	O
DMAHP	O
expression	O
in	O
the	O
cells	O
of	O
DM	S-DISO
patients	O
with	O
loss	O
of	O
the	O
hypersensitive	O
site	O
revealed	O
a	O
two	O
-	O
to	O
fourfold	O
reduction	O
in	O
steady	O
-	O
state	O
DMAHP	O
transcript	O
levels	O
relative	O
to	O
wild	O
-	O
type	O
controls	O
.	O

Allele	O
-	O
specific	O
analysis	O
of	O
DMAHP	O
expression	O
showed	O
that	O
steady	O
-	O
state	O
transcript	O
levels	O
from	O
the	O
expanded	O
allele	O
were	O
greatly	O
reduced	O
in	O
comparison	O
to	O
those	O
from	O
the	O
wild	O
-	O
type	O
allele	O
.	O

Together	O
,	O
these	O
results	O
demonstrate	O
that	O
CTG	O
-	O
repeat	O
expansions	O
can	O
suppress	O
local	O
gene	O
expression	O
and	O
implicate	O
DMAHP	O
in	O
DM	S-DISO
pathogenesis	O
.	O

Constitutively	O
methylated	O
CpG	O
dinucleotides	O
as	O
mutation	O
hot	O
spots	O
in	O
the	O
retinoblastoma	S-DISO
gene	O
(	O
RB1	O
)	O
.	O

A	O
wide	O
spectrum	O
of	O
mutations	O
,	O
ranging	O
from	O
point	O
mutations	O
to	O
large	O
deletions	O
,	O
have	O
been	O
described	O
in	O
the	O
retinoblastoma	S-DISO
gene	O
(	O
RB1	O
)	O
.	O

Mutations	O
have	O
been	O
found	O
throughout	O
the	O
gene	O
;	O
however	O
,	O
these	O
genetic	O
alterations	O
do	O
not	O
appear	O
to	O
be	O
homogeneously	O
distributed	O
.	O

In	O
particular	O
,	O
a	O
significant	O
proportion	O
of	O
disease	O
-	O
causing	O
mutations	O
results	O
in	O
the	O
premature	O
termination	O
of	O
protein	O
synthesis	O
,	O
and	O
the	O
majority	O
of	O
these	O
mutations	O
occur	O
as	O
C	O
-	O
-	O
>	O
T	O
transitions	O
at	O
CpG	O
dinucleotides	O
(	O
CpGs	O
)	O
.	O

Such	O
recurrent	O
CpG	O
mutations	O
,	O
including	O
those	O
found	O
in	O
RB1	O
,	O
are	O
likely	O
the	O
result	O
of	O
the	O
deamination	O
of	O
5	O
-	O
methylcytosine	O
within	O
these	O
CpGs	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
used	O
the	O
sodiumbisulfite	O
conversion	O
method	O
to	O
detect	O
cytosine	O
methylation	O
in	O
representative	O
exons	O
of	O
RB1	O
.	O

We	O
analyzed	O
DNA	O
from	O
a	O
variety	O
of	O
tissues	O
and	O
specifically	O
targeted	O
CGA	O
codons	O
in	O
RB1	O
,	O
where	O
recurrent	O
premature	O
termination	O
mutations	O
have	O
been	O
reported	O
.	O

We	O
found	O
that	O
DNA	O
methylation	O
within	O
RB1	O
exons	O
8	O
,	O
14	O
,	O
25	O
,	O
and	O
27	O
appeared	O
to	O
be	O
restricted	O
to	O
CpGs	O
,	O
including	O
six	O
CGA	O
codons	O
.	O

Other	O
codons	O
containing	O
methylated	O
cytosines	O
have	O
not	O
been	O
reported	O
to	O
be	O
mutated	O
.	O

Therefore	O
,	O
disease	O
-	O
causing	O
mutations	O
at	O
CpGs	O
in	O
RB1	O
appear	O
to	O
be	O
determined	O
by	O
several	O
factors	O
,	O
including	O
the	O
constitutive	O
presence	O
of	O
DNA	O
methylation	O
at	O
cytosines	O
within	O
CpGs	O
,	O
the	O
specific	O
codon	O
within	O
which	O
the	O
methylated	O
cytosine	O
is	O
located	O
,	O
and	O
the	O
particular	O
region	O
of	O
the	O
gene	O
within	O
which	O
that	O
codon	O
resides	O
.	O
.	O

The	O
von	B-DISO
Hippel	I-DISO
-	I-DISO
Lindau	I-DISO
tumor	E-DISO
suppressor	O
gene	O
product	O
interacts	O
with	O
Sp1	O
to	O
repress	O
vascular	O
endothelial	O
growth	O
factor	O
promoter	O
activity	O
.	O

The	O
von	B-DISO
Hippel	I-DISO
-	I-DISO
Lindau	I-DISO
tumor	E-DISO
suppressor	O
gene	O
(	O
VHL	O
)	O
has	O
a	O
critical	O
role	O
in	O
the	O
pathogenesis	O
of	O
clear	B-DISO
-	I-DISO
cell	I-DISO
renal	I-DISO
cell	I-DISO
carcinoma	E-DISO
(	O
RCC	S-DISO
)	O
,	O
as	O
VHL	O
mutations	O
have	O
been	O
found	O
in	O
both	O
von	B-DISO
Hippel	I-DISO
-	I-DISO
Lindau	I-DISO
disease	I-DISO
-	I-DISO
associated	I-DISO
and	I-DISO
sporadic	I-DISO
RCCs	E-DISO
.	O

Recent	O
studies	O
suggest	O
that	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
mRNA	O
is	O
upregulated	O
in	O
RCC	B-DISO
-	I-DISO
and	I-DISO
von	I-DISO
Hippel	I-DISO
-	I-DISO
Lindau	I-DISO
disease	I-DISO
-	I-DISO
associated	I-DISO
tumors	E-DISO
.	O

We	O
have	O
therefore	O
assessed	O
the	O
effect	O
of	O
the	O
VHL	O
gene	O
product	O
on	O
VEGF	O
expression	O
.	O

VEGF	O
promoter	O
-	O
luciferase	O
constructs	O
were	O
transiently	O
cotransfected	O
with	O
a	O
wild	O
-	O
type	O
VHL	O
(	O
wt	O
-	O
VHL	O
)	O
vector	O
in	O
several	O
cell	O
lines	O
,	O
including	O
293	O
embryonic	O
kidney	O
and	O
RCC	S-DISO
cell	O
lines	O
.	O

wt	O
-	O
VHL	O
protein	O
inhibited	O
VEGF	O
promoter	O
activity	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
up	O
to	O
5	O
-	O
to	O
10	O
-	O
fold	O
.	O

Deletion	O
analysis	O
defined	O
a	O
144	O
-	O
bp	O
region	O
of	O
the	O
VEGF	O
promoter	O
necessary	O
for	O
VHL	O
repression	O
.	O

This	O
VHL	O
-	O
responsive	O
element	O
is	O
GC	O
rich	O
and	O
specifically	O
binds	O
the	O
transcription	O
factor	O
Sp1	O
in	O
crude	O
nuclear	O
extracts	O
.	O

In	O
Drosophila	O
cells	O
,	O
cotransfected	O
VHL	O
represses	O
Sp1	O
-	O
mediated	O
activation	O
but	O
not	O
basal	O
activity	O
of	O
the	O
VEGF	O
promoter	O
.	O

We	O
next	O
demonstrated	O
in	O
coimmunoprecipitates	O
that	O
VHL	O
and	O
Sp1	O
were	O
part	O
of	O
the	O
same	O
complex	O
and	O
,	O
by	O
using	O
a	O
glutathione	O
-	O
S	O
-	O
transferase	O
-	O
VHL	O
fusion	O
protein	O
and	O
purified	O
Sp1	O
,	O
that	O
VHL	O
and	O
Sp1	O
directly	O
interact	O
.	O

Furthermore	O
,	O
endogenous	O
VEGF	O
mRNA	O
levels	O
were	O
suppressed	O
in	O
permanent	O
RCC	S-DISO
cell	O
lines	O
expressing	O
wt	O
-	O
VHL	O
,	O
and	O
nuclear	O
run	O
-	O
on	O
studies	O
indicated	O
that	O
VHL	O
regulation	O
of	O
VEGF	O
occurs	O
at	O
least	O
partly	O
at	O
the	O
transcriptional	O
level	O
.	O

These	O
observations	O
support	O
a	O
new	O
mechanism	O
for	O
VHL	O
-	O
mediated	O
transcriptional	O
repression	O
via	O
a	O
direct	O
inhibitory	O
action	O
on	O
Sp1	O
and	O
suggest	O
that	O
loss	O
of	O
Sp1	O
inhibition	O
may	O
be	O
important	O
in	O
the	O
pathogenesis	O
of	O
von	B-DISO
Hippel	I-DISO
-	I-DISO
Lindau	I-DISO
disease	E-DISO
and	O
RCC	S-DISO
.	O
.	O

Adult	B-DISO
onset	I-DISO
globoid	I-DISO
cell	I-DISO
leukodystrophy	E-DISO
(	O
Krabbe	B-DISO
disease	E-DISO
)	O
:	O
analysis	O
of	O
galactosylceramidase	O
cDNA	O
from	O
four	O
Japanese	O
patients	O
.	O

We	O
examined	O
galactosylceramidase	O
(	O
GALC	O
)	O
cDNA	O
in	O
four	O
Japanese	O
patients	O
with	O
adult	B-DISO
onset	I-DISO
globoid	I-DISO
cell	I-DISO
leukodystrophy	E-DISO
(	O
Krabbe	B-DISO
disease	E-DISO
;	O
AO	B-DISO
-	I-DISO
GLD	E-DISO
)	O
by	O
polymerase	O
chain	O
reaction	O
/	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
(	O
PCR	O
-	O
SSCP	O
)	O
analysis	O
,	O
subsequent	O
sequence	O
determination	O
,	O
and	O
restriction	O
enzyme	O
digestion	O
of	O
PCR	O
products	O
,	O
initial	O
symptoms	O
were	O
the	O
onset	O
of	O
slowly	O
progressive	O
spastic	B-DISO
paraplegia	E-DISO
from	O
the	O
middle	O
of	O
the	O
second	O
decade	O
,	O
and	O
all	O
patients	O
had	O
diminished	B-DISO
GALC	I-DISO
activity	E-DISO
in	O
their	O
leukocytes	O
.	O

We	O
identified	O
three	O
missense	O
mutations	O
(	O
I66M	O
,	O
G270D	O
,	O
L618S	O
)	O
and	O
one	O
exon	O
-	O
6	O
skipping	O
(	O
535	O
-	O
573del	O
)	O
.	O

Two	O
of	O
the	O
patients	O
had	O
only	O
the	O
I66M	O
mutant	O
mRNA	O
,	O
and	O
one	O
only	O
the	O
G27OD	O
mutant	O
mRNA	O
.	O

The	O
fourth	O
patient	O
carried	O
a	O
compound	O
heterozygous	O
mutation	O
of	O
535	O
-	O
573del	O
and	O
L618S	O
.	O

To	O
determine	O
the	O
enzymatic	O
activities	O
produced	O
by	O
these	O
mutations	O
,	O
we	O
constructed	O
mutated	O
GALC	O
cDNAs	O
and	O
expressed	O
them	O
in	O
COS	O
-	O
1	O
cells	O
.	O

Three	O
mutations	O
,	O
viz	O
.	O
,	O
G270D	O
,	O
L618S	O
,	O
and	O
exon	O
-	O
6	O
skipping	O
(	O
535	O
-	O
573del	O
)	O
,	O
produced	O
diminished	B-DISO
GALC	I-DISO
activity	E-DISO
as	O
expected	O
.	O

The	O
I66M	O
mutation	O
in	O
the	O
wild	O
-	O
type	O
GALC	O
cDNA	O
(	O
I289	O
)	O
had	O
normal	O
activity	O
,	O
but	O
when	O
this	O
mutation	O
and	O
the	O
V289	O
polymorphism	O
were	O
introduced	O
into	O
the	O
same	O
allele	O
,	O
it	O
had	O
decreased	O
activity	O
.	O

Thus	O
,	O
the	O
combination	O
of	O
a	O
unique	O
mutation	O
and	O
polymorphism	O
causes	O
conformational	O
change	O
in	O
the	O
GALC	O
enzyme	O
,	O
resulting	O
in	O
low	O
enzymatic	O
activity	O
.	O

AO	B-DISO
-	I-DISO
GLD	E-DISO
mutations	O
,	O
including	O
those	O
found	O
here	O
,	O
are	O
located	O
in	O
the	O
N	O
-	O
terminus	O
(	O
I66M	O
,	O
G270D	O
,	O
535	O
-	O
573del	O
)	O
or	O
C	O
-	O
terminus	O
(	O
L618S	O
)	O
of	O
the	O
GALC	O
enzyme	O
,	O
whereas	O
the	O
reported	O
mutations	O
in	O
the	O
infantile	O
form	O
(	O
IF	B-DISO
-	I-DISO
GLD	E-DISO
)	O
are	O
in	O
the	O
central	O
domain	O
.	O

This	O
difference	O
in	O
mutation	O
sites	O
may	O
affect	O
the	O
clinical	O
features	O
of	O
GLD	S-DISO
.	O
